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In light of the versatile synthetic potential of β-lactams on the one hand and the beneficial impact 
of fluorine on biological properties on the other hand, β-lactams bearing a trifluoromethyl group 
comprise interesting entities for the construction of novel targets with promising bioactivities. In 
this PhD thesis, the preparation and deployment of 4-trifluoromethyl-β-lactams as new building 
blocks toward a diverse set of functionalized CF3-amines and CF3-azaheterocycles was 
investigated. In particular, 3-benzyloxy-4-trifluoromethyl-β-lactams were conveniently synthesized 
as a first new class of building blocks. The aptitude of these systems with respect to ring-opening 
reactions was explored to enable an entry to functionalized aminopropane systems by either direct 
reductive β-lactam ring opening or initial carbonyl removal to azetidine intermediates, followed by 
ring opening. In addition, hydrogenolysis of the benzylether fragment in 3-benzyloxy-4-
trifluoromethyl-β-lactams resulted in the formation of 3-hydroxy-4-trifluoromethyl-β-lactams as a 
second class of new building blocks. The latter alcohols enabled the construction of CF3-
containing ring-rearranged products, including aziridines through a ring-contraction protocol via 3-
chloro-β-lactam intermediates and dioxan-2-ones via initial O-allylation. Furthermore, alcohol 
oxidation gave rise to 3-oxo-4-trifluoromethyl-β-lactams as a third class of new building blocks. 
Attempts to form and trap the corresponding 2,3-dioxoazetidin-4-yl anions unexpectedly resulted 
in ring opening through C3-C4 bond fission, culminating in 2-[(2,2-difluorovinyl)amino]-2-
oxoacetate products. This peculiar mechanism was investigated in depth, both experimentally and 
computationally. Finally, an addition/elimination sequence applied to 3-oxo-4-trifluoromethyl-β-
lactams afforded 3-methylene-4-trifluoromethyl-β-lactams as a fourth class of new building blocks, 
which were shown to be eligible substrates for Michael additions, electrophilic additions and 
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Fluorine is the 13th most abundant element in the earth’s crust, where it occurs predominantly in 
minerals as cryolite (Na3AlF6), fluorite (CaF2) and fluorapatite (Ca5(PO4)3F). However, only a few 
simple chemical entities in nature contain a carbon-fluorine bond, which is due to the insolubility 
of fluorine salts.1 It is estimated that only five out of 130 000 unique natural products structurally 
characterized contain fluorine in their structures. Fluoroacetate 1 is the most common, and is 
found in many plants and in the Streptomyces cattleya bacterium.2 Besides fluoroacetate, the 
amino acid 4-fluoro-L-threonine 2 is coproduced in the bacterium S. cattleya by an enzyme-




Although nature produces a limited number of fluorine-containing products, organofluorine 
compounds are emerging as crucial components in organic and medicinal chemistry. This is 
illustrated by their presence in approximately 25% of pharmaceuticals and in 30-40% of 
agrochemicals on the market.4,1b Fluorinated compounds have attracted tremendous attention 
because of the beneficial effects of fluorine on the physicochemical and pharmacokinetic 
properties of bioactive molecules, such as pKa, lipophilicity, metabolic stability and 
bioavailability.5,4b In fact, these pronounced impacts of fluorine are due to its atomic physical 
properties such as high electronegativity, relatively small size, very low polarizability, three tightly 
bonded electron lone pairs and an excellent overlap of the 2s and 2p orbitals with the 
corresponding orbitals of carbon.6  
Because of the high electronegativity of fluorine (χpauling = 4) the carbon-fluorine bond is highly 
polarized, very strong (C-F = 485 kJ/mol) and short. In addition, this bond has a low polarizability, 
which often leads to a higher lipophilicity of fluorinated compounds, especially in the case of 
aromatic fluorination and fluorination adjacent to atoms with π-bonds. The replacement of a single 
aromatic hydrogen by a fluorine atom results only in a modest increase in lipophilicity, whereas 
the replacement of substituents by a CF3 group renders significant modulation of this property. 
Modulation of the lipophilicity of a compound has a profound effect on the absorption of 
pharmaceuticals in the body. Orally administered drugs can be commonly absorbed and 
distributed by passive transport processes, which depend on the permeability of the cell 
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membrane. An effective drug molecule requires a lipophilicity that allows it to penetrate the cell 
membrane without being trapped in it. Another effect of the strong electronegativity of fluorine 
comprises a significant influence on the pKa values of neighboring functional groups such as 
alcohols, carboxylic acids and amines.7 Modulation of the pKa can be exploited to improve the 
solubility and bioavailability of orally administered drugs by affecting the absorption, distribution, 
metabolism and excretion processes (ADME).4b,6b However, the effect of fluorine substitution on 
the bioavailability of drugs can not be accurately predicted.4b In addition, the van der Waals radius 
of fluorine (1.47 Å) lies between oxygen (1.57 Å) and hydrogen (1.20 Å), thus the replacement of 
either oxygen or hydrogen with fluorine is commonly tolerated by biological targets.1b However, 
this is not the case for the trifluoromethyl group, which is actually closer in size to an isopropyl 
group rather than a methyl group.7 Indeed, the CF3 group can exert an effect comparable to a 
phenyl ring or tert-butyl group. The steric variation combined with the electron-withdrawing 
properties can lead to changes in the preferred molecular conformation upon a CF3 group 
introduction.4b 
In light of the emerging interest in fluorinated compounds, many synthetic endeavors have been 
devoted to the construction of organic molecules bearing one or more fluorine atoms, for example 
a trifluoromethyl group, in their structures. Since H. L. Yale acknowledged the remarkable potential 
of a CF3 group in medicinal chemistry in 1959,8 a broad diversity of trifluoromethylated drugs has 
been designed and widely used such as celecoxib 3 (anti-inflammatory agent), efavirenz 4 (HIV-




From a synthetic viewpoint, trifluoromethyl-containing molecules have been prepared based on 
two major strategies. The first one is the building-block approach (fluorinated synthon approach), 
which utilizes a trifluoromethylated starting material to assemble the target molecules. The other 
route concerns the late-stage trifluoromethylation strategy, which introduces a trifluoromethyl 
INTRODUCTION AND GOALS 
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group onto different types of organic substrates by means of either aromatic coupling reactions or 
radical/nucleophilic/electrophilic trifluoromethylation routes.10 Because both strategies have 
advantages and disadvantages, they have been used complementary to each other. For example, 
the late-stage approach can enable the streamlined synthesis of the desired target compounds. 
However, expensive trifluoromethylation reagents and harsh reaction conditions are usually 
required. In addition, the reactive intermediates, which are generated during the 
trifluoromethylation reactions, are often unstable under the reaction conditions. In fact, only three 
of the fluorine-containing drugs introduced on the market in 2001-2011 were manufactured 
through this methodology. A complementary building block strategy can then be utilized to deal 
with the difficulties associated with the trifluoromethylation strategy. In fact 90% of the fluorinated 
pharmaceuticals prevalent over all therapeutic areas are prepared through the latter approach.1b,11 
Besides its pre-eminence, this methodology might appear to limit the position of fluorine in the 
target molecule. However, this obstacle is improved by the presence of many available fluorine-
containing starting materials on the market.  
The building block approach has been extensively exploited for the synthesis of small-ring 
molecules such as CF3-substituted β-lactams or azetidine-2-ones, as the trifluoromethylation 
approach often compromises the structural integrity of these reactive and sensitive molecules.12 
In addition to their interesting pharmacological properties (antibacterial, antitumor and anti-
inflammatory…), β-lactams have been known to be flexible synthons (β-lactam synthon method) 
for the preparation of a wide variety of nitrogen-containing acyclic and heterocyclic compounds.13 
In light of the interesting effects of fluorine introduction, β-lactams bearing a trifluoromethyl group 
can be considered as fascinating templates for the construction of novel targets with a diverse set 
of potential applications. For example, the transformation products of CF3-substituted β-lactams 
have been applied to develop new taxoid anticancer drugs, which have been shown to be 
efficacious drugs with fewer side effects and superior pharmacological properties.14  
Intrigued by the tremendous synthetic potential of β-lactams in combination with the interesting 
effects of a trifluoromethyl group on biological properties, many efforts will be devoted in this PhD 
thesis to the synthesis and synthetic application of 4-trifluoromethyl-β-lactams. In that respect, 4-
trifluoromethyl-β-lactams will be synthesized and deployed as building blocks (β-lactam synthon 
method) in the construction of novel nitrogen-containing acyclic and heterocyclic compounds 
through ring-opening and ring-transformation reactions. These objectives can be divided into four 
work packages based on the unexplored chemistry of 4-trifluoromethyl-β-lactam building blocks I, 
INTRODUCTION AND GOALS 
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II, III, IV, which can be synthesized in an interconnective way starting from CF3-substituted imines 





In analogy with non-fluorinated β-lactams, CF3-β-lactams have previously been shown to be 
suitable precursors for the preparation of aminopropane systems through ring-opening 
reactions.15 However, ring opening of CF3-substituted β-lactams has been mainly performed 
through a methanolysis approach.16 In the first part of this thesis, the synthesis and reactivity of 3-
alkoxy/aryloxy-4-trifluoromethyl-β-lactams 7, as the first building blocks I, toward ring-opening 
reactions will be investigated utilizing various nucleophiles (Scheme 2). In that respect, the 
synthesis of 3-alkoxy/aryloxy-4-trifluoromethyl-β-lactams 7 starting from commercially available 1-
ethoxy-2,2,2-trifluoroethanol 6 will be performed via imination and subsequent Staudinger β-
lactam synthesis with alkyl/aryloxyacetyl chlorides. The ring-opening capability of 4-CF3-β-lactams 
7 will then be explored through an indirect or direct approach. In the indirect approach, initial 
AlH2Cl-induced carbonyl reduction of 4-CF3-β-lactams 7 will be performed to furnish 2-CF3-
azetidine intermediates 8. Activation of the latter azetidines 8 utilizing trimethyloxonium 
tetrafluoroborate (Me3OBF4) and subsequent regiospecific ring opening with different nucleophiles 
(Nu-) could lead to a diversity of functionalized trifluoromethyl-containing aminopropanes 9. On 
the other hand, the direct ring opening of 4-CF3-β-lactams 7 could be expected upon treatment 
with LiAlH4, in line with the behavior of non-CF3-substituted β-lactams, giving rise to CF3-
substituted γ-amino alcohols 10.17 Furthermore, the cyclization of γ-amino alcohols 10 with either 
formaldehyde or ethyl chloroformate will be exploited in order to afford trifluoromethylated 3-
oxazinane and 1,3-oxazinan-2-one azaheterocycles 11.18  





In the second part of this PhD thesis, 3-hydroxy-4-trifluoromethyl-β-lactams 12, as a second class 
of building blocks II, will be synthesized through the hydrogenolysis of 3-benzyloxy-4-
trifluoromethyl-β-lactams 7 (Scheme 3). It should be noted that the preparation of 3-hydroxy-β-
lactam analogs has been documented,16a however, the reactivity of these alcohols has been hardly 
explored. The deployment of alcohols 12 as versatile substrates for the construction of a variety 
of CF3-containing azaheterocyclic products will be pursued via ring-rearrangment reactions. As a 
first objective, ring contraction of alcohols 12 toward the synthesis of 2-substituted 3-
(trifluoromethyl)aziridines 15 via new 3-chloro-β-lactam intermediates 13 will be considered. In 
analogy with non-CF3-substituted 3-chloro-β-lactams,15 the reductive ring opening of chlorides 13 
by means of LiAlH4 could lead to 3-amino-2-chloropropan-1-ols 14, which could be prone to 
subsequent cyclization towards 2-substituted 3-(trifluoromethyl)aziridines 15 under basic 
conditions. This methodology might offer a new approach to the interesting class of trifluorinated 
aziridines, which have been mainly synthesized by using diazo compounds or by applying harsh 
reaction conditions.19 
 





In addition, the treatment of 3-hydroxy-β-lactams 12 with 2-bromoethan-1-ol in the presence of a 
base could afford 3-(2-hydroxyethoxy)-β-lactams 16.20 Due to the combination of the constrained 
β-lactam ring system and a nucleophilic alcohol group at a remote position, the resulting β-lactams 
16 could undergo intramolecular cyclization toward six-membered azaheterocycles 17 upon 
treatment with a suitable base.21 This transformation aptitude of 3-(2-hydroxyethoxy)-β-lactams 
16 will be scrutinized to enable the synthesis of novel CF3-containing 1,4-dioxan-2-ones 17, which 
are known as important intermediates in the synthetic field of e.g. polymers, corrosion inhibitors 
and biomaterials.22 
In the next part, 3-oxo-4-(trifluoromethyl)azetidin-2-ones 18, as a third type of building blocks III, 
will be envisaged from the corresponding 3-hydroxy-4-trifluoromethyl-β-lactams 12 via Albright-
Onodera oxidation using P2O5 in DMSO (Scheme 4). An important aspect of trifluoromethylated 
small-ring azaheterocycles, for example 2-CF3-aziridines, comprises their suitability to undergo 
deprotonation in α-position with regard to the strong electron-withdrawing CF3 group, resulting in 
the corresponding 2-(trifluoromethyl)aziridin-2-yl anions.23 In analogy, the deployment of 4-
trifluoromethyl-3-oxo-β-lactams might offer new opportunities for the introduction of an additional 
side chain through abstraction of the acidic C4-proton in α-position with respect to the oxo group 
and the CF3 moiety. In that respect, treatment of 3-oxo-4-CF3-β-lactams 18 with a suitable base 
could result in the corresponding 3,4-dioxo-2-(trifluoromethyl)azetidin-2-yl anions, followed by 
quenching with dihaloalkanes to afford the desired 3-oxo-4-haloalkyl-β-lactams 19. Subsequently, 
cyclization of the resulting β-lactams 19, which represent with electrophiles bearing an additional 
INTRODUCTION AND GOALS 
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leaving group, will be evaluated toward the synthesis of C-fuse bicyclic β-lactam 20 analogs, a 





In the final part, attempts will be made to synthesize 3-methylene-β-lactams 21 as a fourth class 
of new building blocks IV (Scheme 5). From a synthetic viewpoint, these β-lactams 21 can be 
prepared from 3-oxo-β-lactams 18 via a Wittig olefination upon treatment with 
methylenetriphenylphosphorane. The presence of an exocyclic carbon-carbon double bond 
coupled with the electron-withdrawing CF3 group can allow 3-methylene-4-
(trifluoromethyl)azetidin-2-ones 21 to be suitable synthons for Michael additions, addition 
reactions and cycloadditions en route to a variety of stereodefined mono- and spirocyclic 4-CF3-
β-lactams. More precisely, conjugate addition of nucleophiles (such as primary and secondary 
amines) across the electron-poor double bond in 3-methylene-β-lactams 21 could provide 3-
functionalized 4-CF3-azetidin-2-ones 22. In addition, the suitability of 4-CF3-β-lactams 21 for the 
preparation of CF3-substituted spirocyclic structures via diol intermediates 23 will be investigated. 
As such, the synthesis of diols 23 is contemplated based on the OsO4-mediated oxidation of 3-
methylene-4-(trifluoromethyl)azetidin-2-ones 21 using N-methylmorpholine-N-oxide (NMO).25 
Subsequently, treatment of diols 23 with triphosgene in the presence of pyridine could afford 3-
trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-diones 24. Furthermore, the reactivity of 3-
methylene-4-CF3-β-lactams 21 will be scrutinized toward 1,3-dipolar nitrone-olefin cycloaddition 
to access novel spiro-fused β-lactam isoxazolidine systems. Thus, 3-methylene-β-lactams 21 will 
be treated with an α-phenylnitrone enabling a convenient entry to 7-phenyl-3-trifluoromethyl-5-
oxa-2,6-diazaspiro[3.4]octan-1-ones 25. It should be noted that the determination of the relative 
stereochemistry of all new compounds will be an important aspect of these studies in order to 
assign the correct structures. 





The overall objective of these four work packages is to provide fundamental insights into the 
unexplored chemistry of 4-trifluoromethyl-β-lactams in terms of both synthesis and reactivity. In 
light of the increasing demand for new fluorinated building blocks from a medicinal chemistry 
perspective, the deployment of these CF3-β-lactam building blocks is expected to provide a broad 
range of CF3-decorated nitrogen-containing acyclic and heterocyclic molecules, which can be 



















Because of the beneficial effect of a trifluoromethyl group on the biological properties of bioactive 
compounds on the one hand and the versatile synthetic potential of β-lactams on the other hand, 
4-CF3-β-lactams comprises interesting entities for the preparation of a large variety of CF3-
substituted nitrogen-containing target structures with promising biological characteristics. In this 
review, we present an overview of different building block approach-based routes toward the 
synthesis of 4-(trifluoromethyl)azetidin-2-ones and the application of the “β-lactam synthon 
method” for the synthesis of a diverse set of (a)cyclic CF3-substituted molecules by means of ring-
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The pivotal role of fluorine in medicinal chemistry is reflected by its presence in approximately 
25% of the pharmaceuticals on the market and in the development pipeline. The increasing 
interest in fluorinated compounds is due to the favorable effect of fluorine on their pharmacological 
properties.4a,26,1b In particular, the use of fluorine-substituted molecules has been shown to 
increase the biological half-life by impeding the oxidative metabolism, and to increase 
bioabsorption by lipophilic effects.27,14a Subsequently, synthetic chemistry focused on the 
incorporation of one or more fluorine atoms into organic molecules has resulted in many new 
approaches and strategies.4a,1b,4b An important part of these endeavors has been devoted to the 
introduction of a trifluoromethyl group into constrained nitrogen ring systems, such as β-lactams 
or azetidin-2-ones.28a,18,28b,23b In addition to their well-known significance as antibacterial agents, 
β-lactams have been attracting considerable interest as building blocks and valuable 
intermediates from a synthetic point of view as well.13a Because of the high ring strain associated 
with the four-membered ring system, β-lactams represent prominent substrates susceptible to 
ring-opening and ring-transformation reactions en route to a variety of nitrogen-containing acyclic 
and heterocyclic compounds.13 Given the beneficial effect of fluorine introduction, β-lactams 
bearing a trifluoromethyl group can be considered as interesting entities for the construction of 
novel targets with a diverse set of potential applications. 
The synthesis of trifluoromethyl-containing structures can be accomplished by either a 
trifluoromethylation approach or by a building block strategy (fluorinated synthon approach). 
However, the preparation of sensitive CF3-substituted structures is often hampered by difficulties 
associated with the late-stage introduction of the CF3 group (safety implications, reagent reactivity, 
economics).10c,29a,23a,29b-29f,7,29g,9,29h As an alternative, the application of CF3-containing building 
blocks can be pursued, thus avoiding the use of trifluoromethylating agents during the synthesis. 
In that respect, the functionalization of β-lactams with a trifluoromethyl group comprises an 
interesting field of research and is increasingly applied to modify the biological and 
pharmacological properties of these compounds and their transformation products.14a The goal of 
this literature overview is to provide a short account of the main synthetic routes based on a 
building block approach as well as the reactivity profile of 4-CF3-azetidin-2-ones toward CF3-




2. Synthetic routes toward 4-(trifluoromethyl)azetidin-2-ones 
 





2.1. Staudinger synthesis of 4-CF3-azetidin-2-ones  
The classical, well-known method for the construction of a β-lactam core concerns the Staudinger 
synthesis through a [2+2]-ketene-imine cyclocondensation.30 For instance, this strategy has been 
employed by Kuznetsova et al. for the synthesis of cis-4-CF3-β-lactam 4. The direct use of 
acetoxyketene, generated in situ from acetoxyacetyl chloride and triethylamine, with CF3-imine 131 
did not successfully furnish cis-4-CF3-β-lactam 4. In order to circumvent this unexpected obstacle, 
a short detour was proposed based on the cyclocondensation of benzyloxyketene with imine 1, 
followed by hydrogenolysis and O-acetylation (Scheme 2). The reaction of benzyloxyketene with 
imine 1 was smoothly performed in dichloromethane at 40 °C, giving racemic cis-4-CF3-β-lactam 
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2 in high yield (83%). The cis-selectivity was determined based on the 1H NMR spectrum of β-
lactam 2, showing a coupling constant between the two vicinal protons at the C3 and C4 position 
of 5-6 Hz (CDCl3), as opposed to trans-β-lactams (1-2 Hz, CDCl3).16a,30a Then, cis-β-lactam 2 was 
converted into cis-3-acetoxy-β-lactam 4 through hydrogenolysis with Pd/C as a catalyst, followed 





In addition, [2+2]-cyclocondensation of a chiral imine and achiral ketene comprises a useful route 
toward chiral azetidin-2-ones. The reaction of chiral imine 5, prepared from trifluoroacetaldehyde 
hemiacetal and (S)-phenethylamine, with benzyloxyketene under classical Staudinger reaction 
conditions has been reported to afford a crude mixture of cis-β-lactams 6 and 7 in 90% yield 
(Scheme 3), accompanied by minor amounts (5-8%) of trans-β-lactams. These cis-isomers were 
successfully separated by recrystallization of the crude mixture. Stereoisomer 6 was obtained in 
an excellent diastereomeric purity (> 99%) after recrystallization from ethanol, whereas 
stereoisomer 7 was isolated with a diastereomeric excess of 95% after SiO2 chromatography and 






2.2. Synthesis of 4-CF3-azetidin-2-ones via enolate-imine condensation  
The condensation of imine 1 with the lithium enolate of ethyl dibenzylaminoacetate, produced in 
situ from ethyl dibenzylaminoacetate and lithium diisopropylamide in dry THF, has been 
successfully performed leading to trans-4-CF3-β-lactam 8 in 69% yield (Scheme 4).31 In related 
research, Clader et al. also applied an ester-imine condensation for the preparation of 






Furthermore, chiral 4-trifluoromethyl-substituted azetidin-2-ones can also be prepared via the 
enolate-imine condensation strategy making use of imines containing a chiral fragment. The 
treatment of optically active trifluoromethylimine 9 with lithium enolates, derived from various ester 
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derivatives, provided the trans-configuration at the C3- and C4-position of β-lactams 10 (R1 = Me, 
PhO) with rather high diastereoselectivity (95-99%). The high selectivity was explained by a six-





2.3. Synthesis of 4-CF3-azetidin-2-ones via intramolecular N-acylation  
A convenient entry toward the construction of azetidin-2-ones comprises the cyclization of β-amino 
acid derivatives.35,13b In that respect, Roberts and co-workers have reported the cyclization of 
trifluoromethylated amino acid derivative 14 with methylmagnesium bromide, giving rise to 4-
trifluoromethyl-β-lactam 15 in a yield of 27% and C-silylated compound 16 as a side product 
(Scheme 6). Amino acid derivative 14 was prepared in a quantitative yield by aminolysis and 
treatment with trimethylsilyl chloride of the corresponding unsaturated acid 13, which had been 
effectively synthesized from alcohol 12 by elimination of water, followed by hydrolysis using 
sodium hydroxide in THF. With the desired 4-(trifluoromethyl)azetidin-2-one 15 in hand, the 
preparation of fluorine-containing sulfazecin analogs 17, with interesting bactericidal properties, 






Yang and co-workers have devised a methodology to synthesize a CF3-substituted β-amino acid 
using the aza-Michael reaction (Scheme 7). As such, the major diastereomer (S,R)-20 was 
obtained in a yield of 68% upon treatment of chiral acrylamide 19 with aromatic amine 18, without 
solvent and catalyst. Aza-Michael adduct 20 was hydrolyzed into amino acid 21 with LiOH-H2O2 
in a good yield (73%). It should be noted that analogs of chiral α-trifluoromethyl amino acid 21 can 
also be prepared by reduction of the corresponding enamines or imines.37 Furthermore, β-CF3-β-
amino ester 22, derived from 21, was cyclized in the presence of methylmagnesium bromide to 
construct enantioenriched 4-trifluoromethylated β-lactam 23 in 69% yield. The absolute 
stereochemistry of 23 was determined to be S, hence, the configuration of compound 21 was 






Furthermore, chiral β-amino esters 25 have effectively been prepared by the regio- and 
stereoselective nucleophilic ring-opening reaction of 1-benzyl-3-trifluoromethyl-2-
(ethoxycarbonyl)aziridine 24 (Scheme 8). Via Grignard-mediated intramolecular cyclization, trans-
β-lactams 26 were produced from the corresponding β-amino esters 25. The trans-configuration 
of β-lactams 26 was assigned by means of 1H NMR (JH3,H4 = 1.8 Hz). The stereochemistry of trans-
β-lactams 26 confirms the anti relative configuration of β-amino esters 25 and underlines the 









2.4. Synthesis of 4-CF3-azetidin-2-ones via intramolecular C-alkylation  
Petrik and co-workers have recently published a new methodology for the preparation of trans-4-
trifluoromethylated β-lactams 30 by reaction of N-(1-chloro-2,2,2-trifluoroethyl)-4-
methylbenzenesulfonamide 28 with various nonactivated aliphatic acid chlorides 29 in the 
presence of dimethylethylamine as a base and dichloromethane as a solvent (Scheme 9). 
Sulfonamide 28 was produced by the treatment of hemiaminal 27 with thionyl chloride in CH2Cl2 
at 40 °C. The use of chloroamine 28 in the cyclization reaction can offer a convenient alternative 
for the construction of trifluoromethylated β-lactams based on the use of highly moisture-sensitive 





2.5. Synthesis of 4-CF3-azetidin-2-ones via direct ring expansion of 3-CF3-aziridine-2-
carboxylates  
In analogy with the preparation of non-fluorinated azetidin-2-ones from the corresponding non-
fluorinated aziridines,40 3-chloro-4-CF3-azetidin-2-one 32 was prepared through ring expansion of 
the corresponding fluorinated sodium aziridinyl carboxylate 31 with either oxalyl chloride or thionyl 








The diastereoselectivities were significantly improved by considering the ring expansion of the 
carboxylic acid CF3-aziridine analogs instead of the sodium salts (Scheme 11). Aziridines cis-33 
and trans-33 were treated with NaH and then thionyl chloride in toluene at 70 °C, resulting in the 
corresponding cis- and trans-β-lactams 34 in relatively good yields and excellent 
stereoselectivities. The relative configurations of the products were confirmed by 1H NMR, pointing 
to coupling constants of 6 Hz (cis) and 3 Hz (trans). Continuing efforts have been devoted to 






2.6. Synthesis of 4-CF3-azetidin-2-ones via the Kinugasa reaction  
The Kinugasa reaction offers a general access toward the synthesis of differently substituted β-
lactams via initial [3+2]-cycloaddition of nitrones with terminal alkynes in the presence of a Cu(I) 
salt and a polar solvent (acetonitrile or pyridine).42 El Dine and co-workers have applied this 
method for the preparation of 3-difluoroalkyl- and/or 3-(1-fluoroalkylidene)-β-lactams from 
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propargylic gem-difluorides.43 Very recently, Kowalski and co-workers have presented a new 
application of fluorinated nitrones for the preparation of fluoroalkylated β-lactams via the Kinugasa 
reaction. Trifluorinated nitrones 36 were prepared by treating the corresponding hemiaminals 35, 
derived from fluoral, with para-toluenesulfonic acid using a Dean-Stark apparatus (Scheme 12). 
The isolated and purified nitrones 36 were then treated with different mono-substituted acetylenes 
37 under typical Kinugasa reaction conditions to form the expected 4-trifluoromethyl-β-lactams 38 
in good to high yields. The cis- and trans-diastereoselectivity varied considerably depending on 





2.7. Synthesis of 4-CF3-azetidin-2-ones via the Reformatsky reaction 
The Reformatsky reaction of imine 39 with α-bromocarboxylic esters 40 in the presence of 
activated zinc dust in anhydrous toluene has been reported to furnish β-lactams 41 as the main 
products, accompanied by β-amino esters 42 (Scheme 13).44 However, information concerning 







This method has been further extended toward the use of chiral 1,3-oxazolidines. The reaction of 
2-trifluoromethyl-1,3-oxazolidines 43a,b and ethyl bromoacetate in the presence of zinc dust at 
reflux temperature in THF afforded 4-(trifluoromethyl)azetidin-2-ones 44a,b in 42% yield as a 
74:26 mixture of diastereoisomers (Scheme 14). This mixture was then purified by flash 
chromatography, giving pure 44a. The lower stereoselectivity of this reaction as compared to 
results reported on nonfluorinated oxazolidines can be explained by inhibition of the oxazolidine 
ring opening toward imine formation as a result of the electron-withdrawing CF3 group. The major 










3. The reactivity profile of 4-CF3-azetidin-2-ones 
 
The study of 4-(trifluoromethyl)azetidin-2-ones comprises an appealing, yet rather scarcely 
explored research field to date. In general, 4-(trifluoromethyl)azetidin-2-ones represent useful 
building blocks (β-lactam synthon method)16b for the preparation of a broad spectrum of 
trifluoromethylated N-containing compounds. In this section, both ring-opening and ring-
transformation reactions will be considered. 
 
3.1. Ring-opening reactions of 4-CF3-azetidin-2-ones 
Because of the high ring strain of four-membered cyclic amides, 4-(trifluoromethyl)azetidin-2-ones 
can be deployed as excellent building blocks for the preparation of fluorinated amino acids, 








For example, the ring-opening methanolysis of 4-(trifluoromethyl)azetidin-2-ones 46, catalyzed by 
sodium azide, has been performed in DMF at room temperature to generate the corresponding 
CF3-containing β-amino esters 47 in good to almost quantitative yields as single diastereomers 
(Scheme 16).16 Besides, ring-opening coupling reactions of these 4-CF3-β-lactams with amino 
esters or baccatines have been performed to afford the corresponding CF3-containing dipeptides 
and taxoids, respectively. The synthesized fluoro-taxoids exhibited an excellent cytotoxicity 








3.2. Ring-transformation reactions of 4-CF3-azetidin-2-ones 
In addition to regioselective ring-opening reactions, 4-CF3-β-lactams have also been shown to be 
useful building blocks for Wittig rearrangements and alkylation. The enolates of 3-benzyloxy-4-
CF3-β-lactams 48, generated with LiHMDS in THF at -78 °C, were subjected to [1,2]- and ortho-
[2,3]-Wittig rearrangements producing 3-benzyl-3-hydroxy-β-lactams 49 and 3-(2-methylphenyl)-
3-hydroxy-β-lactams 50, respectively (Scheme 17), which are potential precursors of new 
trifluoromethyl-substituted isoserines. Besides, α-methyl-β-lactams were generated in excellent 





Furthermore, 4-CF3-β-lactams constitute convenient substrates for a Wittig reaction. For example, 
treatment of β-lactam 51 with stabilized ylides in toluene under reflux afforded adducts 52 in high 
yield (Scheme 18). Then, catalytic hydrogenation of 52 provided 4-trifluoromethylated 2-
alkylazetidines 53 in 78-92% yield, in which the diastereoselectivity depended on the catalyst and 
solvent used. Moreover, treatment of one derivative of 52 with potassium bis(trimethylsilyl)amide 
at -78 °C, followed by reaction with an alkyl halide or an aldehyde furnished 3-alkyl-substituted 
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derivatives 54 in 68-75% yield. Hydrogenation of compounds 54 with Pd/C in ethyl acetate gave 







In conclusion, the study of 4-(trifluoromethyl)azetidin-2-ones comprises an interesting, yet hardly 
explored field in terms of both synthesis and reactivity. The most important synthetic routes toward 
these compounds are based on [2+2]-ketene-imine cyclocondensations (Staudinger synthesis), 
enolate-imine cyclocondensations, intramolecular N-acylations, intramolecular C-alkylations, ring 
expansions of aziridines, the Kinugasa reaction and the Reformatsky reaction. Moreover, the 
reactivity of 4-(trifluoromethyl)azetidin-2-ones has received little attention toward ring-opening 
reactions, although they provide an effective approach for the preparation of e.g. fluorinated amino 
acids, dipeptides, taxoids and aminopropanes. In addition, these compounds have shown to be 
powerful substrates for a Wittig reaction, Wittig rearrangements and alkylation reactions. In light 
of the increasing demand for new CF3-substituted nitrogen compounds from a medicinal 
viewpoint, 4-CF3-β-lactams can indeed be considered as very promising structures for further 
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Synthesis of novel trifluoromethylated azetidines, aminopropanes, 1,3-oxazinanes 




This study reports on the preparation of 4-(trifluoromethyl)azetidin-2-ones and their synthetic 
potential as eligible new building blocks for the construction of CF3-containing azetidines, 
diaminopropanes, aminopropanol derivatives, 1,3-oxazinanes and 1,3-oxazinan-2-ones. This β-
lactam building block approach provides a convenient new entry into trifluoromethylated scaffolds 
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Due to their inherent chemical and biological properties, β-lactams or azetidin-2-ones represent 
an important class of four-membered azaheterocycles. In addition to their celebrated antibacterial 
activities, β-lactams are for example known to inhibit HIV-1 protease48 and to exhibit antitumor or 
antimalarial effects,49 enabling their use in different therapeutic areas. Besides their 
pharmacological relevance, β-lactams are also considered as important building blocks in organic 
chemistry for the synthesis of a wide variety of acyclic and heterocyclic compounds, which in their 
turn can serve as synthons for the development of novel, biologically relevant target structures.50 
Because of the specific chemical and physical properties of fluorine, the introduction of a CF3-
moiety in pharmacologically active compounds is known to convey beneficial biological effects to 
the resulting molecules, hence the increasing interest from organic and medicinal chemists in 
polyfunctional CF3-substituted scaffolds.28a,18,51  
In this work, the synthesis of novel 3-alkoxy/aryloxy-4-(trifluoromethyl)azetidin-2-ones is aspired, 
and their synthetic elaboration into a variety of biologically relevant nitrogen compounds is 
evaluated to assess their versatility and applicability. A powerful method in organic synthesis 
involves the use of β-lactams for the preparation of functionalized azetidines by treatment with 
monochloroalane (AlH2Cl), providing selective carbonyl removal without affecting the four-
membered ring system. Although this approach has been widely applied on non-
trifluoromethylated β-lactams,52,17b the selective reduction of 4-(trifluoromethyl)azetidin-2-ones to 
azetidines has not been reported in the literature to date. Therefore, the monochloroalane 
reduction of 4-CF3-azetidin-2-ones as an entry into 2-(trifluoromethyl)azetidines will be evaluated 
in this study. Subsequently, activation of these novel CF3-azetidines and regiospecific ring opening 
of the resulting azetidinium ions with different nucleophiles will be pursued en route to a diversity 
of functionalized trifluoromethyl-substituted aminopropanes as potential leads for the synthesis of 
biologically relevant compounds. In addition, the synthetic potential of 4-CF3-β-lactams will be 
further investigated by converting them into amino alcohols upon a LiAlH4-mediated reductive ring 
opening, analogous to the known reactivity of their non-fluorinated counterparts.53 Furthermore, 
cyclization of the thus obtained CF3-substituted γ-amino alcohols with formation of synthetically 
and biologically relevant 1,3-oxazinane and 1,3-oxazinan-2-one azaheterocycles is proposed. 
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2. Synthesis of cis-3-alkoxy/aryloxy-4-trifluoromethyl-β-lactam building blocks  
 
In a first step of this study, the reaction of commercially available 1-ethoxy-2,2,2-trifluoroethanol 1 
with 4-methoxyaniline or 4-methoxybenzylamine in toluene under Dean-Stark conditions gave rise 
to the desired trifluoroaldimines 2 in excellent yields.54a,16a,54b Subsequently, these imines were 
treated with 4 or 1.1 equiv of an (alkyl/aryl)oxyacetyl chloride in the presence of triethylamine, 
respectively, affording the corresponding cis-3-alkoxy/aryloxy-4-(trifluoromethyl)azetidin-2-ones 3 
in 49-78% yield (Scheme 1).54a,16a,54b,55a,30b,55b Only for 3-methoxy-1-(4-methoxyphenyl)-β-lactam 
3b, a minor amount of the corresponding trans isomer was observed as well (cis/trans: 10/3). The 
cis-selectivity was determined based on the 1H NMR spectra of β-lactams 3, as the observed 
coupling constants between the two vicinal protons at C3 and C4 (J = 5-6 Hz, CDCl3) 
corresponded well with those reported in the literature for cis-β-lactams.16a,30b,55b In this way, novel 
cis-CF3-β-lactams 3a-d were prepared via a diastereoselective cyclocondensation reaction 






3. Ring opening of cis-3-alkoxy/aryloxy-4-trifluoromethyl-β-lactams toward 
trifluoromethylated aminopropanes via azetidine intermediates 
 
In the this part, the reduction of the synthesized 4-CF3-azetidin-2-ones 3 by means of 
monochloroalane was evaluated to provide an entry into 2-(trifluoromethyl)azetidines 4. Treatment 
of β-lactams 3 with three equiv of monochloroalane, in situ prepared from LiAlH4 and AlCl3, in 
RESULTS AND DISCUSSION-PART I 
45 
diethyl ether at room temperature for two to four hours furnished the desired azetidines 4 in 
excellent yields (85-96%, Scheme 2).52,17b It should be noted that little information on 2-CF3-
azetidines is available in the literature.56a,47,56b,56c The application of these novel cis-3-
alkoxy/aryloxy-2-(trifluoromethyl)azetidines 4 as building blocks for the synthesis of a diversity of 
functionalized trifluoromethyl-substituted aminopropanes was evaluated next.54b,52,17b In that 
respect, alkylation of 2-(trifluoromethyl)azetidines 4 towards the corresponding azetidinium ions 5 
utilizing two equiv of trimethyloxonium tetrafluoroborate (Me3OBF4) and subsequent ring opening 
by treatment with four equiv of sodium acetate or tert-butylamine, afforded the desired syn-2-
alkoxy/aryloxy-3-amino-4,4,4-trifluorobutyl acetates 6b,c and syn-2-alkoxy/aryloxy-4,4,4-
trifluorobutan-1,3-diamines 7a,d, respectively, in good to excellent yields (Scheme 2). It should be 
noted that, in line with our previous findings, ring opening of 2-CF3-azetidinium salts 5 proceeded 
regiospecifically at C4, in contrast with the reactivity of azetidinium salts bearing other types of 
electron-withdrawing groups (e.g., acyl or cyano) at C2.18  
In light of the known biological properties of compounds bearing a functionalized aminopropane 
skeleton,57a-57d,53a,57e,53c-53e,57f acetates 6b,c and diamines 7a,d might constitute valuable new 
chemical entities for further elaboration. For example, the class of diaminopropanols is known for 
its protease-inhibiting, antiarrhythmic and anesthetic activity.57b,57c,57f Moreover, due to the specific 
properties of fluorine, trifluoromethyl-containing functionalized aminopropanol derivatives could 
play an important role in the development of analogues of these bioactive compounds.54b,58  
 
 





4. Synthesis and transformation of syn-2-alkoxy/aryloxy-4,4,4-trifluorobutanols toward 
1,3-oxazinanes, 1,3-oxazinan-2-ones and oxazepane analogs 
 
On the other hand, cis-azetidin-2-ones 3 were subjected to a reductive ring opening by means of 
lithium aluminium hydride, in analogy with the known chemical behavior of their non-fluorinated 
counterparts.53a,53c-53e As illustrated in Scheme 3, treatment of β-lactams 3a-c with lithium 
aluminium hydride afforded the corresponding syn-2-alkoxy/aryloxy-4,4,4-trifluorobutanols 8a-c in 
good yields.52c This syn relationship in amino alcohols 8 is a direct consequence of the selective 
Staudinger synthesis of stereodefined cis--lactams 3, followed by transfer of the stereochemical 
information through the following LiAlH4-mediated reduction step. 
These γ-amino alcohols 8 bear significant biological potential because of their structural similarity 
to several classes of bioactive compounds. For example, the 1-alkylamino-3-aryloxypropan-2-ol 
family, including propranolol and timolol, provides β-adrenergic blocking agents (β-blockers) for 
the treatment of various vascular disorders.57a,57d,57e Moreover, 2-alkoxy-3-amino-3-arylpropan-1-
ols have recently been shown to exhibit a promising antimalarial activity.53e The introduction of a 
trifluoromethyl substituent in these scaffolds could induce interesting beneficial changes in their 
biological properties.59,4b Therefore, CF3-substituted γ-amino alcohols 8, which have not been 
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described in the literature so far, are expected to serve as valuable templates for further 
development in the field of medicinal chemistry and chemical biology. 
With the intention to introduce conformational constraint into the target compounds, syn-2-
alkoxy/aryloxy-4,4,4-trifluorobutanols 8a,c were subsequently converted into new 
trifluoromethylated oxazinanes 9 and oxazinan-2-ones 10. Several literature reports describe the 
synthesis of non-fluorinated oxazinanes starting from amino alcohols, either as biologically 
relevant targets or as synthons for further elaboration.57a,57d 3-Aminopropan-1-ols 8a,c were thus 
treated with formaldehyde (37% in water), resulting in new cis-5-benzyloxy-4-trifluoromethyl-1,3-
oxazinanes 9a,c. 3-Aminopropan-1-ols 8a,c were also shown to be efficient precursors for the 
synthesis of a new class of CF3-substituted oxazinan-2-ones 10, of which non-fluorinated 
counterparts have been explored as inhibitors in the treatment of obesity and insulin resistance,60 
and fluorinated analogues have been applied in breast tumor imaging.54a,16a,54b For this purpose, 
3-aminopropan-1-ols 8a,c were treated with ethyl chloroformate and triethylamine, affording cis-
5-benzyloxy-4-trifluoromethyl-1,3-oxazinan-2-ones 10a,c in good yields (66-94%, Scheme 3). The 
1,3-oxazinan-2-one motif has been encountered as a core structure in many natural products and 
pharmaceutical drugs, and these heterocycles have for example been explored as inhibitors of 
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) or as antibacterial agents.60a,60c Besides, 
compounds accommodating the 1,3-oxazinane system have also successfully been screened for 
their in vitro antiplasmodial activity and cytotoxicity.57d 
In addition, the preparation of seven-membered oxazepane analogs 11a,c as potential 
targets60b,60c was attempted by direct treatment of syn-2-benzyloxy-4,4,4-trifluorobutanols 8a,c 
with oxalyl chloride in the presence of pyridine in 1,2-dichloroethane, in analogy with the synthesis 
of 1,3-oxazinane-2-ones 10.61 However, this cyclization reaction did not proceed as anticipated, 
resulting in complex mixtures. Other methods for constructing 1,4-oxazepanes were also tested, 
including the initial conversion of the amino group in butanols 8a,c into the corresponding amides 
12a,c via N-acylation using 1.2 equiv of chloroacetyl chloride and two equiv of trimethylamine 
(Scheme 3), followed by treatment with different bases (KOH, NaOH or NaH) under different 
reaction conditions (solvent-time-temperature combinations) to effect cyclization toward 1,4-
oxazepan-3-ones 13. However, none of the conditions tested seemed appropriate to produce the 
desired seven-membered heterocycles. 
 







In conclusion, 4-trifluoromethyl-β-lactams were efficiently prepared and deployed as novel building 
blocks in the synthesis of CF3-containing molecules with potential biological relevance. To that 
end, a suitable synthetic method was established for the conversion of these 4-CF3-azetidin-2-
ones into novel 3-alkoxy/aryloxy-2-(trifluoromethyl)azetidines by means of a selective 
monochloroalane reduction protocol. Furthermore, the synthetic potential of 2-CF3-azetidines was 
demonstrated by their conversion into a variety of α-CF3-substituted diaminopropanes and 
aminopropanol derivatives via transient azetidinium intermediates, which could serve as valuable 
precursors for the preparation of different target compounds. In addition, the conversion of 4-CF3-
β-lactams by means of reductive ring opening using lithium aluminium hydride furnished 
functionalized CF3-containing γ-amino alcohols in a concise and efficient manner. Cyclization of 
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the latter γ-amino alcohols employing formaldehyde or ethyl chloroformate afforded a convenient 
entry into the corresponding new cis-5-benzyloxy-4-trifluoromethyl-1,3-oxazinanes and cis-5-
benzyloxy-4-trifluoromethyl-1,3-oxazinan-2-ones, respectively.  
 
6. Experimental details 
 
General methods  
 
All reagents were purchased as commercially available sources without further purification. Diethyl 
ether, tetrahydrofuran and toluene were distilled from sodium benzophenone ketyl or sodium, 
while dichloromethane was distilled from calcium hydride prior to use. Solvents were removed 
under reduced pressure using a rotary evaporator. Silica gel (0.035 - 0.070 mm, pore diameter 
ca. 6 nm) was used for column chromatography. Solvent systems were determined via initial TLC 
analysis on glass-backed silica plates (Merck Kieselgel 60 with F254 indicator, precoated 0.25 
mm). These plates were developed using standard visualization techniques or agents, UV 
fluorescence (254 and 366 nm) and/or coloring with a potassium permanganate solution. High 
resolution 1H NMR (300 MHz, 400 MHz), 13C NMR (75 MHz, 100.6 MHz) and 19F NMR (282 MHz, 
376 MHz) spectra were recorded with a Jeol Eclipse FT 300 or a Bruker Avance III Nanobay NMR 
spectrometer using deuterated solvents and tetramethylsilane (TMS) and trichlorofluoromethane 
(CFCl3) as internal standards. Low resolution mass spectra were recorded via direct injection on 
an Agilent 1100 Series (ES, 4000 V) LC/MSD type SL mass spectrometer with Electron Spray 
Ionization Geometry (ESI 70 eV) and using a Mass Selective Detector (quadrupole). High 
resolution electron spray (ES) mass spectra were obtained with an Agilent Technologies 6210 
Series Time-of-Flight. IR spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR 
spectrometer (in neat form) with an ATR (Attenuated Total Reflectance) accessory. Melting points 
of crystalline compounds were measured using a Büchi B-540 apparatus or a Kofler bench, type 
WME Heizbank of Wagner & Munz. 
 
The spectral data and procedures of compounds 1-8 have been reported in the literature.62 
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Synthesis of cis-5-benzyloxy-3-(4-methoxyaryl)-4-trifluoromethyl-1,3-oxazinanes 9 
As a representative example, the synthesis of cis-5-benzyloxy-3-(4-methoxyphenyl)-4-
trifluoromethyl-1,3-oxazinane 9a is described. To a solution of syn-2-benzyloxy-4,4,4-trifluoro-3-
(4-methoxyphenylamino)butan-1-ol 8a (0.50 g, 1.41 mmol, 1 equiv) in THF (20 mL) was added 
formaldehyde (0.11 g, 1.41 mmol, 1 equiv, 37% solution in H2O). The resulting mixture was stirred 
for four hours at room temperature, after which the solvent was removed in vacuo. Water (100 
mL) was added to the mixture. Extraction with ethyl acetate (3 x 70 mL), drying (MgSO4), filtration 
of the drying agent and evaporation of the solvent afforded cis-5-benzyloxy-3-(4-methoxyphenyl)-
4-trifluoromethyl-1,3-oxazinane 9a in 50% yield, which was purified by means of recrystallization 
(Hex/EtOAc, 8/1) in order to obtain an analytically pure sample.  
Cis-5-benzyloxy-3-(4-methoxyphenyl)-4-trifluoromethyl-1,3-oxazinane 9a 
White crystals. Mp 58.5 °C. Recrystallization from Hex/EtOAc, 8/1. Yield 50%. 
1H NMR (400 MHz, CDCl3): δ 3.78 (3H, s, OCH3), 3.85-3.92 (1H, m, CH(HCH)O), 
3.96-4.03 (2H, m, CH(HCH)O and CHO), 4.08-4.17 (1H, m, CHCF3), 4.48 and 
4.65 (2 × 1H, 2 × d, J = 11.6 Hz, O(HCH)Ph), 4.80 and 4.85 (2 × 1H, 2 × d, J = 
11.7 Hz, O(HCH)N), 6.82 and 7.09 (2 × 2H, 2 × d, J = 9.0 Hz, N(CHarom)ortho and O(CHarom)ortho), 
7.28-7.35 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 55.6 (OCH3), 62.1 (q, J = 27.6 Hz, 
CHCF3), 65.8 (CHCH2O), 68.1 (CHO), 71.9 (OCH2Ph), 77.6 (OCH2N), 114.5 (2 × O(HCarom)ortho), 
121.7 (2 × N(CHarom)ortho), 125.8 (q, J = 285.0 Hz, CF3), 127.6, 128.0, 128.5 (5 x HCarom), 137.3 
(Carom,quat CH2O), 144.0 (Carom,quat N), 155.5 (Carom,quat O). 19F NMR (376 MHz, CDCl3): δ -64.87 (3F, 
d, J = 9.2 Hz, CF3). IR (ATR, cm-1): νmax = 1510, 1360, 1252, 1240, 1171, 1154, 1094, 1029, 983, 
909, 810, 737, 696. MS: m/z (%) 368 (M+ + 1, 100). HRMS (ESI): calc. for C19H21F3NO3+: 368.1468 
[M + H]+. Found: 368.1480. 
Cis-5-benzyloxy-3-(4-methoxybenzyl)-4-trifluoromethyl-1,3-oxazinane 9c  
White crystals. Mp 40 °C. Recrystallization from Hexane. Yield 65%. 1H NMR (400 
MHz, CDCl3): δ 3.54 (1H, q × d, J = 9.3, 5.4 Hz, CHCF3), 3.81 (3H, s, OCH3), 3.84-
3.97 (3H, m, OCHCH2O), 3.97 and 4.03 (2 × 1H, 2 × d, J = 13.4 Hz, N(HCH)Ar), 4.23 
(1H, d, J = 11.1 Hz, O(HCH)N), 4.52 (1H, d, J = 11.9 Hz, O(HCH)Ph), 4.55 (1H, d, J 
= 11.1 Hz, O(HCH)N), 4.61 (1H, d, J = 11.9 Hz, O(HCH)Ph), 6.86 and 7.22 (2 × 2H, 2 
× d, J = 9.1 Hz, NCH2(CHarom)ortho and O(CHarom)ortho), 7.30-7.37 (5H, m, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 55.3 (OCH3), 56.8 (NCH2Ar), 58.0 (q, J = 27.3 Hz, CHCF3), 66.6 (OCH2CHO), 
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67.0 (OCH2CHO), 71.6 (OCH2Ph), 79.7 (OCH2N), 113.9 (2 × O(CHarom)ortho), 125.6 (q, J = 284.1 
Hz, CHCF3), 127.7, 128.0, 128.5 (5 × HCarom), 129.8 (OCH2Carom,quat), 130.0 (2 × HCarom), 137.4 
NCH2Carom,quat), 159.1 (OCarom,quat). 19F NMR (376 MHz, CDCl3): δ -64.60 (3F, d, J = 9.3 Hz, CF3). 
IR (ATR, cm-1): νmax = 1610, 1509, 1247, 1150, 1103, 1032, 932, 731. MS (70 eV): m/z (%): 382 
(M+ + 1, 100). HRMS (ESI): calc. for C20H23F3NO3+: 382.1525 [M + H]+. Found: 382.1624. 
Synthesis of cis-5-benzyloxy-3-(4-methoxyaryl)-4-trifluoromethyl-1,3-oxazinan-2-ones 10 
As a representative example, the synthesis of cis-5-benzyloxy-3-(4-methoxyphenyl)-4-
trifluoromethyl-1,3-oxazinan-2-one 10a is described. To a solution of syn-2-benzyloxy-4,4,4-
trifluoro-3-(4-methoxyphenylamino)butan-1-ol 8a (0.10 g, 0.28 mmol, 1 equiv.) in dry THF (20 mL) 
was added triethylamine (0.06 g, 0.56 mmol, 2 equiv) at 0 °C. Ethyl chloroformate (0.12 g, 1.13 
mmol, 4 equiv) was added dropwise to the solution. The mixture was stirred at room temperature 
for four hours, the solvent was removed in vacuo, and the residue was redissolved in ethyl acetate 
(20 mL) and washed with water (2 x 20 mL). The aqueous phase was extracted with ethyl acetate 
(2 x 20 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent in vacuo 
afforded cis-5-benzyloxy-3-(4-methoxyphenyl)-4-trifluoromethyl-1,3-oxazinan-2-one 10a in 66% 
yield, which was further purified by means of recrystallization from ethanol to obtain a pure sample. 
Cis-5-benzyloxy-3-(4-methoxyphenyl)-4-trifluoromethyl-1,3-oxazinan-2-one 10a 
White crystals. Mp 141 °C. Recrystallization from EtOH. Yield 66%. 1H NMR 
(400 MHz, CDCl3): δ 3.81 (3H, s, OCH3), 4.32-4.43 (3H, m, CHCF3, 
CHO(HCH)O), 4.47-4.52 (1H, m, CHO(HCH)O), 4.67 and 4.75 (2 × 1H, 2 × d, 
J = 11.6 Hz, O(HCH)Ph), 6.90 and 7.14 (2 × 2H, 2 × d, J = 8.9 Hz, N(CHarom)ortho 
and O(CHarom)ortho), 7.35-7.43 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 55.5 (OCH3), 60.9 
(q, J = 28.0 Hz, CHCF3), 65.8 (CHOCH2O), 68.0 (CHOCH2O), 72.5 (OCH2Ph), 114.6 (2 × 
O(CHarom)ortho), 124.0 (q, J = 285.8 Hz, CF3), 128.0, 128.5, 128.7, 128.8 (7 × HCarom), 134.3, 136.1 
1 (CH2Carom,quat and NCarom,quat), 151.3 (OCarom,quat), 159.0 (C=O). 19F NMR (376 MHz, CDCl3): δ -
66.96 (3F, d, J = 7.7 Hz, CF3). IR (ATR, cm-1): νC=O = 1700, νmax = 1514, 1415, 1261, 1238, 1136, 
1167, 1036, 827, 747. MS: m/z (%) 382 (M+ + 1, 100). HRMS (ESI): calc. for C19H19F3NO4+: 
382.1261 [M + H]+. Found: 382.1261. 
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Cis-5-benzyloxy-3-(4-methoxybenzyl)-4-trifluoromethyl-1,3-oxazinan-2-one 10c  
Brownish oil. Rf = 0.10 (Hex/EtOAc, 6/1). Yield 94%. 1H NMR (400 MHz, CDCl3): δ 
3.71-3.82 (2H, m, CHCF3 and CHO), 3.85 (3H, s, OCH3), 3.89 (1H, d, J = 14.9 Hz, 
(HCH)N), 4.20-4.25 and 4.31-4.37 (2 × 1H, 2 × m, (HCH)OC=O), 4.36 and 4.54 (2 × 
1H, 2 × d, J = 11.9 Hz, O(HCH)Ph), 5.39 (1H, d, J = 14.9 Hz, (HCH)N), 6.89 (2H, d, 
J = 8.6 Hz, O(CHarom)ortho), 7.09-7.12 (2H, m, CHarom), 7.14 (2H, d, J = 8.6 Hz, 
NCH2(CHarom)ortho), 7.28-7.30 (3H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 51.9 (ArCH2N), 
53.4 (q, J = 28.3 Hz, CHCF3), 55.3 (OCH3), 65.7 (CH2OC=O), 67.2 (CHO), 72.2 (OCH2Ph), 114.5 
(2 × O(HCarom)ortho), 124.8 (q, J = 286.2 Hz, CF3), 127.0 (NCH2Carom,quat), 128.0, 128.6, 128.7, 129.9 
(7 × HCarom), 135.8 (OCH2Carom,quat), 151.8 (OCarom,quat), 159.7 (C=O). 19F NMR (376 MHz, CDCl3): 
δ -67.23 (3F, d, J = 7.3 Hz, CF3). IR (ATR, cm-1): νC=O = 1704, νmax = 1513, 1454, 1247, 1207, 
1164, 1095, 1030, 817, 747, 699. MS (70 eV): m/z (%) 396 (M+ + 1, 100). HRMS (ESI): calc. for 
C20H21F3NO4+: 396.1417 [M + H]+. Found: 396.1412. 
Synthesis of syn-N-(3-benzyloxy-1,1,1-trifluoro-4-hydroxybut-2-yl)-2-chloro-N-(4-
methoxyaryl)acetamides 12 
As a representative example, the synthesis of syn-N-(3-benzyloxy-1,1,1-trifluoro-4-hydroxybut-2-
yl)-2-chloro-N-(4-methoxyphenyl)acetamide 12a is described. To a solution of syn-2-benzyloxy-
4,4,4-trifluoro-3-(4-methoxyphenylamino)butan-1-ol 8a (80 mg, 0.23 mmol, 1 equiv) in dry CH2Cl2 
(20 mL) was added triethylamine (0.06 mL, 0.46 mmol, 2 equiv) at 0 °C. Chloroacetyl chloride 
(0,02 mL, 0.26 mmol, 1.2 equiv) was added dropwise to the solution. The mixture was stirred at 
room temperature for four hours, after which water (20 mL) was added, followed by extraction with 
CH2Cl2 (3 x 10 mL) and washing of the combined organic phases with brine (2 x 10 mL). Drying 
(MgSO4), filtration of drying agent, and removal of the solvent in vacuo afforded syn-N-(3-
benzyloxy-1,1,1-trifluoro-4-hydroxybut-2-yl)-2-chloro-N-(4-methoxyphenyl)acetamide 12a in 86% 
yield, which was further purified by means of column chromatography (Hex/EtOAc, 8/1) in order 
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Syn-N-(3-benzyloxy-1,1,1-trifluoro-4-hydroxybut-2-yl)-2-chloro-N-(4-
methoxyphenyl)acetamide 12a  
Yellow oil. Rf = 0.23 (Hex/EtOAc, 8/1). Yield 86%. 1H NMR (400 MHz, 
CDCl3): δ 3.74 (3H, s, OCH3), 3.89-3.97 (3H, m, CH2Cl and CHCF3), 4.10-
4.16 (3H, m, (HCH)OH and CHO), 4.36 (1H, d × d × d, J = 9.3, 9.3, 6.5 Hz, 
(HCH)OH), 4.66 and 4.70 (2 × 1H, 2 × d, J = 11.1 Hz, O(HCH)Ph), 6.64 and 
6.77 (2 × 2H, 2 × d, J = 8.9 Hz, N(CHarom)ortho and O(CHarom)ortho), 7.34-7.39 (5H, m, CHarom). 13C 
NMR (100.6 MHz, CDCl3): δ 40.4 (CH2Cl), 55.7 (OCH3), 56.9 (q, J = 28.8 Hz, CHCF3), 64.0 
(CH2OH), 73.6 (CHO), 73.8 (OCH2Ph), 115.0, 115.1 (4 × HCarom,ortho), 125.5 (q, J = 284.9 Hz, CF3), 
128.3, 128.4, 128.6 (5 × HCarom), 136.9 (CH2Carom,quat), 140.1 (NCarom,quat), 153.1 (OCarom,quat), 166.7 
(C=O). 19F NMR (376 MHz, CDCl3): δ -72.93 (3F, d, J = 7.8 Hz, CF3). IR (ATR, cm-1): νOH = 3396, 
νCO = 1759, νmax = 1514, 1234, 1168, 1130, 1026, 820, 698. MS (70 eV): m/z (%) 432 (M+ + 1, 
100). HRMS (ESI): calc. for C20H21ClF3NO4+: 432.1111 [M + H]+. Found: 432.1202. 
Syn-N-(3-benzyloxy-1,1,1-trifluoro-4-hydroxybut-2-yl)-2-chloro-N-(4-
methoxybenzyl)acetamide 12c 
Yellow oil. Rf = 0.26 (Hex/EtOAc, 8/1). Yield 83%. 1H NMR (400 MHz, CDCl3): δ 
2.11 (1H, s (broad), OH), 3.12 (1H, q × d, J = 7.5, 1.7 Hz, CHCF3), 3.81 (1H, d, J 
= 12.8 Hz, (HCH)N), 3.82 (3H, s, OCH3), 3.86 and 3.92 (2 × 1H, 2 × d, J = 15.0 
Hz, (HCH)Cl), 3.98 (1H, t × d, J = 6.4, 1.7 Hz, CHO), 4.03 (1H, d, J = 12.8 Hz, 
(HCH)N), 4.28 and 4.31 (2 × 1H, 2 × (d × d), J = 10.9, 10.9, 6.4 Hz, (HCH)OH), 
4.62 (2H, s, OCH2Ph), 6.88 and 7.25 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho), 7.32-7.39 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 40.5 (CH2Cl), 50.7 
(NCH2Ar), 55.3 (OCH3), 57.2 (q, J = 26.2 Hz, CHCF3), 64.5 (CH2OH), 73.6 (OCH2Ph), 74.3 (q, J 
= 2.5 Hz, CHO), 113.8 (2 × O(HCarom)ortho), 126.5 (q, J = 287.7 Hz, CF3), 128.08, 128.10, 128.5, 
129.9 (7 x HCarom), 131.2 (Carom,quatN), 137.3 (Carom,quatCH2O), 158.9 (Carom,quatO), 166.7 (C=O). 19F 
NMR (376 MHz, CDCl3): δ -69.91 (3F, d, J = 7.5 Hz, CF3). IR (ATR, cm-1): νOH = 3371, νCO = 1762, 
νmax = 1512, 1246, 1130, 1027, 830, 736, 697. MS (70 eV): m/z (%) 446 (M+ + 1, 100). HRMS 
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Use of 3-hydroxy-4-(trifluoromethyl)azetidin-2-ones as versatile building blocks for 
the preparation of trifluoromethyl-containing aminopropanes, 1,3-oxazinan(-2-




3-Hydroxy-4-(trifluoromethyl)azetidin-2-ones were synthesized from the corresponding 3-
benzyloxy-β-lactams and successfully transformed into new 3-chloro-4-(trifluoromethyl)azetidin-
2-one building blocks. The latter chlorides were shown to be eligible precursors for the 
construction of CF3-containing aminopropanes, 1,3-oxazinanes, 1,3-oxazinan-2-ones and 
aziridines. In addition, 3-hydroxy-4-(trifluoromethyl)azetidin-2-ones proved to be interesting 
substrates for the synthesis of novel 3-[2,2,2-trifluoro-1-(arylamino)ethyl]-1,4-dioxan-2-ones via 
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In light of the favorable effects of fluorine introduction, β-lactams bearing a trifluoromethyl group 
comprise interesting entities for the construction of novel targets with promising bioactivities. The 
most important synthetic routes toward 4-(trifluoromethyl)azetidin-2-ones using the building block 
strategy are based on [2+2]-ketene-imine cyclocondensations (Staudinger synthesis), enolate-
imine cyclocondensations, intramolecular N-acylations, intramolecular C-alkylations, ring 
expansions of aziridines, the Kinugasa reaction and the Reformatsky reaction.12 However, the 
reactivity study of 4-(trifluoromethyl)azetidin-2-ones toward both ring opening and ring 
transformation for the preparation of trifluoromethylated amines and heterocyclic compounds has 
received very little attention up to now, in sharp contrast to their non-fluorinated analogs.14a,32,46,16b  
In continuation of our studies on the deployment of 4-trifluoromethyl-β-lactams as new building 
blocks in organic chemistry, we recently embarked on the synthesis and synthetic application of 
3-hydroxy-4-trifluoromethyl-β-lactams. Within that framework, [2+2]-cyclocondensation between 
2,2,2-trifluoroethan-1-imines and 2,2,2-trifluoro-1-(amino)ethan-1-ols, prepared from the 
commercially available 1-ethoxy-2,2,2-trifluoroethanol under Dean-Stark conditions, and the 
ketene derived from benzyloxyacetyl chloride furnished 3-benzyl-4-trifluoromethyl-β-lactams. The 
latter β-lactams were subjected to hydrogenolysis (Pd/C) to provide a convenient access to 3-
hydroxy-4-CF3-β-lactams. The aptitude of these systems with respect to ring-opening and ring-
contraction reactions via 3-chloro-β-lactam intermediates was explored to enable an entry to 
functionalized CF3-containing aminopropane and aziridine systems. In addition, manipulation of 
the alcohol group of 3-hydroxy-4-CF3-β-lactams enabling the construction of CF3-containing 
dioxan-2-ones via initial O-allylation was investigated. 
 
2. Synthesis of 3-hydroxy-4-CF3-β-lactam building blocks 
 
In addition to the preparation of 3-benzyloxy-4-CF3-β-lactams 2a-b as described in our previous 
part, a set of four new 3-benzyloxy-4-CF3-β-lactams 2c-f was successfully synthesized, with slight 
modifications in the procedure. In the first step, 1-ethoxy-2,2,2-trifluoroethanol 1 was condensed 
with (a) isopropylamine in dichloromethane in the presence of MgSO4 as drying agent or with (b) 
different arylamines (p-phenetidine, p-toluidine, 4-iodoaniline) in toluene in the presence of a 
catalytic amount of p-toluenesulfonic acid under Dean-Stark conditions. The resulting mixtures of 
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imines and their hemiaminal precursors were immediately used for the Staudinger synthesis, 
yielding cis-3-benzyloxy-β-lactams 2c-f in acceptable yields (Scheme 1, Table 1). Besides the 
expected cis-β-lactams 2, minor to rather significant amounts of trans-isomers of 2 were also 
detected (2-46%). The formation of these trans-β-lactams was confirmed based on 1H NMR 
analysis, showing a coupling constant of 1-2 Hz (CDCl3) between the two vicinal protons at the 
C3 and C4 position, as opposed to cis-β-lactams (5-6 Hz, CDCl3).39 The previously reported 
synthesis of β-lactams 2a-b was achieved through a [2+2]-ketene-imine cyclocondensation 
between a trifluoromethylaldimine and benzyloxyacetyl chloride in the presence of Et3N. Under 
these conditions, the cis-β-lactams 2a-b were obtained in a relatively high stereoselectivity 
(cis/trans 95-98/5-2). However, the relative amount of trans-β-lactams in the 2c-f cases was higher 
compared to those of 2a-b (cis/trans 54-78/46-22, Table 1). This stereoselectivity issue might be 
due to the outcome of the cyclocondensation reaction between either a hemiaminal or a mixture 
of hemiaminal and imine, with benzyloxyacetyl chloride in the presence of Et3N in the synthetic 
procedure toward β-lactams 2c-f. It should indeed be noted that the treatment of 1-ethoxy-2,2,2-
trifluoroethan-1-ol 1 with isopropylamine (a) led to 2,2,2-trifluoro-1-(isopropylamino)ethan-1-ol, 
whereas the use of arylamines (b) afforded a mixture of hemiaminals and imines. The cis-β-
lactams 2a-f were easily isolated through chromatography and subjected to hydrogenolysis (Pd/C) 
to produce the corresponding cis-alcohols 3a-f in excellent yields (Scheme 1, Table 1). In the case 
of cis-3-benzyloxy-1-(4-iodophenyl)-4-(trifluoromethyl)azetidin-2-one 2d, the hydrogenolysis 
furnished cis-3-benzyloxy-1-phenyl-4-(trifluoromethyl)azetidin-2-one instead of the expected cis-
3-hydroxy-1-(4-iodophenyl)-4-(trifluoromethyl)azetidin-2-one, probably due to hydrogenolytic 
scission of the Carene-I bond over the Pd/C catalyst.63 Because the high adsorption of the in situ 
produced iodide anion led to a decrease in the catalytic activity of Pd/C, the resulting cis-3-
benzyloxy-1-phenyl-4-(trifluoromethyl)azetidin-2-one was filtered through Celite® prior to 
debenzylation.63 The latter was finally transformed into the corresponding cis-3-hydroxy-1-phenyl-
4-(trifluoromethyl)azetidin-2-one 3d, in an overall yield of 84%.  
 
 





Table 1: Isolated yields of compounds 2, 3 and cis:trans ratios of compounds 2 
Entry R Compound 2 cis:transa 2 Compound 3 
1 4-MeOC6H4 2a (49%) 98:2 3a (87%) 
2 4-MeOC6H4CH2 2b (72%) 95:5 3b (93%) 
3 4-C2H5OC6H4 2c (47%) 78:22 3c (94%) 
4 4-IC6H4/C6H5 2d (35%)b 54:46 3d (84%)c 
6 4-MeC6H4 2e (31%) 67:33 3e (87%) 
7 iPr 2f (59%) 75:25 3f (97%) 
aDetermined by 19F NMR spectroscopy (CDCl3) of the crude reaction mixture 2 
bR = 4-IC6H4 
cR = C6H5 
 
3. Reactivity profile of 3-hydroxy-4-CF3-β-lactams 
 
3.1. Ring opening and ring transformation of 3-hydroxy-4-CF3-β-lactams via 3-chloro-β-
lactams 
In the next part, the eligibility of these 3-hydroxy-4-CF3-β-lactams 3 as building blocks for the 
synthesis of functionalized trifluoromethyl-substituted compounds was assessed. In that respect, 
representative cis-3-hydroxy-4-(trifluoromethyl)azetidin-2-ones 3a,b were transformed into trans-
3-chloro-β-lactams 4a,b in excellent yields (91-97%, Scheme 2) upon treatment with 2 equiv of 
Ph3P and a small amount of NaHCO3 catalyst in CCl4 under reflux for 10 hours.64 The trans 
configuration of β-lactams 4a,b was confirmed based on the 1H NMR spectrum (JH3,H4 = 1-2 Hz, 
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CDCl3), implying a clean SN2 process. In order to simplify the synthetic procedure, the preparation 
of β-lactams 4 was attempted directly through the Staudinger synthesis using the same imines 
combined with chloroacetyl chloride and a variety of bases (2,6-lutidine, Et3N, pyridine, proton 
sponge), in analogy with the synthesis of their non-fluorinated β-lactam counterparts.65 However, 
this direct approach appeared to be unsuccessful for the preparation of trifluoromethylated β-
lactams 4. Therefore, a short detour was necessary, utilizing alcohols 3a,b as valuable synthons 
to obtain the desired β-lactams 4a,b. Besides this method, two complementary approaches have 
been reported to furnish 3-chloro-4-CF3-β-lactam analogs, either by intramolecular cyclization of 
the corresponding β-amino esters39 or by ring expansion of the corresponding aziridines.41 The 
reactivity of 3-chloro-4-CF3-β-lactams is virtually unexplored in the literature to date, in contrast to 
3-chloro-β-lactams having no trifluoromethyl group at the C4 position. In that respect, the selective 
reduction of trans-3-chloro-4-CF3-β-lactams 4a,b by means of monochloroalane was evaluated to 
provide an entry into trans-3-chloro-2-(trifluoromethyl)azetidines 5a,b. Treatment of β-lactams 
4a,b with two equiv of monochloroalane, in diethyl ether at room temperature for five minutes, 
produced the desired azetidines 5a,b in good yields (54-78%, Scheme 2). In contrast to the 
reduction of 3-non-chlorinated 4-CF3-β-lactams, the use of monochloroalane for the reduction of 
3-chloro-2-(trifluoromethyl)azetidin-2-ones 4 required precise and optimized reaction conditions 
(time, temperature and molar equivalents of the reductant) to limit the formation of side products 
due to ring opening. Having these azetidines 5 in hand, their eligibility for the synthesis of a 
diversity of functionalized trifluoromethyl-substituted aminopropanes was evaluated. N-Alkylation 
of 3-chloro-2-(trifluoromethyl)azetidines 5 was performed prior to ring opening, upon treatment 
with trimethyloxonium tetrafluoroborate, furnishing the corresponding azetidinium salts 6a,b in a 
quantitative way (Scheme 2). Subsequently, these salts were subjected to ring opening by using 
an oxygen and nitrogen nucleophile, providing a convenient entry toward a variety of α-
(trifluoromethyl)amines. In particular, azetidinium salts 6 were treated with four equiv of sodium 
acetate or tert-butylamine, affording anti-2-chloro-3-amino-4,4,4-trifluorobutyl acetates 7a,b and 
anti-2-chloro-4,4,4-trifluorobutane-1,3-diamines 8a,b, respectively (Scheme 2), accompanied by 
a certain amount of azetidines 5 (20-47%). These results can be rationalized by considering 
competition between a ring-opening reaction at the C4 position and a N-demethylation reaction of 
azetidinium salts 6a,b by the deployed nucleophiles.66 Sodium acetate and tert-butylamine were 
selected as nucleophiles in analogy with previous investigations on the ring opening of cis-3-
alkoxy-2-(trifluoromethyl)azetidines. In line with our previous findings on the chemistry of 2-CF3-
azetidinium ions,18 ring opening of trans-3-chloro-2-(trifluoromethyl)azetidinium salts 6 proceeded 
regiospecifically at the non-substituted C4 position, in contrast with the reactivity of azetidinium 
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salts bearing other types of electron-withdrawing groups (acyl, cyano). It is also noteworthy that 
the treatment of non-chlorinated 2-CF3-azetidinium salts with nucleophiles exclusively led to a 






In analogy with 3-non-chlorinated 4-(trifluoromethyl)azetidin-2-ones, 3-chloro-β-lactams 4a,b 
might be valuable precursors for the stereoselective synthesis of fluorinated β-amino alcohols. In 
that respect, trans-3-chloro-4-(trifluoromethyl)azetidin-2-ones 4a,b were subjected to a LiAlH4-
mediated reductive ring opening, using 1 equiv of LiAlH4 in Et2O at room temperature for five 
minutes, furnishing the corresponding anti-3-amino-2-chloro-4,4,4-trifluorobutanols 9a,b in 
excellent yields (90-96%, Scheme 3). It should be noted that utilizing a stoichiometric amount of 
LiAlH4 and a precise timing is required to avoid the generation of undesired side products. The 
use of 2 equiv of LiAlH4 in different solvents (Et2O, THF) at room temperature or under reflux only 
led to decomposition of the starting material 4, as opposed to the results obtained upon treatment 
of non-CF3-substituted 2-chloro-β-lactams with LiAlH4.17 CF3-Substituted 1,3-aminoalcohols have 
been recognized as potential substrates for the preparation of a wide range of interesting 
trifluoromethyl-containing azaheterocyclic compounds.67 For that purpose, the cyclization of anti-
3-amino-2-chloro-4,4,4-trifluorobutanols 9a,b was pursued to generate novel trifluoromethylated 
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oxazinanes and oxazinan-2-ones. As such, the treatment of 3-aminopropan-1-ols 9a,b with 
formaldehyde (37% in water) in THF resulted in the corresponding new trans-5-chloro-4-
trifluoromethyl-1,3-oxazinanes 10a,b in 54-80% yield (Scheme 3). 1,3-Oxazinane scaffolds have 
been encountered as a core structure in many natural products and pharmaceuticals, because 
they possess a wide spectrum of biological activities such as anti-HIV, antibacterial, antitumor, 
antituberculosis and fungicidal properties.68 Hence, a number of methods has been developed to 
enable their synthesis. However, reports on the synthesis of 1,3-oxazinanes with new functional 
groups remain rather scarce in the literature.67b,18 In that respect, the deployment of β-
aminoalcohols bearing a trifluoromethyl group might provide interesting trifluorinated 1,3-
oxazinanes with promising biological properties.  
In addition, the cyclization of 3-aminopropan-1-ols 9a,b was performed utilizing three times one 
equiv of ethyl chloroformate and two equiv of triethylamine in CH2Cl2 at room temperature for three 
hours, furnishing the corresponding trans-5-chloro-4-trifluoromethyl-1,3-oxazinan-2-ones 11a,b in 
29-85% yield (Scheme 3).69 1,3-Oxazinan-2-ones are of interest due to their valuable biological 
activities as well. For example, they have been employed in the treatment of Alzheimer’s disease, 
in herbicides with excellent crop-weed selectivity, in the treatment of diseases related to kinase 
activity, and in the regulation of cholesterol.70,69 Therefore, new trans-5-chloro-4-trifluoromethyl-
1,3-oxazinan-2-ones 11a,b might possess interesting properties for further applications. 
 
Scheme 3 
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In addition, the reactivity of trans-3-chloro-4-CF3-β-lactams 4a,b was explored to effect ring 
contraction toward the synthesis of 2-substituted 3-(trifluoromethyl)aziridines. According to a 
previous study from our group, reductive ring contraction of trans-4-aryl-3-chloroazetidin-2-ones 
toward aziridines was directly achieved utilizing LiAlH4 in THF or Et2O.17a,65b However, the 
analogous reduction of trans-3-chloro-4-CF3-β-lactams 4 with 1-2 equiv of LiAlH4 in Et2O at room 
temperature or under reflux for two hours did not furnish the desired aziridines 12. This could be 
due to the strong inductive effect of the trifluoromethyl group, rendering the nitrogen atom less 
basic, thus prohibiting the cyclization. To provide access to the aziridines 12a,b, a base-induced 
ring closure of amino alcohols 9a,b upon treatment with 0.8-1 equiv of tBuOK in THF was explored 
successfully (Scheme 3).71 On the other hand, treatment of trans-3-chloro-4-CF3-azetidine-2-ones 
4a,b with 2 equiv of KOH in methanol under reflux for 20 min afforded the corresponding aziridine-
2-carboxylates 13a,b in 25-73% yield. Although 2-substituted 3-(trifluoromethyl)aziridines 
constitute eligible substrates for the synthesis of valuable fluorinated compounds, synthetic 
pathways toward these structures remain scarce, and most of these methods use diazo 
compounds or require harsh reaction conditions. For instance, Akiyama et al. have reported the 
preparation of cis-2-hydroxymethyl-3-(trifluoromethyl)aziridine 12a from the corresponding CF3-
substituted aziridine carboxylate, which was also derived from a diazoacetate.72 In recent research 
of our group, a novel stereoselective approach toward the synthesis of trans-2-substituted 3-
(trifluoromethyl)aziridines starting from the commercially available trifluoromethyl ketones has 
been developed.19 The use of trans-3-chloro-4-CF3-β-lactams as versatile substrates for the 
synthesis of trifluoromethylated aziridines offers a new approach to this interesting aziridine 
subclass. 
 
3.2. Ring-transformation study of 3-hydroxy-4-CF3-β-lactams toward 3-[2,2,2-trifluoro-1-
(arylamino)ethyl]-1,4-dioxan-2-ones 
In the final part of this study, alcohols 3a-f were evaluated as building blocks toward the synthesis 
of novel CF3-containing 1,4-dioxan-2-ones. In that respect, cis-alcohols 3a-f were subjected to 
initial O-allylation, yielding the corresponding cis-3-allyloxy-4-(trifluoromethyl)azetidin-2-ones 14a-
f in high yields (71-95%, Table 2) upon treatment with 1.6 equiv of allyl bromide in the presence 
of TBAI as a catalyst, under basic conditions (Scheme 4).73 The direct preparation of β-lactams 
14 was attempted using the Staudinger synthesis between the corresponding imine and 
allyloxyacetyl chloride, in accordance with the preparation of their non-fluorinated β-lactam 
counterparts.21 However, this approach only resulted in a complex mixture instead of the desired 
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products 14. In the following step, cis-3-allyloxy-4-(trifluoromethyl)azetidin-2-ones 14a-f were 
subjected to an ozonolysis reaction followed by a reductive workup with 2.5 equiv of Me2S, 
providing the corresponding aldehyde intermediates. These aldehydes were immediately reduced 
with 2.5 equiv of BH3 (1M in Et2O) in THF at room temperature for three hours, furnishing the 
corresponding cis-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-ones 15a-f in yields of 47-
95% (Table 2).21 It should be noted that the use of BH3 (1M in Et2O) was observed to be superior 
to the use of NaBH4 or LiBH4 in this reductive reaction, because attempts with the latter agents 
were always accompanied by a reductive β-lactam ring opening. 
Due to the combination of the constrained β-lactam ring system and a nucleophilic alcohol group 
at a remote position, 3-(2-hydroxyethoxy)- and 3-(2-hydroxyethyl)-β-lactams have been 
documented to undergo ring rearrangement to generate five- and six-membered 
azaheterocycles.21,74 Hence, the potency of cis-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-
ones 15a-f with respect to ring transformation toward 1,4-dioxan-2-ones 16 was evaluated in the 
next step. In order to transform β-lactams 15a-f into ring-rearranged products 16, a set of different 
reaction conditions was assessed. In particular, treatment of β-lactams 15 with a variety of bases 
(NaH, pyridine, Et3N, LiOH) in different solvents (THF, toluene, DMF, CH2Cl2) under different 
temperatures (0 °C, r.t., reflux) led to either complex mixtures or recuperation of the substrates. 
Fortunately, treatment of cis-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-ones 15 with an 
excess of K2CO3 in toluene under reflux proved to be optimal to enable the desired intramolecular 
ring-opening reaction, furnishing an inseparable diastereomeric mixture of 3-[2,2,2-trifluoro-1-
(arylamino)ethyl]-1,4-dioxan-2-ones 16 in excellent yields (71-98%, Scheme 4, Table 2).21,74a Only 
in the case of β-lactams 15b,f, no ring transformation products 16b,f were observed. These results 
show that the presence of electron-withdrawing substituents at the N1 position might accelerate 
the intramolecular ring opening of β-lactams to give trifluoromethylated 1,4-dioxan-2-ones 16. 
Indeed, the stabilizing effect of an aromatic ring at nitrogen in 15a,c-e promotes the formation of 
the corresponding nitrogen anion after ring opening, whereas the presence of an electron-donating 
alkyl group in 15b,f impedes this process.  





Table 2: Isolated yields of compounds 14, 15, 16 and syn:anti ratios of compounds 16 
Entry R Compound 14 Compound 15 Compound 16 d.r. (16) 
1 4-MeOC6H4 14a (94%) 15a (72%) 16a (81%) 78:22 
2 4-MeOC6H4CH2 14b (95%) 15b (77%) 16b (0%) - 
3 4-C2H5OC6H4 14c (84%) 15c (72%) 16c (86%) 72:28 
4 C6H5 14d (77%) 15d (95%) 16d (71%) 69:31 
5 4-MeC6H4 14e (71%) 15e (63%) 16e (98%) 75:25 
6 iPr 14f (79%) 15f (47%) 16f (0%) - 
 
In the course of our study on CF3-substituted β-lactams, we realized that a CF3-group does 
significantly affect the behavior of these molecules. Therefore, in order to gain insight into the 
influence of the trifluoromethyl group with respect to intramolecular cyclization, cis-3-(2-
hydroxyethoxy)-1,4-bis(4-methoxyphenyl)azetidin-2-one 19 was synthesized (Scheme 5), which 
bears a 4-methoxyphenyl group at the C4 position (instead of the trifluoromethyl group). This 
compound 19 was prepared from the corresponding cis-3-allyloxy-1,4-bis(4-
methoxyphenyl)azetidin-2-one 18, derived from alcohol 17,75 using the above-described 
procedure (Scheme 5). The preparation of β-lactam 18 has also been reported by Zarei upon the 
treatment of allyloxyacetic acid with Schiff base and phosphonitrilic chloride 
(hexachlorotriphosphazene) in the presence of triethylamine.76 Surprisingly, the treatment of cis-
3-(2-hydroxyethoxy)-1,4-bis(4-methoxyphenyl)azetidin-2-one 19 with an excess of K2CO3 in 
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toluene under reflux for four days solely led to recuperation of the starting material 19. As K2CO3 
might not be strong enough as a base to realize nucleophilic ring opening in this case, a more 
potent base (NaH) was used. However, the intramolecular cyclization toward 1,4-dioxan-2-one 20 
was never observed, and this approach resulted in either the recovery of starting material 19 or a 
complex mixture (Scheme 5). This observation indicates that the specific combination of the 
aromatic group at N1 and the CF3 group at C4, as in cis-3-(2-hydroxyethoxy)-4-
(trifluoromethyl)azetidin-2-ones 15, is important for the base-induced transformation into CF3-
substituted 1,4-dioxan-2-ones 16. It should be stressed that the synthetic chemistry concerning 
1,4-dioxan-2-one scaffolds, starting from monocyclic β-lactams, has been sporadically 
documented in the literature (as side products).21 These 1,4-dioxan-2-one derivatives have been 
mainly synthesized from 1,2-diol,77 glycolic acid78 and glycerol derivatives.79 In addition, 1,4-
dioxan-2-one derivatives play an important role as intermediates in the synthetic field of polymers, 
corrosion inhibitors and biomaterials.22 In that respect, the convenient approach toward CF3-
substituted 1,4-dioxan-2-ones 16 using CF3-substituted β-lactam alcohols 15 as building blocks 





Because the resulting diastereoisomers 16 could not be separated by means of column 
chromatography on silica gel, preparative HPLC (Supelco Ascentis C18; H2O/CH3CN) and 
recrystallization (CH2Cl2/Et2O 1/1 or Et2O), other attempts were made to determine the relative 
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stereochemistry of 3-[2,2,2-trifluoro-1-(arylamino)ethyl]-1,4-dioxan-2-ones 16. For that reason, 
three additional experiments were performed to examine the behavior of cis-β-lactams 15 toward 
intramolecular cyclization under basic conditions. In a first experiment, the intramolecular 
cyclization of trans-1-(4-ethoxyphenyl)-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-one 21 
(the trans counterpart of cis-β-lactam 15c, derived from the corresponding trans-1-(4-
ethoxyphenyl)-3-allyloxy-4-(trifluoromethyl)azetidin-2-one in an overall yield of 11%) as a model 
compound toward 3-{1-[(4-ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-one 16c was 
tested. Remarkably, the use of identical reactions conditions (excess of K2CO3 in toluene under 
reflux for five days) applied to trans-1-(4-ethoxyphenyl)-3-(2-hydroxyethoxy)-4-
(trifluoromethyl)azetidin-2-one 21 also led to a mixture of two isomers 16c in a ratio of 66:34, 





In a second experiment, the pure diastereoisomer cis-3-allyloxy-1-(4-ethoxyphenyl)-4-
(trifluoromethyl)azetidin-2-one 14c was treated with an excess of K2CO3 in toluene under reflux 
for five days, resulting in a cis/trans mixture of 3-allyloxy-1-(4-ethoxyphenyl)-4-
(trifluoromethyl)azetidin-2-one in a ratio of 40:60 (cis:trans). In the last experiment, the 
diastereomeric mixture of 3-{1-[(4-ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-one 16c 
(d.r. 72:28) was treated with an excess of K2CO3 in toluene under reflux for one day, which did not 
affect the diastereomeric ratio. 
Based on these experimental results, we propose that a dynamic equilibrium between 
intramolecular ring opening and epimerization of cis-alcohols 15 occurred in the presence of 
K2CO3, which led to the corresponding (3S,1’R;3R,1’S)-3-[2,2,2-trifluoro-1-(arylamino)ethyl]-1,4-
dioxan-2-ones 16 (as major products) and trans-alcohols 15. Then, trans-alcohols 15 were in turn 
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subjected to intramolecular ring opening, leading to the corresponding (3R,1’R;3S,1’S)-3-[2,2,2-
trifluoro-1-(arylamino)ethyl]-1,4-dioxan-2-ones 16 (as minor isomers). In addition to the 
experiments, DFT calculations were performed to assess the stability of the diastereomeric pairs. 
Relative Gibbs free energies indicate that (3S,1’R;3R,1’S)-16 is more stable than (3R,1’R;3S,1’S)-
16 if the mixture of the two diastereoisomers is considered (see SI). Hence, 3-(2,2,2-trifluoro-1-
aminoethyl-1,4-dioxan-2-ones (3S,1’R)- and (3R,1’S)-16 are proposed to be the major products 
in the inseparable mixture of diastereoisomers (Fig. 1). 
 
 




In conclusion, a set of cis-3-hydroxy-4-(trifluoromethyl)azetidin-2-ones was effectively synthesized 
and successfully deployed as versatile new building blocks for the construction of a variety of CF3-
containing amines and heterocyclic molecules. To that end, cis-3-hydroxy-4-CF3-β-lactams were 
transformed into trans-3-chloro-4-CF3-β-lactams, which served as eligible substrates for the 
preparation of α-CF3-substituted aminopropane derivatives through a regiospecific ring opening 
of intermediate azetidinium salts. Besides, new trans-5-chloro-4-trifluoromethyl-1,3-oxazinanes 
and trans-5-chloro-4-trifluoromethyl-1,3-oxazinan-2-ones were produced through cyclization of 
trifluoromethylated γ-amino alcohols, with formaldehyde or ethyl chloroformate, respectively. 
Moreover, 2-substituted 3-trifluoromethylated aziridines were synthesized, either by base-induced 
ring closure of γ-amino alcohols or upon direct treatment of 3-chloro-β-lactams with KOH. In 
addition, 3-hydroxy-4-(trifluoromethyl)azetidin-2-ones proved to be suitable substrates for the 
synthesis of novel 3-[2,2,2-trifluoro-1-(arylamino)ethyl]-1,4-dioxan-2-ones in high yields through 
ring rearrangement. 
 




To gain an insight into the scope of the intramolecular ring rearrangement of monocyclic β-lactams 
bearing a nucleophilic moiety at the remote C3 position, cis-3-(2-hydroxyethoxy)-4-
(trifluoromethyl)azetidin-2-ones 15 could be converted into cis-3-(2-aminoethoxy)-4-
(trifluoromethyl)azetidin-2-ones 23 (Scheme 7).21 In that respect, the azides 22 could be 
synthesized upon treatment of alcohols 15 with MsCl in the presence of Et3N, followed by 
substitution of the resulting mesylates with NaN3. Then, Staudinger reduction of latter azides with 
triphenylphosphane could result in the free amines 23, which might be suitable for a base-induced 
rearrangement toward trifluoromethylated morpholin-3-one derivatives 24. Morpholin-3-one 
chemistry is of significant importance due to their broad range of pharmacological activities 
including analgesic, anti-inflammatory, anticancer, antidepressant and HIV-protease inhibitor 
activity.80 The search for new, functionalized morpholin-2-one derivatives remains a relevant issue 
in medicinal chemistry, thus CF3-substituted morpholin-3-ones 24 attained in this way could 





6. Experimental details 
 
General methods  
 
The ozonolysis reaction was performed with an Ozonia Triogen Model LAB2B laboratory ozone 
generator, connected to a Bronkhorst Flow-Bus E-7000 type mass flow meter to control the dry 
air inflow and an Anseros Ozomat Model GM Non-Dispersive UV-analyzer to measure the ozone 
concentration. 
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Synthesis of 3-benzyloxy-4-(trifluoromethyl)azetidin-2-ones 2 
To a solution of 1-ethoxy-2,2,2-trifluoroethanol (1.00 g, 0.82 mL, 6,94 mmol, 1 equiv) in toluene 
(30 mL) was added p-phenetidine (0.76 g, 0.71 mL, 5.55 mmol, 0.8 equiv) and an amount of p-
toluenesulfonic acid catalyst (13.2 mg, 0.07 mmol, 0.01 equiv). The resulting mixture was heated 
at reflux temperature for three hours under Dean-Stark conditions, affording N-(4-ethoxyphenyl)-
2,2,2-trifluoroethan-1-imine in high purity (> 90 % based on NMR). Due to its hydrolytic instability, 
after evaporation of the crude mixture, the resulting product (1.23 g, 5.67 mmol, 1equiv) was 
immediately dissolved in in dry CH2Cl2 (50 mL) at 0 °C under argon atmosphere and triethylamine 
(2.87 g, 3.95 mL, 28.4 mmol, 5 equiv) was added to the solution. Benzyloxyacetyl chloride (4.17 
g, 3.57 mL, 22.68 mmol, 4 equiv) was then added dropwise to the reaction mixture. After stirring 
the reaction mixture for three days under reflux, water (20 mL) was added to the mixture. 
Extraction with CH2Cl2 (3 × 20 mL), washing with brine (3 × 20 mL), drying (MgSO4), filtration of 
the drying agent and evaporation of solvent afforded a mixture of two isomers cis:trans in a ratio 
of 78:22. The two isomers were separated by means of column chromatography on silica gel 
(PE/EtOAc, 9/1), then recrystallization from EtOH was performed to obtain analytically pure cis-3-
benzyloxy-1-(4-ethoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 2c (47%) and trans-3-benzyloxy-
1-(4-ethoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 2c (10%). 
Cis-3-benzyloxy-1-(4-ethoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 2c  
White crystals. Mp 83 °C. Rf = 0.23 (PE/EtOAc, 9/1). Then, recrystallization 
from EtOH. Cis:trans 78:22. Yield 47%. 1H NMR (400 MHz, CDCl3): δ 1.40 (3H, 
t, J = 7.0 Hz, OCH2CH3), 4.01 (2H, q, J = 7.0 Hz, OCH2CH3), 4.61 (1H, quintet, 
J = 5.4 Hz, CHCF3), 4.80 and 4.85 (2H, 2 × d, J = 11.8 Hz, OCH2Ph), 4.98 (1H, 
d, J = 5.4 Hz, OCHCHCF3), 6.87 (2H, d, J = 9.0 Hz, O(CHarom)ortho), 7.32-7.41 (7H, m, N(CHarom)ortho 
and CHarom). 13C NMR (100.6 MHz, CDCl3): δ 14.8 (OCH2CH3), 57.7 (q, J = 33.1 Hz, CHCF3), 63.7 
(OCH2CH3), 73.8 (CH2Ph), 80.2 (OCHCHCF3), 115.0 (2 × O(CHarom)ortho), 119.4 (2 × N(CHarom)ortho), 
123.8 (q, J = 284.4 Hz, CHCF3), 127.9, 128.3, 128.6, 129.3 (6 × CHarom), 136.1 (CH2Carom,quat), 
156.6 (OCarom,quat), 163.8 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.37 (3F, d, J = 5.4 Hz, CF3). 
IR (ATR, cm-1): νC=O = 1749, νmax = 1514, 1364, 1267, 1163, 1136, 1022, 922, 825, 735, 505. MS 
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Trans-3-benzyloxy-1-(4-ethoxyphenyl)-4-(trifluoromethyl)azetidin-2-one  
White crystals. Mp 71 °C. Rf = 0.49 (PE/EtOAc, 9/1). Yield 10%. 1H NMR (400 
MHz, CDCl3): δ 1.40 (3H, t, J = 7.0 Hz, OCH2CH3), 4.01 (2H, q, J = 7.0 Hz, 
OCH2CH3), 4.41 (1H, q × d, J = 5.6, 1.1 Hz, CHCF3), 4.76 and 4.82 (2H, 2 × d, 
J = 11.5 Hz, OCH2Ph), 4.88 (1H, d, J = 1.1 Hz, OCHCHCF3), 6.88 and 7.32 (2 
× 2H, 2 × d, J = 8.9 Hz, N(CHarom)ortho and O(CHarom)ortho), 7.33-7.39 (5H, m, CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 14.8 (OCH2CH3), 59.8 (q, J = 34.2 Hz, CHCF3), 63.7 (OCH2CH3), 73.2 
(CH2Ph), 82.0 (OCHCHCF3), 115.0 (2 × O(CHarom)ortho), 120.1 (2 × N(CHarom)ortho), 123.6 (q, J = 
280.5 Hz, CHCF3), 128.2, 128.5, 128.7 (5 × CHarom), 128.9 (NCarom,quat), 135.9 (CH2Carom,quat), 156.8 
(OCarom,quat), 162.5 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -71.38 (3F, d, J = 5.6 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1763, νmax = 1514, 1398, 1281, 1244, 1148, 1113, 1045, 843, 735, 694. MS 
(70eV): 366 (M+ + 1, 100).  
Cis-3-benzyloxy-1-(4-iodophenyl)-4-(trifluoromethyl)azetidin-2-one 2d  
White crystals. Mp 125 °C. Rf = 0.15 (PE/EtOAc, 12/1). Then, recrystallization 
from EtOH. Yield 35%. Cis:trans, 54:46. 1H NMR (400 MHz, CDCl3): δ 4.64 (1H, 
quintet, J = 5.4 Hz, CHCF3), 4.79 and 4.85 (2H, 2 × d, J = 11.8 Hz, OCH2Ph), 
4.99 (1H, d, J = 5.4 Hz, OCHCHCF3), 7.23 (2H, d, J = 8.7 Hz, N(CHarom)ortho), 7.32-
7.39 (5H, m, CHarom), 7.67 (2H, d, J = 8.7 Hz, I(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 57.4 
(q, J = 33.4 Hz, CHCF3), 73.9 (CH2Ph), 80.2 (OCHCHCF3), 89.0 (ICarom,quat), 119.4 (2 × 
N(CHarom)ortho), 123.6 (q, J = 280.1 Hz, CHCF3), 128.0, 128.4, 128.7 (5 × CHarom), 135.8 
(NCarom,quat), 135.9 (CH2Carom,quat), 138.2 (2 × I(CHarom)ortho), 164.1 (C=O). 19F NMR (376.5 MHz, 
CDCl3): δ -68.21 (3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1761, νmax = 1489, 1364, 1267, 
1238, 1165, 1128, 816, 737, 694, 498. MS (70eV): 465 (M+ + 18, 100), 448 (M+ + 1, 55).  
Trans-3-benzyloxy-1-(4-iodophenyl)-4-(trifluoromethyl)azetidin-2-one  
White crystals. Mp 78 °C. Rf = 0.52 (PE/EtOAc, 9/1). Then, recrystallization from 
EtOH. Yield 27%. 1H NMR (400 MHz, CDCl3): δ 4.36 (1H, q × d, J = 5.6, 1.3 Hz, 
CHCF3), 4.69 and 4.76 (2H, 2 × d, J = 11.6 Hz, OCH2Ph), 4.82 (1H, d, J = 1.3 Hz, 
OCHCHCF3), 7.11 (2H, d, J = 8.7 Hz, N(CHarom)ortho), 7.28-7.34 (5H, m, CHarom), 
7.61 (2H, d, J = 8.7 Hz, I(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 59.6 (q, J = 34.5 Hz, 
CHCF3), 73.3 (CH2Ph), 82.2 (q, J = 1.5 Hz, OCHCHCF3), 89.4 (ICarom,quat), 119.8 (2 × 
N(CHarom)ortho), 123.4 (q, J = 280.2 Hz, CHCF3), 128.2, 128.65, 128.74 (5 × CHarom), 135.6 
(CH2Carom,quat), 138.3 (2 × I(CHarom)ortho), 162.6 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -71.12 (3F, 
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d, J = 5.6 Hz, CF3). IR (ATR, cm-1): νC=O = 1757, νmax = 1587, 1489, 1393, 1364, 1111, 1001, 696, 
498. MS (70eV): 448 (M+ + 1, 50).  
Cis-3-benzyloxy-1-(4-methylphenyl)-4-(trifluoromethyl)azetidin-2-one 2e  
White crystals. Mp 113 °C. Rf = 0.25 (PE/EtOAc, 9/1). Then, recrystallization from 
EtOH. Yield 35%. Cis:trans, 67:33. 1H NMR (400 MHz, CDCl3): δ 2.31 (3H, s, 
CH3), 4.63 (1H, quintet, J = 5.3 Hz, CHCF3), 4.78 and 4.84 (2H, 2 × d, J = 11.8 
Hz, OCH2Ph), 4.96 (1H, d, J = 5.3 Hz, OCHCHCF3), 7.14 (2H, d, J = 8.3 Hz, 
N(CHarom)ortho), 7.33-7.40 (7H, m, CH3(CHarom)ortho and CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
20.9 (CH3), 57.4 (q, J = 33.2 Hz, CHCF3), 73.8 (CH2Ph), 80.2 (OCHCHCF3), 117.7 (2 × 
CH3(CHarom)ortho), 123.8 (q, J = 280.4 Hz, CHCF3), 127.9, 128.3, 128.6 (5 × CHarom), 129.8 (2 × 
N(CHarom)ortho), 133.7, 135.3, 136.1 (3 × Carom,quat), 164.0 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -
68.29 (3F, d, J = 5.3 Hz, CF3). IR (ATR, cm-1): νC=O = 1769, νmax = 1514, 1360, 1265, 1167, 1130, 
812, 760, 694, 494. MS (70eV): 336 (M+ + 1, 100).  
Trans-3-benzyloxy-1-(4-methylphenyl)-4-(trifluoromethyl)azetidin-2-one  
White crystals. Mp 62 °C. Rf = 0.52 (PE/EtOAc, 9/1). Then, recrystallization from 
EtOH. Yield 14%. 1H NMR (400 MHz, CDCl3): δ 2.24 (3H, s, CH3), 4.35 (1H, q × 
d, J = 5.6, 1.2 Hz, CHCF3), 4.67 and 4.74 (2H, 2 × d, J = 11.6 Hz, OCH2Ph), 4.80 
(1H, d, J = 1.2 Hz, OCHCHCF3), 7.08 and 7.22 (2 × 2H, 2 × d, J = 8.3 Hz, 
N(CHarom)ortho, CH3(CHarom)ortho), 7.25-7.30 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 21.0 
(CH3), 59.6 (q, J = 34.4 Hz, CHCF3), 73.2 (CH2Ph), 82.0 (q, J = 2.0 Hz, OCHCHCF3), 118.2 (2 × 
CH3(CHarom)ortho), 123.6 (q, J = 280.4 Hz, CHCF3), 128.2, 128.5, 128.7 (5 × CHarom), 129.8 (2 × 
N(CHarom)ortho), 133.4 (NCarom,quat), 135.6 (CH3Carom,quat), 135.9 (CH2Carom,quat), 162.6 (C=O). 19F 
NMR (376.5 MHz, CDCl3): δ -71.22 (3F, d, J = 5.6 Hz, CF3). IR (ATR, cm-1): νC=O = 1759, νmax = 
1512, 1391, 1348, 1277, 1163, 1138, 1109, 810, 739, 698, 509, 436. MS (70eV): 336 (M+ + 1, 
100).  
Cis-3-benzyloxy-1-isopropyl-4-(trifluoromethyl)azetidin-2-one 2f 
To a solution of 1-ethoxy-2,2,2-trifluoroethanol (1.00 g, 0.82 mL, 6,94 mmol, 1 equiv) in anhydrous 
CH2Cl2 (20 mL) was added isopropylamine (0.41 g, 0.60 mL, 6.94 mmol, 1 equiv) and MgSO4 
(1.67 g, 13.88 mmol, 2 equiv). After stirring for two hours under reflux, MgSO4 was removed by 
filtration. Evaporation of the solvent in vacuo gave 2,2,2-trifluoro-1-(isopropylamino)ethan-1-ol 
(0.76 g, 4.84 mmol, 70%) as white crystals. Benzyloxyacetyl chloride (3.56 g, 3.04 mL, 19.36 
mmol, 4 equiv) was added dropwise to an ice-cooled solution of the latter N-isopropyl hemiaminal 
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(0.76 g, 4.84 mmol, 1 equiv) and triethylamine (2.44 g, 3.37 mL, 24.2 mmol, 5 equiv) in anhydrous 
CH2Cl2 (30 mL). After stirring for 19 hours under reflux, water (30 mL) was poured into the reaction 
mixture and extracted with CH2Cl2 (2 × 25 mL). Drying (MgSO4), filtration of the drying agent and 
removal of the solvent afforded a mixture of two isomers cis:trans in a ratio of 75:25. Pure cis-3-
benzyloxy-1-isopropyl-4-(trifluoromethyl)azetidin-2-one 2f (59%) was obtained by means of 
column chromatography on silica gel (PE/EtOAc, 9/1).  
Yellowish solid. Mp 45 °C. Rf = 0.11 (PE/EtOAc, 9/1). Yield 59%. 1H NMR (400 
MHz, CDCl3): δ 1.25 and 1.29 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CHN), 3.88 (1H, 
septet, J = 6.8 Hz, (CH3)2CH), 4.11 (1H, q × d, J = 6.1, 5.2 Hz, CHCF3), 4.73 (1H, 
2 × d, J = 11.8 Hz, O(HCH)Ph), 4.75 (1H, d, J = 5.2 Hz, CHCHCF3), 4.77 (1H, 2 × 
d, J = 11.8 Hz, O(HCH)Ph), 7.28-7.36 (5H, m, CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 19.4 and 21.1 ((CH3)2CH), 45.1 ((CH3)2CH), 56.5 (q, J = 33.1 Hz, CHCF3), 73.4 
(OCH2Ph), 80.0 (CHCHCF3), 123.9 (q, J = 279.8 Hz, CF3), 127.9, 128.2, 128.5 (5 × CHarom), 136.3 
(Carom,quat), 166.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.33 (3F, d, J = 6.1 Hz, CF3). IR (ATR, 
cm-1): νC=O = 1763, νmax = 1393, 1354, 1277, 1161, 1138, 1113, 735, 696. MS (70eV): 288 (M+ + 
1, 100).  
Cis-3-benzyloxy-1-phenyl-4-(trifluoromethyl)azetidin-2-one  
White crystals. Mp 95 °C. Rf = 0.24 (PE/EtOAc, 9/1). Yield 86%. 1H NMR (400 
MHz, CDCl3): δ 4.67 (1H, quintet, J = 5.4 Hz, CHCF3), 4.80 and 4.85 (2H, 2 × d, 
J = 11.8 Hz, OCH2Ph), 4.98 (1H, d, J = 5.4 Hz, OCHCHCF3), 7.17 (1H, t, J = 7.4 
Hz, CHarom), 7.31-7.41 (7H, m, CHarom), 7.46 (2H, d, J = 8.1 Hz, CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 57.4 (q, J = 33.3 Hz, CHCF3), 73.8 (CH2Ph), 80.1 
(OCHCHCF3), 117.6 (2 × CHarom), 123.7 (q, J = 281.0 Hz, CF3), 125.5, 128.0, 128.4, 128.6, 129.3 
(8 × CHarom), 136.1, 136.2 (2 × Carom,quat), 164.2 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.26 
(3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1757, νmax = 1499, 1366, 1167, 1138, 739, 752, 
669, 490. MS (70eV): 322 (M+ + 1, 100).  
Synthesis of 3-hydroxy-4-(trifluoromethyl)azetidin-2-ones 3 
As a representative example, the synthesis of cis-3-hydroxy-1-(4-methoxyphenyl)-4-
(trifluoromethyl)azetidin-2-one 3a is described. Palladium on activated carbon (20% w/w) was 
added to a solution of cis-3-benzyloxy-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 2a 
(6.00 g, 17.09 mmol, 1 equiv) in methanol (15 mL) and the resulting mixture was placed in a Parr 
apparatus. The inside of the Parr apparatus was then degassed and filled with hydrogen gas, after 
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which the mixture was stirred at room temperature for 41 hours while applying 5 bar of hydrogen 
gas. Filtration of the heterogenous mixture through Celite® and evaporation of the solvent in vacuo 
afforded cis-3-hydroxy-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 2a, which was 
purified by recystallization from Hex/EtOAc, 30/1 in a yield of 87%. 
Cis-3-hydroxy-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 3a 
White crystals. Mp 160 oC. Recrystallization from Hex/EtOAc, 30/1. Yield 87%. 
1H NMR (400 MHz, CDCl3): δ 3.25 (1H, s, OH), 3.80 (3H, s, OCH3), 4.62 (1H, 
quintet, J = 5.6 Hz, CHCF3), 5.28 (1H, d, J = 5.6 Hz, CHOH), 6.90 and 7.40 (2 
× 2H, 2 × d, J = 9.1 Hz, N(CHarom)ortho) and O(CHarom)ortho). 13C NMR (100.6 MHz, 
CDCl3): δ 55.5 (OCH3), 58.1 (q, J = 32.1, CHCF3), 75.5 (CHOH), 114.5 (2 × O(CHarom)ortho), 119.4 
(2 × N(CHarom)ortho), 123.7 (q, J = 282.4 Hz, CF3), 129.3 (Carom,quatN), 157.4 (Carom,quatO), 164.8 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.47 (3F, d, J = 5.6 Hz, CF3). IR (ATR, cm-1): νOH = 3320, 
νC=O = 1729, νmax = 1515, 1248, 1169, 1141, 1021, 821, 645. MS (70eV): m/z (%): 262 (M+ + 1, 
100). HRMS (ESI) calcd for C11H11F3NO3+: 262.06861 [M + H]+. Found: 262.0682. 
Cis-3-hydroxy-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 3b 
 White crystals. Mp 114 oC. Recrystallization from Hex/EtOAc, 30/1. Yield 93%. 1H 
NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 3.89 (1H, q × d, J = 5.1, 6.2 Hz, 
CHCF3), 3.97 (1H, d, J = 14.8 Hz, N(HCH)), 4.70 (1H, d, J = 6.8 Hz, OH), 4.78 (1H, 
d, J = 14.8 Hz, N(HCH)), 5.06 (1H, d × d, J = 6.8, 5.1 Hz, CHOH), 6.88 and 7.15 (2 × 
2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and O(CHarom)meta). 13C NMR (100.6 MHz, CDCl3): 
δ 44.8 (NCH2), 55.3 (OCH3), 57.1 (q, J = 31.8, CHCF3), 75.7 (CHOH), 114.4 (2 × O(CHarom)ortho), 
123.9 (q, J = 280.2 Hz, CF3), 125.8 (NCH2Carom,quat), 129.9 (2 × O(CHarom)meta), 159.6 (Carom,quatO), 
168.7 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.33 (3F, d, J = 6.2 Hz, CF3). IR (ATR, cm-1): νOH 
= 3296, νC=O = 1733, νmax = 1513, 1409, 1247, 1158, 1126, 1033, 919, 840, 814, 655. MS (70eV): 
m/z (%): 276 (M+ + 1, 100). HRMS (ESI) calcd for C12H13F3NO3+: 276.0842 [M + H]+. Found: 
276.0844. 
Cis-1-(4-ethoxyphenyl)-3-hydroxy-4-(trifluoromethyl)azetidin-2-one 3c 
White crystals. Mp 144 °C. Recrystallization from Hex/EtOAc, 30/1. Yield 94%. 
1H NMR (400 MHz, CDCl3): δ 1.40 (3H, t, J = 7.0 Hz, OCH2CH3), 4.01 (2H, q, J 
= 7.0 Hz, OCH2CH3), 4.20 (1H, s, OH), 4.63 (1H, quintet, J = 5.5 Hz, CHCF3), 
5.31 (1H, d, J = 5.5 Hz, OCHCHCF3), 6.87 and 7.37 (2 × 2H, 2 × d, J = 9.0 Hz, 
N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 14.8 (OCH2CH3), 58.2 (q, J = 
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32.0 Hz, CHCF3), 63.8 (OCH2CH3), 75.2 (OCHCHCF3), 115.0 (2 × O(CHarom)ortho), 119.5 (2 × 
N(CHarom)ortho), 123.7 (q, J = 281.6 Hz, CF3), 129.1 (NCarom,quat), 156.8 (OCarom,quat), 165.6 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -68.48 (3F, d, J = 5.5 Hz, CF3). IR (ATR, cm-1): νOH = 3306, νC=O 
= 1728, νmax = 1514, 1296, 1250, 1167, 1136, 1038, 860, 822, 652, 522. MS (70eV): 276 (M+ + 1, 
70).  
Trans-1-(4-ethoxyphenyl)-3-hydroxy-4-(trifluoromethyl)azetidin-2-one  
White crystals. Mp 102 °C. Recrystallization from Hex/EtOAc, 30/1. Yield 84%. 
1H NMR (400 MHz, CDCl3): δ 1.41 (3H, t, J = 7.0 Hz, OCH2CH3), 4.00 (2H, q, 
J = 7.0 Hz, OCH2CH3), 4.42 (1H, q × d, J = 5.7, 1.1 Hz, CHCF3), 4.93 (1H, s, 
OH), 5.03 (1H, ~s, OCHCHCF3), 6.85 and 7.26 (2 × 2H, 2 × d, J = 9.0 Hz, 
N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 14.7 (OCH2CH3), 61.4 (q, J = 
34.2 Hz, CHCF3), 63.8 (OCH2CH3), 76.2 (q, J = 2.2 Hz, OCHCHCF3), 115.0 (2 × O(CHarom)ortho), 
120.4 (2 × N(CHarom)ortho), 123.5 (q, J = 280.3 Hz, CF3), 128.3 (NCarom,quat), 157.1 (OCarom,quat), 166.0 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ -71.72 (3F, d, J = 5.7 Hz, CF3). IR (ATR, cm-1): νOH = 3237, 
νC=O = 1736, νmax = 1512, 1479, 1400, 1283, 1250, 1144, 1103, 1049, 876, 822, 696. MS (70eV): 
276 (M+ + 1, 100).  
Cis-3-hydroxy-1-phenyl-4-(trifluoromethyl)azetidin-2-one 3d 
White crystals. Mp 164 °C. Recrystallization from Hex/EtOAc, 30/1. Yield 84%. 1H 
NMR (400 MHz, CD3OD): δ 4.98 (1H, quintet, J = 5.7 Hz, CHCF3), 5.29 (1H, d, J = 
5.7 Hz, CHCHCF3), 7.19 (1H, t, J = 7.7 Hz, N(CHarom)para), 7.39 (2H, t, J = 7.8 Hz, 
N(CHarom)meta), 7.51 (2H, d, J = 7.8 Hz, N(CHarom)ortho). 13C NMR (100.6 MHz, CD3OD): δ 57.8 (q, J 
= 31.5 Hz, CHCF3), 74.9 (CHCHCF3), 117.4 (2 × N(CHarom)ortho), 124.3 (q, J = 279.7 Hz, CHCF3), 
124.9 (N(CHarom)para), 128.8 (2 × N(CHarom)meta), 136.7 (NCarom,quat), 167.0 (C=O). 19F NMR (376.5 
MHz, CD3OD): δ -70.18 (3F, d, J = 5.7 Hz, CF3). IR (ATR, cm-1): νOH = 2448, νC=O = 1724, νmax = 
1499, 1393, 1281, 1252, 1142, 758, 691, 664. MS (70eV): 249 (M+ + 18, 100).  
Cis-3-hydroxy-1-(4-methylphenyl)-4-(trifluoromethyl)azetidin-2-one 3e 
White crystals. Mp 176 °C. Recrystallization from Hex/EtOAc, 30/1. Yield 
87%. 1H NMR (400 MHz, CDCl3): δ 2.33 (3H, s, CH3), 3.22 (1H, brs, OH), 4.66 
(1H, quintet, J = 5.5 Hz, CHCF3), 5.28 (1H, d × d, J = 8.2, 5.5 Hz, OCHCHCF3), 
7.17 and 7.36 (2 × 2H, 2 × d, J = 8.3 Hz, N(CHarom)ortho and CH3(CHarom)ortho). 
13C NMR (100.6 MHz, CD3OD): δ 19.5 (CH3), 57.8 (q, J = 31.5 Hz, CHCF3), 
74.9 (OCH), 117.5 (2 × CH3(CHarom)ortho), 124.3 (q, J = 279.9 Hz, CHCF3), 
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129.2 (2 × N(CHarom)ortho), 134.1 (NCarom,quat), 134.9 (CH3Carom,quat), 166.8 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -68.41 (3F, d, J = 5.5 Hz, CF3). IR (ATR, cm-1): νOH = 2455, νC=O = 1732, νmax = 
1512, 1389, 1281, 1248, 1167, 1082, 860, 810, 646, 471. MS (70eV): 263 (M+ + 18, 100), 246 (M+ 
+ 1, 40).  
Cis-3-hydroxy-1-isopropyl-4-(trifluoromethyl)azetidin-2-one 3f 
White crystals. Mp 85 °C. Recrystallization from Hex/EtOAc, 30/1. Yield 97%. 1H 
NMR (400 MHz, CDCl3): δ 1.26 and 1.30 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CHN), 
3.87 (1H, septet, J = 6.8 Hz, (CH3)2CHN), 4.12 (1H, q × d, J = 6.3, 5.1 Hz, CHCF3), 
4.61 (1H, d, J = 5.9 Hz, OH), 5.07 (1H, d × d, J = 5.9, 5.1 Hz, CHCHCF3). 13C NMR (100.6 MHz, 
CDCl3): δ 19.3 and 21.0 ((CH3)2CH), 45.4 ((CH3)2CH), 57.2 (q, J = 32.1 Hz, CHCF3), 74.7 (OCH), 
123.8 (q, J = 279.7 Hz, CF3), 168.6 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.44 (3F, d, J = 6.3 
Hz, CF3). IR (ATR, cm-1): νOH = 3240, νC=O = 1719, νmax = 1580, 1385, 1371, 1217, 1153, 1119, 
1053, 932, 854, 810, 646. MS (70eV): 198 (M+ + 1, 70).  
Synthesis of trans-3-chloro-4-(trifluoromethyl)azetidin-2-ones 4 
To a solution of cis-3-hydroxy-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 3a (1.49 g, 
5.71 mmol, 1 equiv) in CCl4 (10 mL) at room temperature was added triphenylphosphine (2.99 g, 
11.42 mmol, 2 equiv) and NaHCO3 as a catalyst (0.07 g, 0.86 mmol, 0.15 equiv). The mixture was 
heated under reflux for 10 hours. Filtration of the heterogenous mixture through Celite® and 
evaporation of the solvent in vacuo afforded trans-3-chloro-1-(4-methoxyphenyl)-4-
(trifluoromethyl)azetidin-2-one 4a (1.54 g, 5.52 mmol, 97%), which was purified by means of 
column chromatography on silica gel (PE/EtOAc, 8/1).  
Trans-3-chloro-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 4a 
Colorless solid. Mp 52 °C. Rf = 0.32 (PE/EtOAc, 8/1). Yield 97%. 1H NMR (400 
MHz, CDCl3): δ 3.80 (3H, s, OCH3), 4.55 (1H, q × d, J = 5.3, 1.8 Hz, CHCF3), 
4.93 (1H, d, J = 1.8 Hz, CHCl), 6.91 and 7.35 (2 × 2H, 2 × d, J = 9.1 Hz, 
N(CHarom)ortho) and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.5 (OCH3), 
55.8 (q, J = 2.0 Hz, CHCl), 61.8 (q, J = 34.9 Hz, CHCF3), 114.6 (2 × O(CHarom)ortho), 120.1 (2 × 
N(CHarom)ortho), 123.1 (q, J = 281.1 Hz, CF3), 128.7 (Carom,quatN), 157.8 (Carom,quatO), 159.0 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -72.36 (3F, d, J = 5.3 Hz, CF3). IR (ATR, cm-1): νC=O = 1771, νmax 
= 1510, 1269, 1256, 1173, 1159, 1132, 1113, 1090, 1038, 878, 820, 800, 689, 588, 511, 424. MS 
(70eV): m/z (%): 297 (M+ + 18, 100).  
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Trans-3-chloro-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 4b 
Yellowish oil. Rf = 0.40 (PE/EtOAc, 8)/1). Yield 91%. 1H NMR (400 MHz, CDCl3): δ 
3.808 (1H, q × d, J = 5.7, 1.4 Hz, CHCF3), 3.811 (3H, s, OCH3), 3.96 (1H, d, J = 15.0 
Hz, N(HCH)Ar), 4.81 (1H, d, J = 1.4 Hz, CHCl), 4.86 (1H, d, J = 15.0 Hz, N(HCH)Ar), 
6.91 and 7.19 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C 
NMR (100.6 MHz, CDCl3): δ 45.6 (NCH2Ar), 55.3 (OCH3), 55.9 (q, J = 2.4 Hz, CHCl), 
60.1 (q, J = 34.7 Hz, CHCF3), 114.5 (2 × O(CHarom)ortho), 123.1 (q, J = 280.2 Hz, CF3), 125.3 
(Carom,quatN), 129.9 (2 × NCH2(CHarom)ortho), 159.8 (Carom,quatO), 161.9 (C=O). 19F NMR (376.5 MHz, 
CDCl3): δ -73.72 (3F, d, J = 5.7 Hz, CF3). IR (ATR, cm-1): νC=O = 1786, νmax = 1514, 1275, 1246, 
1190, 1161, 1132, 1107, 1032, 835, 687, 621. MS (70eV): m/z (%): 294 (M+ + 1, 10), 311 (M+ + 
18, 100).  
The synthesis of trans-3-chloro-2-(trifluoromethyl)azetidines 5 
To an ice-cooled solution of AlCl3 (0.38 g, 2.86 mmol, 2 equiv) in dry Et2O (10 mL), LiAlH4 (1M in 
THF, 0.11 g, 2.86 mL, 2.86 mmol, 2 equiv) was carefully added dropwise. The reaction mixture 
was allowed to reach room temperature, and then was heated for 30 minutes at reflux 
temperature. Afterwards, the reaction mixture was cooled to 0 °C and trans-3-chloro-1-(4-
methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 4a (0.40 g, 1.43 mmol, 1 equiv) was added. 
After stirring for five minutes at room temperature, the reaction was quenched with water (10 mL) 
and filtered through a short pad of Celite®. Extraction with Et2O (3 × 10 mL), drying (MgSO4), 
filtration of the drying agent and evaporation of the solvent afforded a crude mixture. The 1H NMR 
and 19F NMR of this mixture showed it to consist of trans-3-chloro-1-(4-methoxyphenyl)-2-
(trifluoromethyl)azetidine 5a and a ring-opening product anti-2-chloro-4,4,4-trifluoro-3-[(4-
methoxyphenyl)amino]butan-1-ol in a ratio of 66:34. The mixture was separated by flash column 
chromatography (PE/EtOAc, 12/1) to give pure trans-3-chloro-1-(4-methoxyphenyl)-2-
(trifluoromethyl)azetidine 5a (54%). 
Trans-3-chloro-1-(4-methoxyphenyl)-2-(trifluoromethyl)azetidine 5a 
Yellow solid. Mp 50 °C. Rf = 0.55 (PE/EtOAc, 12/1). Yield 54%. 1H NMR (400 
MHz, CDCl3): δ 3.76 (3H, s, OCH3), 3.78 (1H, d × d, J = 7.9, 6.7 Hz, 
(HCH)CHCl), 4.38 (1H, q, J = 5.5 Hz, CHCF3), 4.49 (1H, d × d, J = 7.9, 6.7 Hz, 
(HCH)CHCl), 4.69 (1H, d × d × d, J = 6.7, 6.7, 5.5 Hz, CHCl), 6.61 and 6.85 (2 
× 2H, 2 × d, J = 9.0 Hz, N(CHarom)ortho) and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 44.2 
(q, J = 3.4 Hz, CHCl), 55.7 (OCH3), 61.3 (CH2CHCl), 73.0 (q, J = 33.4 Hz, CHCF3), 114.0 (q, J = 
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1.2 Hz, 2 × N(CHarom)ortho), 114.8 (2 × O(CHarom)ortho), 123.9 (q, J = 279.6 Hz, CF3), 143.6 
(Carom,quatN), 154.1 (Carom,quatO). 19F NMR (376.5 MHz, CDCl3): δ -75.70 (3F, d, J = 5.5 Hz, CF3). IR 
(ATR, cm-1): νmax = 1508, 1273, 1263, 1242, 1157, 1126, 1034, 824, 795, 692, 529. MS (70eV): 
m/z (%): 266 (M+ + 1, 100).  
Trans-3-chloro-1-(4-methoxybenzyl)-2-(trifluoromethyl)azetidine 5b  
Yellowish solid. Mp 56 °C. Rf = 0.78 (PE/EtOAc, 12/1). Yield 78%. 1H NMR (400 MHz, 
CDCl3): δ 3.05 (1H, t, J = 7.4 Hz, (HCH)CHCl), 3.54 (1H, d, J = 12.7 Hz, N(HCH)Ar), 
3.69-3.75 (2H, m, CHCF3, (HCH)CHCl), 3.80 (3H, s, OCH3), 3.93 (1H, d, J = 12.7 Hz, 
N(HCH)Ar), 4.39 (1H, q, J = 6.7 Hz, CHCl), 6.87 and 7.18 (2 × 2H, 2 × d, J = 8.6 Hz, 
NCH2(CHarom)ortho) and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 43.6 (q, J = 3.5 
Hz, CHCl), 55.3 (OCH3), 60.2 (CH2CHCl), 61.1 (NCH2Ar), 72.7 (q, J = 32.3 Hz, CHCF3), 113.9 (2 
× O(CHarom)ortho), 123.9 (q, J = 278.6 Hz, CF3), 127.8 (Carom,quatN), 130.1 (2 × NCH2(CHarom)ortho), 
159.2 (Carom,quatO). 19F NMR (376.5 MHz, CDCl3): δ -75.98 (3F, d, J = 6.7 Hz, CF3). IR (ATR, cm-
1): νmax = 1514, 1283, 1250, 1236, 1161, 1142, 1123, 1082, 1032, 827, 781, 762, 696. MS (70eV): 
m/z (%): 280 (M+ + 1, 13).  
Synthesis of anti-2-chloro-4,4,4-trifluoro-3-[N-(4-methoxybenzyl/phenyl)-N-
methylamino]butyl acetates 7 
In a flame-dried flask under nitrogen atmosphere, Me3OBF4 (0.11 g, 0.74 mmol, 2 equiv) was 
added to an ice-cooled solution of trans-3-chloro-1-(4-methoxyphenyl)-2-(trifluoromethyl)azetidine 
5a (0.10 g, 0.37 mmol, 1 equiv) in dry CH2Cl2 (5 mL). After stirring for one hour at room 
temperature, the solvent was evaporated and the resulting residue was redissolved in CH3CN (5 
mL), after which NaOAc (0.12 g, 1.48 mmol, 4 equiv) was added. After stirring at reflux 
temperature for one hour, the reaction mixture was extracted with CH2Cl2 (3 × 5 mL) and washed 
with brine (3 × 5 mL). Drying (MgSO4), filtration of the drying agent and evaporation of the solvent 
afforded a crude mixture of anti-2-chloro-4,4,4-trifluoro-3-[N-(4-methoxyphenyl)-N-
methylamino]butyl acetate 7a (43%) and the recovery of trans-3-chloro-1-(4-methoxyphenyl)-2-
(trifluoromethyl)azetidine 5a (0.02 g, 0.08 mmol) in a ratio of 53:47, which were separated by 
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Anti-2-chloro-4,4,4-trifluoro-3-[N-(4-methoxyphenyl)-N-methylamino]butyl acetate 7a 
Yellowish solid. Mp 48 °C. Rf = 0.30 (Hex/EtOAc, 9/1). Yield 43%. 1H NMR (400 
MHz, CDCl3): δ 1.93 (3H, s, COOCH3), 2.79 (3H, q, J = 1.3 Hz, NCH3), 3.70 
(3H, s, OCH3), 4.20-4.25 (1H, m, CHCF3), 4.33-4.43 (3H, m, CHCl, OCH2CHCl), 
6.73-6.78 (4H, m, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, 
CDCl3): δ 20.5 (COOCH3), 33.2 (NCH3), 52.5 (CHCl), 55.6 (OCH3), 64.7 (q, J = 27.2 Hz, CHCF3), 
65.2 (OCH2CHCl), 114.7 (2 × O(CHarom)ortho), 116.5 (2 × N(CHarom)ortho), 125.5 (q, J = 289.4 Hz, 
CHCF3), 143.5 (NCarom,quat), 153.6 (OCarom,quat), 170.3 (C=O). 19F NMR (376 MHz, CDCl3): δ -64.59 
(3F, d, J = 6.1 Hz, CF3). IR (ATR, cm-1): νC=O = 1734, νmax = 1514, 1252, 1227, 1163, 1140, 1107, 
1045, 1034, 826. MS (70 eV): m/z (%): 340 (M+ + 1, 100).  
Anti-2-chloro-4,4,4-trifluoro-3-[N-(4-methoxybenzyl)-N-methylamino]butyl acetate 7b 
Yellowish solid. Mp 47 °C. Rf = 0.23 (Hex/EtOAc,10/1). Yield 18%. 1H NMR (400 
MHz, CDCl3): δ 2.05 (3H, s, COOCH3), 2.38 (3H, q, J = 1.8 Hz, NCH3), 3.49 (1H, 
d × q, J = 9.1, 7.7 Hz, CHCF3), 3.77 (1H, 2 × d, J = 12.8 Hz, (HCH)N), 3.80 (3H, 
s, OCH3), 3.82 (1H, 2 × d, J = 12.8 Hz, (HCH)N), 4.25-4.35 (2H, m, CHCl, 
O(HCH)CHCl), 4.55 (1H, d × d, J = 11.8, 2.7 Hz, O(HCH)CHCl), 6.86 and 7.15 
(2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 
20.7 (COOCH3), 36.5 (NCH3), 53.1 (CHCl), 55.3 (OCH3), 60.0 (NCH2Ar), 65.0 (q, J = 24.9 Hz, 
CHCF3), 65.6 (OCH2CHCl), 113.9 (2 × O(CHarom)ortho), 126.6 (q, J = 293.4 Hz, CHCF3), 129.7 
(NCH2Carom,quat), 130.1 (2 × NCH2(CHarom)ortho), 159.1 ( OCarom,quat), 170.6 (C=O). 19F NMR (376 
MHz, CDCl3): δ -62.33 (3F, d, J = 7.7 Hz, CF3). IR (ATR, cm-1): νC=O = 1744, νmax = 1512, 1233, 
1169, 1119, 1107, 1061, 1034. MS (70 eV): m/z (%): 371 (M+ + 18, 40).  
Synthesis of anti-N1-(tert-butyl)-2-chloro-4,4,4-trifluoro-N3-(4-methoxybenzyl/phenyl)-N3-
methylbutane-1,3-diamines 8 
In a flame-dried flask under nitrogen atmosphere, Me3OBF4 (0.11 g, 0.74 mmol, 2 equiv) was 
added to an ice-cooled solution of trans-3-chloro-1-(4-methoxyphenyl)-2-(trifluoromethyl)azetidine 
5a (0.10 g, 0.37 mmol, 1 equiv) in dry CH2Cl2 (5 mL). After stirring for one hour at room 
temperature, the solvent was evaporated and the resulting residue was redissolved in CH3CN (5 
mL), followed by the addition of tert-butylamine (0.11 g, 0.16 mL, 1.48 mmol, 4 equiv). After stirring 
at reflux temperature for one hour, the reaction mixture was extracted with CH2Cl2 (3 × 5 mL) and 
washed with brine (3 × 5 mL). Drying (MgSO4), filtration of the drying agent and evaporation of the 
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solvent afforded a crude mixture of anti-N1-(tert-butyl)-2-chloro-4,4,4-trifluoro-N3-(4-
methoxyphenyl)-N3-methylbutane-1,3-diamine 8a (38%) and the recuperation of trans-3-chloro-1-
(4-methoxyphenyl)-2-(trifluoromethyl)azetidine 5a (0.005 g, 0.02 mmol) in a ratio of 80:20, which 
were separated by means of preparative TLC (Hex/EtOAc, 10/1) to obtain analytically pure 
samples. 
Anti-N1-(tert-butyl)-2-chloro-4,4,4-trifluoro-N3-(4-methoxyphenyl)-N3-methylbutane-1,3-
diamine 8a  
Yellow oil. Solidified in fridge. Rf = 0.14 (Hex/EtOAc,10/1). Yield 38%. 1H NMR 
(400 MHz, CDCl3): δ 0.94 (9H, s, Cquat(CH3)3), 2.76 (3H, q, J = 1.4 Hz, NCH3), 
2.83 (1H, d × d, J = 12.3, 5.6 Hz, (HCH)NH), 2.94 (1H, d × d, J = 12.3, 3.2 Hz, 
(HCH)NH)), 3.70 (3H, s, OCH3), 4.32 (1H, d × d × d, J = 9.6, 5.6, 3.2 Hz, CHCl), 
4.53 (1H, d × q, J = 9.6, 7.5 Hz, CHCF3), 6.76 and 6.85 (2 × 2H, 2 × d, J = 9.3 Hz, N(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 29.0 (Cquat(CH3)3), 32.9 (NCH3), 45.5 
(ClCHCH2), 50.1 (Cquat(CH3)3), 55.6 (OCH3), 57.1 (CHCl), 64.7 (q, J = 26.5 Hz, CHCF3), 114.5 (2 
× O(CHarom)ortho), 116.5 (2 × N(CHarom)ortho), 125.9 (q, J = 290.0 Hz, CHCF3), 144.0 (NCarom,quat), 
153.2 (OCarom,quat). 19F NMR (376 MHz, CDCl3): δ -64.15 (3F, d, J = 7.5 Hz, CF3). IR (ATR, cm-1): 
νNH = 2959, νmax = 1512, 1246, 1225, 1165, 1132, 1101, 1038, 818, 698. MS (70 eV): m/z (%): 353 
(M+ + 1, 100).  
Anti-N1-(tert-butyl)-2-chloro-4,4,4-trifluoro-N3-(4-methoxybenzyl)-N3-methylbutane-1,3-
diamine 8b  
Yellowish oil. Rf = 0.25 (PE/EtOAc,12/1). Yield 11%. 1H NMR (400 MHz, CDCl3): 
δ 0.98 (9H, s, Cquat(CH3)3), 1.49 (1H, d, J = 3.1 Hz, (HCH)NH), 1.63 (1H, d, J = 
6.5 Hz, (HCH)NH)), 2.02 (1H, d × d × d, J = 8.3, 6.5, 3.1 Hz, CHCl), 2.44 (3H, q, 
J = 1.2 Hz, NCH3), 2.70 (1H, quintet, J = 8.3 Hz, CHCF3), 3.73 and 3.79 (2 × 1H, 
2 × d, J = 13.3 Hz, N(HCH) Ar), 3.80 (3H, s, OCH3), 6.84 and 7.21 (2 × 2H, 2 × 
d, J = 8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 24.5 
(ClCHCH2), 26.4 (Cquat(CH3)3), 29.4 (CHCl), 38.2 (NCH3), 53.2 (Cquat(CH3)3), 55.3 (OCH3), 58.9 
(NCH2Ar), 66.8 (q, J = 24.6 Hz, CHCF3), 113.8 (2 × O(CHarom)ortho), 127.2 (q, J = 290.9 Hz, CHCF3), 
129.6 (2 × NCH2(CHarom)ortho), 131.0 (NCH2Carom,quat), 158.8 (OCarom,quat). 19F NMR (376 MHz, 
CDCl3): δ -67.19 (3F, d, J = 8.3 Hz, CF3). IR (ATR, cm-1): νNH = 2967, 2928, νmax = 1512, 1244, 
1169, 1103, 1034, 829, 814. MS (70 eV): m/z (%): 331 (M+ - 35, 100).  
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Synthesis of anti-2-chloro-4,4,4-trifluoro-3-[(4-methoxybenzyl/phenyl)amino]butan-1-ols 9 
To an ice-cooled solution of trans-3-chloro-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 
4a (0.50 g, 1.79 mmol, 1 equiv) in Et2O (10 mL) was added LiAlH4 (1M in THF, 0.07 g, 1.79 mL, 
1.79 mmol, 1 equiv) in small portions whilst stirring. After stirring for five minutes at room 
temperature, the reaction mixture was cooled to 0 °C, quenched with water (5 mL) and filtered 
through a short pad of Celite®. Extraction with Et2O (3 × 5 mL), drying (MgSO4), filtration of the 
drying agent and evaporation of the solvent afforded anti-2-chloro-4,4,4-trifluoro-3-[(4-
methoxyphenyl)amino]butan-1-ol 9a, which was purified by means of column chromatography on 
silica gel (Hex/EtOAc, 3/1) to obtain an analytically pure sample (0.49 g, 1.73 mmol, 96%). 
Anti-2-chloro-4,4,4-trifluoro-3-[(4-methoxyphenyl)amino]butan-1-ol 9a 
Yellowish oil. Rf = 0.32 (Hex/EtOAc, 3/1). Yield 96%. 1H NMR (400 MHz, 
CDCl3): δ 2.43 (1H, t, J = 6.4 Hz, OH), 3.74 (3H, s, OCH3), 3.92-4.29 (5H, 
m, CH2CHCl, CHCl, NH, CHCF3), 6.70 and 6.80 (2 × 2H, 2 × d, J = 8.9 Hz, 
O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.7 
(OCH3), 59.0 (CHCl), 60.8 (q, J = 28.5 Hz, CHCF3), 64.1 (q, J = 2.0 Hz, CH2CHCl), 115.0 (2 × 
N(HCarom)ortho), 115.9 (2 × O(HCarom)ortho), 125.1 (q, J = 284.8 Hz, CF3), 139.9 (NCarom,quat), 153.6 
(OCarom,quat). 19F NMR (376 MHz, CDCl3): δ -71.30 (3F, d, J = 6.6 Hz, CF3). IR (ATR, cm-1): νNH,OH 
= 3387, νmax = 1510, 1233, 1171, 1125, 1032, 820. MS (70 eV): m/z (%) 284 (M+ + 1, 100).  
Anti-2-chloro-4,4,4-trifluoro-3-[(4-methoxybenzyl)amino]butan-1-ol 9b 
Yellowish oil. Rf = 0.43 (Hex/EtOAc, 3/1). Yield 90%. 1H NMR (400 MHz, CDCl3): 
δ 3.54 (1H, q × d, J = 7.4, 5.6 Hz, CHCF3), 3.83 (3H, s, OCH3), 3.876 (1H, d, J = 
12.7 Hz, (HCH)N), 3.877 (1H, d × d, J = 12.3, 4.5 Hz, (HCH)CHCl), 3.99 (1H, d × 
d, J = 12.3, 5.0 Hz, (HCH)CHCl), 4.02 (1H, d, J = 12.7 Hz, (HCH)N), 4.17 (1H, q, 
J = 5.6 Hz, CHCl), 6.91 and 7.28 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and 
NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 52.4 (ArCH2N), 55.3 (OCH3), 58.6 (CHCl), 
62.3 (q, J = 27.1 Hz, CHCF3), 64.8 (q, J = 1.2 Hz, CH2CHCl), 114.0 (2 × O(HCarom)ortho), 125.6 (q, 
J = 285.6 Hz, CF3), 129.8 (2 × N(HCarom)ortho), 130.4 (NCarom,quat), 159.2 (OCarom,quat). 19F NMR (376 
MHz, CDCl3): δ -70.36 (3F, d, J = 7.4 Hz, CF3). IR (ATR, cm-1): νNH,OH = 3356, νmax = 1512, 1244, 
1163, 1126, 1032, 831, 816. GC-MS: m/z (%) = 297 (M+, 2), 174 (6), 136 (11), 121 (100), 78 (8). 
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Synthesis of trans-5-chloro-3-(4-methoxybenzyl/phenyl)-4-trifluoromethyl-1,3-oxazinanes 
10 
To a solution of anti-2-chloro-4,4,4-trifluoro-3-[(4-methoxyphenyl)amino]butan-1-ol 9a (0.10 g, 
0.35 mmol, 1 equiv) in THF (5 mL) in a pressure vial was added an excess of formaldehyde (37% 
solution in H2O,1 mL) at room temperature. The resulting mixture was stirred for three hours under 
reflux, after which water (5 mL) was added to the mixture. Extraction with ethyl acetate (3 x 7 mL), 
drying (MgSO4), filtration of the drying agent and evaporation of the solvent afforded trans-5-
chloro-3-(4-methoxyphenyl)-4-trifluoromethyl-1,3-oxazinane 10a, which was purified by means of 
preparative TLC (Hex/EtOAc, 10/1) to provide an analytically pure sample in a yield of 54% (0.06 
g, 0.20 mmol). 
Trans-5-chloro-3-(4-methoxyphenyl)-4-trifluoromethyl-1,3-oxazinane 10a  
Yellowish solid. Mp 64 °C. Rf = 0.53 (Hex/EtOAc, 10/1). Yield 54%. 1H NMR 
(400 MHz, CDCl3): δ 3.81 (3H, s, OCH3), 4.11-4.20 (2H, m, CHCF3, 
O(HCH)CHCl), 4.26-4.33 (2H, m, O(HCH)CHCl, CHCl), 4.98 (1H, d × q, J = 
11.7, 1.4 Hz, O(HCH)N), 5.04 (1H, d, J = 11.7 Hz, O(HCH)N), 6.86 and 7.22 (2 
× 2H, 2 × d, J = 9.0 Hz, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 49.9 
(CHCl), 55.5 (OCH3), 66.5 (q, J = 29.6 Hz, CHCF3), 69.4 (OCH2CHCl), 78.7 (q, J = 1.7 Hz, 
OCH2N), 114.4 (2 × O(CHarom)ortho), 122.0 (2 × N(CHarom)ortho), 124.8 (q, J = 284.8 Hz, CHCF3), 
145.0 (NCarom,quat), 155.7 (OCarom,quat). 19F NMR (376 MHz, CDCl3): δ -70.96 (3F, d, J = 9.0 Hz, 
CF3). IR (ATR, cm-1): νmax = 1508, 1238, 1223, 1182, 1167, 1136, 1109, 1074, 1051, 1034, 999, 
972, 851, 833, 824, 785, 665, 530. MS (70 eV): m/z (%): 296 (M+ + 1, 100).  
Trans-5-chloro-3-(4-methoxybenzyl)-4-trifluoromethyl-1,3-oxazinane 10b 
White yellowish solid. Mp 89 °C. Rf = 0.41 (Hex/EtOAc, 10/1). Yield 80%. 1H NMR 
(400 MHz, CDCl3): δ 3.65 (1H, q × d, J = 9.2, 2.3 Hz, CHCF3), 3.81 (3H, s, OCH3), 
4.06 (1H, d × d, J = 14.2, 3.4 Hz, O(HCH)CHCl), 4.20-4.25 (3H, m, O(HCH)CHCl, 
CHCl, N(HCH)Ar), 4.30 (1H, d, J = 13.3 Hz, N(HCH)Ar), 4.38 (1H, d, J = 11.5 Hz, 
O(HCH)N), 4.59 (1H, d × q, J = 11.5, 1.1 Hz, O(HCH)N), 6.87 and 7.28 (2 × 2H, 2 × 
d, J = 8.7 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 49.2 (CHCl), 
55.3 (OCH3), 57.8 (NCH2Ar), 62.6 (q, J = 29.0 Hz, CHCF3), 70.8 (OCH2CHCl), 80.2 (q, J = 1.2 Hz, 
OCH2N), 113.8 (2 × O(CHarom)ortho), 124.5 (q, J = 283.9 Hz, CHCF3), 129.5 (NCH2Carom,quat), 130.4 
(2 × NCH2(CHarom)ortho), 159.2 (OCarom,quat). 19F NMR (376 MHz, CDCl3): δ -69.60 (3F, d, J = 9.2 
RESULTS AND DISCUSSION-PART II 
85 
Hz, CF3). IR (ATR, cm-1): νmax = 1510, 1246, 1182, 1167, 1109, 1090, 1053, 1034, 999, 970, 837, 
665, 515. GC-MS: m/z (%) = 309 (M+, 8), 121 (100), 78 (8). 
Synthesis of trans-5-chloro-3-(4-methoxybenzyl/phenyl)-4-trifluoromethyl-1,3-oxazinan-2-
ones 11 
To a solution of anti-2-chloro-4,4,4-trifluoro-3-[(4-methoxyphenyl)amino]butan-1-ol 9a (0.10 g, 
0.35 mmol, 1 equiv) in dry CH2Cl2 (8 mL) was added triethylamine (0.07 g, 0.1 mL, 0.70 mmol, 2 
equiv) at 0 °C. Ethyl chloroformate (0.04 g, 0.04 mL, 0.35 mmol, 1 equiv) was added dropwise to 
the solution. The mixture was stirred at room temperature for three hours, after which the reaction 
mixture was extracted with CH2Cl2 (3 × 5 mL) and washed with brine (3 × 5 mL). Drying (MgSO4), 
filtration of the drying agent, and removal of the solvent in vacuo afforded a mixture of anti-2-
chloro-4,4,4-trifluoro-3-[(4-methoxyphenyl)amino]butan-1-ol 9a and trans-5-chloro-3-(4-
methoxyphenyl)-4-trifluoromethyl-1,3-oxazinan-2-one 11a in a ratio of 66:34. The mixture was 
redissolved in dry CH2Cl2 (5 mL) and an analogous procedure was repeated two more times. In 
this way, the starting material 9a was completely converted into trans-5-chloro-3-(4-
methoxyphenyl)-4-trifluoromethyl-1,3-oxazinan-2-one 11a (29%), which was purified by means of 
preparative TLC (Hex/EtOAc, 4/1) to obtain an analytically pure sample.  
Trans-5-chloro-3-(4-methoxyphenyl)-4-trifluoromethyl-1,3-oxazinan-2-one 11a 
White yellowish solid. Mp 100 °C. Rf = 0.12 (Hex/EtOAc, 4/1). Yield 29%. 1H 
NMR (400 MHz, CDCl3): δ 3.82 (3H, s, OCH3), 4.43 (1H, q × t, J = 6.5, 2.3 Hz, 
CHCF3), 4.51 (1H, d, J = 13.3 Hz, O(HCH)CHCl), 4.68 (1H, q, J = 2.3 Hz, 
CHCl), 4.83 (1H, d × d, J = 13.3, 2.3 Hz, O(HCH)CHCl), 6.94 and 7.25 (2 × 2H, 
2 × d, J = 8.9 Hz, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 46.8 (q, J = 
1.2 Hz, CHCl), 55.5 (OCH3), 67.0 (q, J = 29.9 Hz, CHCF3), 69.0 (q, J = 2.2 Hz, OCH2CHCl), 114.8 
(2 × O(CHarom)ortho), 123.1 (q, J = 285.7 Hz, CHCF3), 128.7 (2 × N(CHarom)ortho), 134.2 (NCarom,quat), 
150.2 (OCarom,quat), 159.3 (C=O). 19F NMR (376 MHz, CDCl3): δ -71.67 (3F, d, J = 6.5 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1705, νmax = 1514, 1429, 1319, 1184, 1167, 1134, 1115, 1026, 827, 748, 665, 
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Trans-5-chloro-3-(4-methoxybenzyl)-4-trifluoromethyl-1,3-oxazinan-2-one 11b 
Yellow solid. Mp 68 °C. Rf = 0.21 (Hex/EtOAc, 4/1). Yield 85%. 1H NMR (400 MHz, 
CDCl3): δ 3.81 (3H, s, OCH3), 3.91 (1H, q × t, J = 6.5, 2.4 Hz, CHCF3), 3.96 (1H, d, J 
= 14.8 Hz, N(HCH)Ar), 4.31 (1H, d × q, J = 13.1, 1.1 Hz, O(HCH)CHCl), 4.45 (1H, q, 
J = 2.4 Hz, CHCl), 4.68 (1H, d × d, J = 13.1, 2.4 Hz, O(HCH)CHCl), 5.54 (1H, d, J = 
14.8 Hz, N(HCH)Ar), 6.89 and 7.26 (2 × 2H, 2 × d, J = 8.5 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 46.3 (q, J = 1.2 Hz, CHCl), 51.0 (q, J = 1.2 Hz, 
NCH2Ar), 55.3 (OCH3), 59.8 (q, J = 30.0 Hz, CHCF3), 68.3 (q, J = 2.0 Hz, OCH2CHCl), 114.2 (2 × 
O(CHarom)ortho), 123.6 (q, J = 286.1 Hz, CHCF3), 125.9 (NCH2Carom,quat), 130.8 (2 × 
NCH2(CHarom)ortho), 151.0 (OCarom,quat), 159.8 (C=O). 19F NMR (376 MHz, CDCl3): δ -71.03 (3F, d, 
J = 6.5 Hz, CF3). IR (ATR, cm-1): νC=O = 1697, νmax = 1512, 1435, 1250, 1231, 1209, 1165, 1148, 
1111, 1092, 1032, 1011, 750, 669, 588. MS (70 eV): m/z (%): 324 (M+ + 1, 60).  
Synthesis of trans-2-hydroxymethyl-1-(4-methoxybenzyl/phenyl)-3-
(trifluoromethyl)aziridines 12 
t-BuOK (1M in THF, 0.03 g, 0.28 mL, 0.28 mmol, 0.8 equiv) was added dropwise to a stirred 
solution of anti-2-chloro-4,4,4-trifluoro-3-[(4-methoxyphenyl)amino]butan-1-ol 9a (0.10 g, 0.35 
mmol, 1 equiv) in dry THF (5 mL), and the resulting suspension was stirred at room temperature 
under argon for 10 minutes. The reaction mixture was extracted with EtOAc (3 × 5 mL) and washed 
with brine (3 × 5 mL). Drying (MgSO4), filtration of the drying agent, and removal of the solvent in 
vacuo afforded trans-2-hydroxymethyl-1-(4-methoxyphenyl)-3-(trifluoromethyl)aziridine 12a (0.02 
g, 0.08 mmol, 27%), which was purified by means of preparative TLC (Hex/EtOAc, 5/1) to obtain 
an analytically pure sample. 
Trans-2-hydroxymethyl-1-(4-methoxyphenyl)-3-(trifluoromethyl)aziridine 12a 
Orange solid. Mp 53 °C. Rf = 0.38 (Hex/EtOAc, 5/1). Yield 27%. 1H NMR (400 MHz, 
CDCl3): δ 2.68 (1H, d × d, J = 4.8, 2.6 Hz, (HCH)OH), 2.79 (1H, d × d, J = 4.8, 4.2 Hz, 
(HCH)OH), 3.37-3.39 (1H, m, CHCHCF3), 3.65 (1H, d, J = 9.4 Hz, OH), 3.74 (3H, s, 
OCH3), 4.03-4.11 (1H, m, CHCF3), 6.62 and 6.78 (2 × 2H, 2 × d, J = 8.9 Hz, 
O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 42.3 (CH2OH), 48.1 
(q, J = 2.7 Hz, CHCHCF3), 55.6 (q, J = 29.3 Hz, CHCF3), 55.7 (OCH3), 115.0 (2 × N(HCarom)ortho), 
115.1 (2 × O(HCarom)ortho), 125.4 (q, J = 284.0 Hz, CF3), 139.9 (NCarom,quat), 153.3 (OCarom,quat). 19F 
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NMR (376 MHz, CDCl3): δ -74.78 (3F, d, J = 7.9 Hz, CF3). IR (ATR, cm-1): νOH = 3374, νmax = 1514, 
1258, 1231, 1165, 1148, 1125, 1111, 1034, 824, 764, 525. MS (70 eV): m/z (%) 248 (M+ + 1, 100).  
Trans-2-hydroxymethyl-1-(4-methoxybenzyl)-3-(trifluoromethyl)aziridine 12b 
Light yellow oil. Rf = 0.46 (Hex/EtOAc, 4/1). Yield 61%. 1H NMR (400 MHz, CDCl3): 
δ 2.78 (1H, d × d, J = 5.1, 2.6 Hz, (HCH)OH), 2.82 (1H, d × d, J = 5.1, 4.3 Hz, 
(HCH)OH), 3.05 (1H, q × d, J = 7.3, 4.3 Hz, CHCF3), 3.17 (1H, t × d, J = 4.3, 2.6 
Hz, CHCHCF3), 3.83 (3H, s, OCH3), 3.90 and 3.98 (2 × 1H, 2 × d, J = 13.1 Hz, 
NCH2Ar), 6.89 and 7.28 (2 × 2H, 2 × d, J = 8.7 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 13C NMR 
(100.6 MHz, CDCl3): δ 43.6 (CH2OH), 49.7 (q, J = 2.9 Hz, CHCHCF3), 51.0 (ArCH2N), 55.3 (OCH3), 
59.1 (q, J = 27.5 Hz, CHCF3), 113.9 (2 × O(HCarom)ortho), 125.8 (q, J = 284.3 Hz, CF3), 129.5 (2 × 
NCH2(CHarom)ortho), 131.2 (NCH2Carom,quat), 158.9 (OCarom,quat). 19F NMR (376 MHz, CDCl3): δ -73.15 
(3F, d, J = 7.3 Hz, CF3). IR (ATR, cm-1): νOH = 3350, νmax = 1512, 1246, 1150, 1123, 1105, 1034, 
831, 816. GC-MS: m/z (%) = 261 (M+, 17), 136 (19), 121 (100), 78 (9). 
Synthesis of trans-2-methoxycarbonyl-1-(4-methoxybenzyl/phenyl)-3-
(trifluoromethyl)aziridines 13 
KOH (0.02 g, 0.36 mmol, 2 equiv) was added to an solution of trans-3-chloro-1-(4-methoxyphenyl)-
4-(trifluoromethyl)azetidin-2-one 4a (0.05 g, 0.18 mmol, 1 equiv) in MeOH (6 mL). After stirring for 
20 minutes under reflux, the reaction mixture was cooled to 0 °C, and quenched with water (5 mL). 
Extraction with EtOAc (3 × 5 mL), drying (MgSO4), filtration of the drying agent and evaporation of 
the solvent afforded trans-2-methoxycarbonyl-1-(4-methoxyphenyl)-3-(trifluoromethyl)aziridine 
13a, which was purified by means of preparative TLC (Hex/EtOAc, 5/1) to provide white yellowish 
solid in a yield of 73% (0.04 g, 0.14 mmol). 
Trans-2-methoxycarbonyl-1-(4-methoxyphenyl)-3-(trifluoromethyl)aziridine 13a 
White yellowish solid. Mp 74 °C. Rf = 0.40 (Hex/EtOAc, 5/1). Yield 73%. 1H NMR 
(400 MHz, CDCl3): δ 3.30-3.33 (2H, m, CHCHCF3, CHCHCF3), 3.57 (3H, s, 
COOMe), 3.68 (3H, s, OCH3), 6.71-6.76 (4H, m, O(CHarom)ortho and 
N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 39.2 (q, J = 1.9 Hz, CHCHCF3), 
42.1 (q, J = 40.7 Hz, CHCF3), 52.8 (COOCH3), 55.4 (OCH3), 114.5 (2 × O(HCarom)ortho), 120.3 (2 × 
N(HCarom)ortho), 122.9 (q, J = 273.9 Hz, CF3), 139.3 (NCarom,quat), 156.2 (OCarom,quat), 165.7 (C=O). 
RESULTS AND DISCUSSION-PART II 
88 
19F NMR (376 MHz, CDCl3): δ -71.08 (3F, ~s, CF3). IR (ATR, cm-1): νC=O = 1730, νmax = 1508, 1265, 
1246, 1148, 1080, 1030, 1013, 872, 833, 696. MS (70 eV): m/z (%) 276 (M+ + 1, 100).  
Trans-1-(4-methoxybenzyl)-2-methoxycarbonyl-3-(trifluoromethyl)aziridine 13b 
Light yellow oil. Rf = 0.21 (Hex/EtOAc, 5/1). Yield 25%. 1H NMR (400 MHz, 
CDCl3): δ 2.86-2.91 (2H, m, CHCHCF3, CHCHCF3), 3.66 (3H, s, COOMe), 
3.73 (3H, s, OCH3), 3.80 and 3.94 (2 × 1H, 2 × d, J = 13.0 Hz, NCH2Ar), 6.79 
and 7.17 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 13C 
NMR (100.6 MHz, CDCl3): δ 37.3 (CHCHCF3), 43.7 (q, J =39.7 Hz, CHCF3), 52.2 (COOCH3), 53.8 
(NCH2Ar), 55.2 (OCH3), 113.8 (2 × O(HCarom)ortho), 123.0 (q, J = 273.9 Hz, CF3), 129.49 
(NCarom,quat), 129.53 (2 × NCH2(CHarom)ortho), 159.0 (OCarom,quat), 167.3 (C=O). 19F NMR (376 MHz, 
CDCl3): δ -71.28 (3F, ~s, CF3). IR (ATR, cm-1): νC=O = 1736, νmax = 1514, 1344, 1246, 1207, 1175, 
1144, 1032, 804. GC-MS: m/z (%) = 290 (M+, 4), 274 (10), 258 (8), 220 (17), 188 (16), 136 (16), 
121 (100), 78 (7). 
Synthesis of cis-3-allyloxy-4-(trifluoromethyl)azetidin-2-ones 14 
To a solution of cis-3-hydroxy-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 3b (0.30 g, 
1.09 mmol, 1 equiv), tetrabutylammonium iodide (0.003 g, 0.01 mmol, 0.01 equiv) and allyl 
bromide (0.21 g, 0.15 mL, 1.74 mmol, 1.6 equiv) in CH2Cl2 (10 mL) was added aqueous sodium 
hydroxide (50%, 5 g, 10 mL). After stirring for three hours at room temperature, the reaction 
mixture was extracted with CH2Cl2 (3 × 5 mL). Drying (MgSO4), filtration of the drying agent and 
evaporation of the solvent in vacuo afforded cis-3-allyloxy-1-(4-methoxybenzyl)-4-
(trifluoromethyl)azetidin-2-one 14b, which was purified by means of column chromatography 
(Hex/EtOAc, 5/1) to obtain an analytically pure sample (0.33 g, 1.04 mmol, 95%). 
Cis-3-allyloxy-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 14a 
White crystals. Mp 81 °C. Rf = 0.61 (Hex/EtOAc, 2/1) or recrystallization 
(CH2Cl2/Et2O, 1/3). Yield 94%. 1H NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 
4.22-4.32 (2H, m, OCH2CHCH2), 4.61 (1H, quintet, J = 5.4 Hz, CHCF3), 4.96 
(1H, d, J = 5.4 Hz, OCHCHCF3), 5.30 (1H, d × q, J = 10.6, 1.3 Hz, 
OCH2CH(HCH)), 5.39 (1H, d × q, J = 17.2, 1.6 Hz, OCH2CH(HCH)), 5.94 (1H, d 
× d × t, J = 17.2, 10.6, 5.4 Hz, OCH2CHCH2), 6.89 and 7.40 (2 × 2H, 2 × d, J = 9.0 Hz, N(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.5 (OCH3), 57.8 (q, J = 33.0 Hz, CHCF3), 
73.1 (OCH2CHCH2), 80.4 (OCHCHCF3), 114.4 (2 × O(CHarom)ortho), 118.9 (COCH2CHCH2), 119.4 
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(2 × N(CHarom)ortho), 123.7 (q, J = 280.7 Hz, CF3), 129.4 (NCarom,quat), 132.8 (OCH2CHCH2), 157.2 
(OCarom,quat), 163.9 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.52 (3F, d, J = 5.4 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1759, νmax = 1516, 1389, 1273, 1134, 982, 837, 808, 642, 505. MS (70eV): 
302 (M+ + 1, 100).  
Cis-3-allyloxy-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 14b 
White crystals. Mp 67 °C. Rf = 0.27 (Hex/EtOAc, 5/1). Yield 95%. 1H NMR (400 MHz, 
CDCl3): δ 3.80 (3H, s, OCH3), 3.87 (1H, quintet, J = 5.6 Hz, CHCF3), 3.95 (1H, d, J = 
14.8 Hz, N(HCH), 4.18 (2H, d, J = 5.5 Hz, OCH2CHCH2), 4.74 (1H, d, J = 5.6 Hz, 
OCH), 4.81 (1H, d, J = 14.8 Hz, N(HCH), 5.25 (1H, d, J = 10.6 Hz, OCH2CH(HCH)), 
5.33 (1H, d × q, J = 17.2, 1.5 Hz, OCH2CH(HCH)), 5.88 (1H, d × d × t, J = 17.2, 10.6, 
5.5 Hz, OCH2CHCH2), 6.87 and 7.16 (2 × 2H, 2 × d, J = 8.5 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 44.5 (NCH2), 55.3 (OCH3), 56.4 (q, J = 32.7 Hz, 
CHCF3), 72.8 (OCH2CHCH2), 81.1 (OCHCHCF3), 114.4 (2 × O(CHarom)ortho), 118.7 (OCH2CHCH2), 
123.9 (q, J = 280.2 Hz, CHCF3), 126.1 (NCH2Carom,quat), 129.9 (2 × NCH2(CHarom)ortho), 132.9 
(COCH2CHCH2), 159.6 (OCarom,quat), 166.4 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.33 (3F, d, 
J = 5.6 Hz, CF3). IR (ATR, cm-1): νC=O = 1759, νmax = 1514, 1352, 1279, 1244, 1152, 1126, 1113, 
1032, 920, 837, 669, 635, 590, 519. MS (70eV): 316 (M+ + 1, 100).  
Cis-3-allyloxy-1-(4-ethoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 14c 
White crystals. Mp 83 °C. Recrystallization (CH2Cl2/Et2O, 1/3). Yield 84%. 1H 
NMR (400 MHz, CDCl3): δ 1.39 (3H, t, J = 7.0 Hz, OCH2CH3), 4.00 (2H, q, J = 
7.0 Hz, OCH2CH3), 4.21-4.30 (2H, m, OCH2CHCH2), 4.61 (1H, quintet, J = 5.4 
Hz, CHCF3), 4.95 (1H, d, J = 5.4 Hz, OCHCHCF3), 5.29 (1H, d × q, J = 10.7, 1.4 
Hz, OCH2CH(HCH)), 5.38 (1H, d × q, J = 17.2, 1.6 Hz, OCH2CH(HCH)), 5.93 
(1H, d × d × t, J = 17.2, 10.7, 5.4 Hz, OCH2CHCH2), 6.86 and 7.37 (2 × 2H, 2 × d, J = 9.0 Hz, 
N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 14.8 (OCH2CH3), 57.8 (q, J = 
33.0 Hz, CHCF3), 63.7 (OCH2CH3), 73.0 (OCH2CHCH2), 80.5 (OCHCHCF3), 115.0 (2 × 
O(CHarom)ortho), 118.8 (OCH2CHCH2), 119.4 (2 × N(CHarom)ortho), 123.7 (q, J = 280.8 Hz, CF3), 129.3 
(NCarom,quat), 132.8 (OCH2CHCH2), 156.6 (OCarom,quat), 164.0 (C=O). 19F NMR (376.5 MHz, CDCl3): 
δ -68.54 (3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1757, νmax = 1518, 1391, 1258, 1136, 
1111, 980, 922, 824, 650, 525. MS (70eV): 316 (M+ + 1, 100).  
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Cis-3-allyloxy-1-phenyl-4-(trifluoromethyl)azetidin-2-one 14d 
White yellowish solid. Mp <45 °C. Rf = 0.36 (PE/EtOAc, 4/1). Yield 77%. 1H NMR 
(400 MHz, CDCl3): δ 4.24-4.32 (2H, m, OCH2CHCH2), 4.67 (1H, quintet, J = 5.4 Hz, 
CHCF3), 4.98 (1H, d, J = 5.4 Hz, OCHCHCF3), 5.31 (1H, d × q, J = 10.6, 1.3 Hz, 
OCH2CH(HCH)), 5.40 (1H, d × q, J = 17.3, 1.5 Hz, OCH2CH(HCH)), 5.94 (1H, d × d 
× t, J = 17.3, 10.6, 5.4 Hz, OCH2CHCH2), 7.18 (1H, t, J = 7.7 Hz, N(CHarom)para), 7.36 
(2H, t, J = 7.7 Hz, N(CHarom)meta), 7.47 (2H, d, J = 7.7 Hz, N(CHarom)ortho). 13C NMR (100.6 MHz, 
CDCl3): δ 57.5 (q, J = 33.2 Hz, CHCF3), 73.1 (OCH2CHCH2), 80.3 (OCHCHCF3), 117.6 (2 × 
N(CHarom)ortho), 119.0 (OCH2CHCH2), 123.7 (q, J = 280.8 Hz, CF3), 125.5 (N(CHarom)para), 129.3 (2 
× N(CHarom)meta), 132.8 (OCH2CHCH2), 136.2 (NCarom,quat), 164.3 (C=O). 19F NMR (376.5 MHz, 
CDCl3): δ -68.41 (3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1767, νmax = 1599, 1499, 1360, 
1279, 1134, 989, 930, 752, 689, 490. MS (70eV): 272 (M+ + 1, 100).  
Cis-3-allyloxy-1-(4-methylphenyl)-4-(trifluoromethyl)azetidin-2-one 14e 
White crystals. Mp 78 °C. Recrystallization (CH2Cl2/Et2O, 1/3). Yield 71%. 1H NMR 
(400 MHz, CDCl3): δ 2.25 (3H, s, CH3), 4.15-4.24 (2H, m, OCH2CHCH2), 4.57 (1H, 
quintet, J = 5.4 Hz, CHCF3), 4.89 (1H, d, J = 5.4 Hz, OCHCHCF3), 5.23 (1H, d, J = 
10.7 Hz, OCH2CH(HCH)), 5.32 (1H, d, J = 17.2 Hz, OCH2CH(HCH)), 5.87 (1H, d × 
d × t, J = 17.2, 10.7, 5.5 Hz, OCH2CHCH2), 7.09 and 7.28 (2 × 2H, 2 × d, J = 8.2 
Hz, N(CHarom)ortho and CH3(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 20.9 (CH3), 57.5 (q, J = 
33.2 Hz, CHCF3), 73.1 (OCH2CHCH2), 80.3 (OCHCHCF3), 117.7 (2 × CH3(CHarom)ortho), 118.9 
(OCH2CHCH2), 123.7 (q, J = 280.9 Hz, CF3), 129.7 (2 × N(CHarom)ortho), 132.8 (OCH2CHCH2), 
133.7 (NCarom,quat), 135.3 (CH3Carom,quat), 164.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.46 (3F, 
d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1748, νmax = 1516, 1396, 1364, 1275, 1246, 1167, 1134, 
1005, 816, 646, 482. MS (70eV): 286 (M+ + 1, 100).  
Cis-3-allyloxy-1-isopropyl-4-(trifluoromethyl)azetidin-2-one 14f  
White yellowish oil. Solidified in fridge. Rf = 0.42 (PE/EtOAc, 4/1). Yield 79%. 1H NMR 
(400 MHz, CDCl3): δ 1.26 and 1.29 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CH), 3.88 (1H, 
septet, J = 6.8 Hz, (CH3)2CH), 4.11 (1H, q × d, J = 6.0, 4.8 Hz, CHCF3), 4.15-4.24 (2H, 
m, OCH2CHCH2), 4.74 (1H, d, J = 4.8 Hz, OCHCHCF3), 5.26 (1H, d × q, J = 10.6, 1.4 
Hz, OCH2CH(HCH), 5.35 (1H, d × q, J = 17.2, 1.6 Hz, OCH2CH(HCH), 5.90 (1H, d × q × t, J = 
17.2, 10.6, 5.4 Hz, OCH2CHCH2). 13C NMR (100.6 MHz, CDCl3): δ 19.3 and 21.1 ((CH3)2CH), 45.1 
((CH3)2CH), 56.6 (q, J = 33.0 Hz, CHCF3), 72.7 (OCH2CHCH2), 80.2 (OCHCHCF3), 118.5 
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(OCH2CHCH2), 123.9 (q, J = 279.8 Hz, CF3), 133.0 (OCH2CHCH2), 166.2 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -69.49 (3F, d, J = 6.0 Hz, CF3). IR (ATR, cm-1): νC=O = 1761, νmax = 1281, 1213, 
1148, 1123, 1009, 928, 660. MS (70eV): 238 (M+ + 1, 100). 
Synthesis of 3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-ones 15 
In a 250 mL flame-dried flask, cis-3-allyloxy-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-
one 14a (0.12 g, 0.40 mmol, 1 equiv) was dissolved in a mixture of dry CH2Cl2 (15 mL) and dry 
MeOH (10 mL). A small pinch of Sudan III indicator was added to the reaction mixture. The 
reaction mixture was sparged with ozone at -78 °C until the red color of the reaction mixture 
dissipated. The mixture was stirred for one hour at room temperature in the presence of dimethyl 
sulfide (0.06 g, 0.07 mL, 1 mmol, 2.5 equiv), after which the reaction mixture was extracted with 
water (10 mL). The water phase was then extracted three times with CH2Cl2 (3 × 5 mL). The 
combined organic extracts were washed three times with brine (3 × 5 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure, affording a crude mixture. To the crude mixture 
in dry THF (6 mL) at 0 °C was added gradually BH3 (1M in Et2O, 1 mL, 1 mmol, 2.5 equiv). The 
temperature was allowed to rise to room temperature and the reaction was stirred for three hours 
at this temperature. The mixture was extracted with EtOAc (3 × 8 mL) and washed with brine (3 × 
5 mL). Drying (MgSO4), filtration of the drying agent and evaporation of the solvent in vacuo 
afforded cis-3-(2-hydroxyethoxy)-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 15a (0.09 
g, 0.30 mmol, 72%), which was purified by means of column chromatography (Hex/EtOAc, 3/1) to 
obtain an analytically pure sample. 
Cis-3-(2-hydroxyethoxy)-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 15a 
Yellow oil. Rf = 0.14 (Hex/EtOAc, 3/1). Yield 72%. 1H NMR (400 MHz, CDCl3): δ 
2.67 (1H, t, J = 5.7 Hz, OH), 3.73 (3H, s, OCH3), 3.75-3.80 (3H, m, O(HCH)CH2 
and CH2OH), 3.85-3.91 (1H, m, O(HCH)CH2), 4.60 (1H, quintet, J = 5.4 Hz, 
CHCF3), 4.95 (1H, d, J = 5.4 Hz, OCHCHCF3), 6.83 and 7.32 (2 × 2H, 2 × d, J = 
9.0 Hz, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.5 
(OCH3), 58.0 (q, J = 33.1 Hz, CHCF3), 62.2 (CH2OH), 74.9 (CH2CH2OH), 82.2 (OCHCHCF3), 114.5 
(2 × O(CHarom)ortho), 119.6 (2 × N(CHarom)ortho), 123.6 (q, J = 281.0 Hz, CHCF3), 129.1 (NCarom,quat), 
157.4 (OCarom,quat), 164.6 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.42 (3F, d, J = 5.4 Hz, CF3). 
IR (ATR, cm-1): νOH = 3393; νC=O = 1744, νmax =1512, 1233, 1128, 1032, 822, 681. MS (70eV): 306 
(M+ + 1, 100).  
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Cis-3-(2-hydroxyethoxy)-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 15b 
Yellowish oil. Rf = 0.15 (Hex/EtOAc, 1/1). Yield 77%. 1H NMR (400 MHz, CDCl3): δ 
2.89 (1H, t, J = 6.6 Hz, OH), 3.71-3.79 (3H, m, O(HCH)CH2 and CH2OH), 3.81 (3H, s, 
OCH3), 3.82-3.88 (1H, m, O(HCH)CH2), 3.94 (1H, q × d, J = 6.1, 4.9 Hz, CHCF3), 3.97 
(1H, d, J = 14.5 Hz, N(HCH)), 4.80 (1H, d, J = 4.9 Hz, OCHCHCF3), 4.81 (1H, d, J = 
14.5 Hz, N(HCH)), 6.88 and 7.16 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 44.6 (NCH2), 55.3 (OCH3), 56.7 (q, J 
= 32.9 Hz, CHCF3), 62.2 (CH2OH), 74.8 (CH2CH2OH), 82.7 (OCHCHCF3), 114.4 (2 × 
O(CHarom)ortho), 123.8 (q, J = 280.2 Hz, CHCF3), 125.8 (NCarom,quat), 129.9 (2 × NCH2(CHarom)ortho), 
159.6 (OCarom,quat), 167.2 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.26 (3F, d, J = 6.1 Hz, CF3). 
IR (ATR, cm-1): νOH = 3431; νC=O = 1759, νmax = 1514, 1279, 1246, 1159, 1130, 1030, 800, 664, 
513. MS (70eV): 320 (M+ + 1, 100).  
Cis-1-(4-ethoxyphenyl)-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-one 15c  
White solid. Mp 81 °C. Rf = 0.10 (PE/EtOAc, 2/1). Yield 72%. 1H NMR (400 MHz, 
CDCl3): δ 1.40 (3H, t, J = 7.0 Hz, OCH2CH3), 2.93 (1H, t, J = 6.2 Hz, CH2OH), 
3.77-3.89 (3H, m, O(HCH)CH2 and CH2OH), 3.91-395 (1H, m, O(HCH)CH2), 4.01 
(2H, q, J = 7.0 Hz, OCH2CH3), 4.67 (1H, quintet, J = 5.4 Hz, CHCF3), 5.02 (1H, 
d, J = 5.4 Hz, OCHCHCF3), 6.88 and 7.37 (2 × 2H, 2 × d, J = 9.0 Hz, N(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 14.8 (OCH2CH3), 58.0 (q, J = 33.1 Hz, 
CHCF3), 62.1 (CH2OH), 63.8 (OCH2CH3), 74.9 (CH2CH2OH), 82.1 (OCHCHCF3), 115.0 (2 × 
O(CHarom)ortho), 119.5 (2 × N(CHarom)ortho), 123.6 (q, J = 280.9 Hz, CHCF3), 129.0 (NCarom,quat), 156.8 
(OCarom,quat), 164.6 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.44 (3F, d, J = 5.4 Hz, CF3). IR 
(ATR, cm-1): νOH = 3399; νC=O = 1759, νmax = 1510, 1391, 1250, 1169, 1146, 1121, 1043, 841, 824, 
656. MS (70eV): 320 (M+ + 1, 100).  
Cis-3-(2-hydroxyethoxy)-1,4-bis(4-methoxyphenyl)azetidin-2-one 19 
White crystals. Mp 105 °C. Rf = 0.10 (PE/EtOAc, 1/1). Yield 51%. 1H NMR (400 
MHz, CDCl3): δ 2.32 (1H, t, J = 6.7 Hz, OH), 3.30-3.55 (4H, m, OCH2CH2OH), 
3.66 and 3.72 (2 × 3H, 2 × s, OCH3), 4.85 (1H, d, J = 4.8 Hz, OCHCH), 5.11 (1H, 
d, J = 4.8 Hz, OCHCH), 6.71 (2H, d, J = 9.0 Hz, N(CHarom)meta), 6.84 (2H, d, J = 
8.6 Hz, CH(CHarom)meta), 7.19 (2H, d, J = 9.0 Hz, N(CHarom)ortho), 7.24 (2H, d, J = 
8.6 Hz, CH(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.3 and 55.4 (2 × OCH3), 61.9 (CH2OH), 
62.0 (OCHCH), 73.4 (CH2CH2OH), 83.9 (OCHCH), 114.1 (2 × CH(CHarom)meta), 114.3 (2 × 
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N(CHarom)meta), 118.9 (2 × N(CHarom)ortho), 125.1 (NCarom,quat), 129.3 (2 × CH(CHarom)ortho), 130.4 
(CHCarom,quat), 156.5 and 160.0 (2 × OCarom,quat), 164.5 (C=O). IR (ATR, cm-1): νOH = 3273, νC=O = 
1736, νmax = 1510, 1396, 1298, 1236, 1175, 1132, 1028, 835, 800, 540. MS (70eV): 344 (M+ + 1, 
100). 
Trans-1-(4-ethoxyphenyl)-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-one 21  
Colorless oil. Rf = 0.42 (PE/EtOAc, 1/1). Yield 60%. 1H NMR (400 MHz, CDCl3): 
δ 1.41 (3H, t, J = 7.0 Hz, OCH2CH3), 2.77 (1H, t, J = 5.5 Hz, OH), 3.78-3.93 (4H, 
m, OCH2CH2OH), 4.02 (2H, q, J = 7.0 Hz, OCH2CH3), 4.45 (1H, q × d, J = 5.6, 
1.3 Hz, CHCF3), 4.87 (1H, d, J = 1.3 Hz, OCHCHCF3), 6.89 and 7.33 (2 × 2H, 2 
× d, J = 8.9 Hz, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): 
δ 14.8 (OCH2CH3), 60.1 (q, J = 34.3 Hz, CHCF3), 61.9 (CH2OH), 63.8 (OCH2CH3), 73.6 
(CH2CH2OH), 83.3 (q, J = 1.5 Hz, OCHCHCF3), 115.1 (2 × O(CHarom)ortho), 120.2 (2 × 
N(CHarom)ortho), 123.5 (q, J = 280.3 Hz, CHCF3), 128.6 (NCarom,quat), 157.0 (OCarom,quat), 163.2 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -71.48 (3F, d, J = 5.6 Hz, CF3). IR (ATR, cm-1): νOH = 3447, νC=O 
= 1755, νmax =1512, 1395, 1246, 1159, 1115, 1045, 829, 700, 515. MS (70eV): 320 (M+ + 1, 100).  
Cis-3-(2-hydroxyethoxy)-1-phenyl-4-(trifluoromethyl)azetidin-2-one 15d 
Yellowish oil. Rf = 0.31 (PE/EtOAc, 1/1). Yield 95%. 1H NMR (400 MHz, CDCl3): δ 
2.55 (1H, t, J = 5.6 Hz, OH), 3.72-3.92 (4H, m, OCH2CH2OH), 4.67 (1H, quintet, J = 
5.4 Hz, CHCF3), 4.97 (1H, d, J = 5.4 Hz, OCHCHCF3), 7.13 (1H, t, J = 7.8 Hz, 
N(CHarom)para), 7.31 (2H, t, J = 7.8 Hz, N(CHarom)meta), 7.40 (2H, d, J = 7.8 Hz, 
N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 57.7 (q, J = 33.3 Hz, CHCF3), 62.2 
(CH2OH), 74.9 (OCH2CH2), 82.1 (OCHCHCF3), 117.7 (2 × N(CHarom)ortho), 123.6 (q, J = 280.2 Hz, 
CF3), 125.7 (N(CHarom)para), 129.3 (2 × N(CHarom)meta), 136.0 (NCarom,quat), 164.9 (C=O). 19F NMR 
(376.5 MHz, CDCl3): δ -68.31 (3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νOH = 3428, νC=O = 1761, 
νmax = 1599, 1499, 1360, 1277, 1136, 752, 689, 486. MS (70eV): 276 (M+ + 1, 100).  
Cis-3-(2-hydroxyethoxy)-1-(4-methylphenyl)-4-(trifluoromethyl)azetidin-2-one 15e  
White crystals. Mp 79 °C. Rf = 0.14 (PE/EtOAc, 2/1). Yield 63%. 1H NMR (400 MHz, 
CDCl3): δ 2.26 (3H, s, CH3), 2.65 (1H, brs, OH), 3.73-3.91(4H, m, OCH2CH2OH), 
4.63 (1H, quintet, J = 5.4 Hz, CHCF3), 4.95 (1H, d, J = 5.4 Hz, OCHCHCF3), 7.10 
and 7.28 (2 × 2H, 2 × d, J = 8.3 Hz, N(CHarom)ortho and CH3(CHarom)ortho). 13C NMR 
(100.6 MHz, CDCl3): δ 21.0 (CH3), 57.8 (q, J = 33.1 Hz, CHCF3), 62.2 (CH2OH), 
74.9 (CH2CH2OH), 82.1 (OCHCHCF3), 117.8 (2 × CH3(CHarom)ortho), 123.6 (q, J = 281.0 Hz, CF3), 
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129.8 (2 × N(CHarom)ortho), 133.5 (NCarom,quat), 135.6 (CH3Carom,quat), 164.8 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -68.36 (3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νOH = 3358, νC=O = 1753, νmax = 
1514, 1398, 1366, 1275, 1244, 1140, 1028, 814, 646, 494. MS (70eV): 290 (M+ + 1, 100).  
Cis-3-(2-hydroxyethoxy)-1-isopropyl-4-(trifluoromethyl)azetidin-2-one 15f 
Yellow oil. Rf = 0.15 (PE/EtOAc, 1/1). Yield 47%. 1H NMR (400 MHz, CDCl3): δ 1.27 
and 1.31 (2 × 3H, 2 × d, J = 6.8 Hz, (CH3)2CH), 3.12 (1H, t, J = 6.4 Hz, OH), 3.71-3.91 
(5H, m, (CH3)2CH, OCH2CH2OH), 4.17 (1H, q × d, J = 6.1, 4.9 Hz, CHCF3), 4.79 (1H, 
d, J = 4.9 Hz, OCHCHCF3). 13C NMR (100.6 MHz, CDCl3): δ 19.4 and 21.0 ((CH3)2CH), 
45.4 ((CH3)2CH), 56.9 (q, J = 33.1 Hz, CHCF3), 62.2 (CH2OH), 74.8 (CH2CH2OH), 81.8 
(OCHCHCF3), 123.7 (q, J = 279.8 Hz, CF3), 167.2 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.40 
(3F, d, J = 6.1 Hz, CF3). IR (ATR, cm-1): νOH = 3428, νC=O = 1755, νmax = 1281, 1217, 1148, 1042, 
849, 660. MS (70eV): 242 (M+ + 1, 100).  
Synthesis of 3-[2,2,2-trifluoro-1-(arylamino)ethyl]-1,4-dioxan-2-ones 16 
A solution of cis-1-(4-ethoxyphenyl)-3-(2-hydroxyethoxy)-4-(trifluoromethyl)azetidin-2-one 15c 
(0.05 g, 0.16 mmol, 1 equiv) and an excess of K2CO3 in toluene was heated at reflux temperature 
for 28 hours. The reaction mixture was then filtered through a small pad of Celite® and 
concentrated under reduced pressure, resulting in a crude mixture. The 19F NMR of this mixture 
showed it to consist of syn-3-{1-[(4-ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-one 
and anti-3-{1-[(4-ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-one 16c in a ratio of 
72:28. The mixture was purified by means of preparative TLC (PE/EtOAc, 6/1), providing an pure 
but inseparable mixture of syn-3-{1-[(4-ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-
one and anti-3-{1-[(4-ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-one 16c (86%). 
3-{2,2,2-Trifluoro-1-[(4-methoxyphenyl)amino]ethyl}-1,4-dioxan-2-one 16a 
Spectral data derived from the mixture of diastereomers 
Yellow oil. Rf = 0.18 (PE/EtOAc, 3/1). Yield 
81%. Syn:anti 78:22. 1H NMR (400 MHz, 
CDCl3): δ 3.68 and 3.69 (3H, s, OMe), 3.73-
4.05 (3H, m, OCH2CH2OCO, NH), 4.32-4.36 (1H, m, (HCH)OCO), 4.47-4.67 (3H, m, (HCH)OCO, 
CHCF3 and OCHCHCF3), 6.65-6.77 (4H, m, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 
MHz, CDCl3): δ 55.6 and 55.7 (OCH3), 59.0 (q, J = 28.8 Hz, CHCF3), 62.7 and 62.8 
(OCH2CH2OCO), 68.53 and 68.55 (CH2OCO), 74.1 and 75.4 (q, J = 1.5 and 1.9 Hz, OCHCO), 
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114.8 and 115.1 (2 × O(CHarom)ortho), 116.5 and 116.8 (2 × N(CHarom)ortho), 124.9 (q, J = 285.9 Hz, 
CHCF3), 138.0 and 138.9 (NCarom,quat), 154.0 (OCarom,quat), 165.9 and 166.2 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -72.22 and -69.98 (3F, d, J = 7.5 and 6.9 Hz, CF3). IR (ATR, cm-1): νNH = 3393, 
2922, νC=O = 1721, νmax = 1520, 1458, 1244, 1233, 1140, 1123, 1074, 826, 694, 519. MS (70eV): 
306 (M+ + 1, 100). HRMS (ESI) for C13H15F3NO4+: 306.0948 [M + H]+. Found: 306.0935. 
3-{1-[(4-Ethoxyphenyl)amino]-2,2,2-trifluoroethyl}-1,4-dioxan-2-one 16c 
Spectral data derived from the mixture of diastereomers 
Yellow crystals. Mp 108 °C. Rf = 0.08 
(PE/EtOAc, 6/1). Yield 86%. Syn:anti 72:28. 
1H NMR (400 MHz, CDCl3): δ 1.37 and 1.38 
(3H, t, J = 6.9 and 7.1 Hz, CH2CH3), 3.80-4.11 (5H, m, OCH2CH2OCO, NH and CH2CH3), 4.39-
4.42 (1H, m, (HCH)OCO), 4.54-4.74 (3H, m, (HCH)OCO, CHCF3 and OCHCHCF3), 6.71-6.83 (4H, 
m, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 14.9 (CH2CH3), 59.0 and 
59.2 (q, J = 29.0 and 28.3 Hz, CHCF3), 62.7 and 62.8 (OCH2CH2OCO), 63.86 and 63.95 (CH2CH3), 
68.5 (CH2OCO), 74.1 and 75.4 (q, J = 1.5 and 1.9 Hz, OCHCO), 115.6 and 115.9 (2 × 
O(CHarom)ortho), 116.5 and 116.8 (2 × N(CHarom)ortho), 124.5 and 124.9 (q, J = 283.5 and 285.9 Hz, 
CHCF3), 137.9 and 138.8 (NCarom,quat), 153.3 (OCarom,quat), 165.9 and 166.2 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -72.21 and -70.00 (3F, d, J = 7.7 and 6.9 Hz, CF3). IR (ATR, cm-1): νNH = 3374, 
3352; νC=O = 1721, νmax = 1520, 1231, 1105, 1049, 949, 926, 808, 694, 521. MS (70eV): 320 (M+ 
+ 1, 100). HRMS (ESI) for C14H17F3NO4+: 320.1104 [M + H]+. Found: 320.1094.  
3-[2,2,2-Trifluoro-1-(phenylamino)ethyl]-1,4-dioxan-2-one 16d 
Spectral data derived from the mixture of diastereomers 
Yellowish solid. Mp 85 °C. Rf = 0.38 (PE/EtOAc, 
2/1). Yield 71%. Syn:anti 69:31. 1H NMR (400 
MHz, CDCl3): δ 3.75-4.29 (3H, m, OCH2CH2OCO, 
NH), 4.41-4.44 (1H, m, (HCH)OCO), 4.56-4.89 (3H, m, (HCH)OCO, CHCF3 and OCHCHCF3), 
6.71-6.89 and 7.19-7.27 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 57.1 and 57.6 (q, J = 
29.5 and 28.8 Hz, CHCF3), 62.8 and 62.9 (OCH2CH2OCO), 68.5 and 68.6 (OCH2CH2OCO), 74.4 
and 75.3 (q, J = 1.5 and 1.9 Hz, OCHCO), 114.4 and 114.6 (2 × N(CHarom)ortho), 120.10 and 120.11 
(N(CHarom)para), 124.4 and 124.8 (q, J = 282.2 and 285.7 Hz, CHCF3), 129.4 and 129.7 (2 × 
N(CHarom)meta), 144.2 and 145.0 (NCarom,quat), 165.7 and 166.0 (C=O). 19F NMR (376.5 MHz, 
CDCl3): δ - 72.51 and -70.00 (3F, d, J = 7.2 and 6.8 Hz, CF3). IR (ATR, cm-1): νNH = 3385; νC=O = 
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1722, νmax = 1603, 1254, 1167, 1140, 1111, 1074, 930, 750, 691, 505. MS (70eV): 276 (M+ + 1, 
100). HRMS (ESI) for C12H13F3NO3+: 276.0842 [M + H]+. Found: 276.0846. 
3-{2,2,2-Trifluoro-[1-(4-methylphenyl)amino]ethyl}-1,4-dioxan-2-one 16e 
Spectral data derived from the mixture of diastereomers 
White solid. Mp 109 °C. Rf = 0.38 (PE/EtOAc, 
2/1). Yield 98%. Syn:anti 75:25. 1H NMR (400 
MHz, CDCl3): δ 2.24 and 2.26 (3H, s, CH3), 3.79-
4.16 (3H, m, OCH2CH2OCO, NH), 4.39-4.43 (1H, m, (HCH)OCO), 4.54-4.61 and 4.70-4.83 (3H, 
m, (HCH)OCO, CHCF3 and OCHCHCF3), 6.68 and 7.01; 6.69 and 7.05 (2 × 2H, 2 × d, J = 8.3 and 
8.4 Hz, N(CHarom)ortho and CH3(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 20.43 and 20.45 
(CH3), 57.8 and 58.2 (q, J = 29.3 and 28.8 Hz, CHCF3), 62.7 and 62.8 (OCH2CH2OCO), 68.5 
(OCH2CH2OCO), 74.2 and 75.3 (q, J = 1.2 and 1.8 Hz, OCHCO), 114.8 and 115.0 (2 × 
N(CHarom)ortho), 124.5 and 124.9 (q, J = 283.6 and 285.8 Hz, CHCF3), 129.5 and 129.6 
(CH3Carom,quat), 129.9 and 130.2 (2 × CH3(CHarom)ortho), 141.8 and 142.7 (NCarom,quat), 165.8 and 
166.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -72.41 and -70.00 (3F, d, J = 7.0 and 6.9 Hz, CF3). 
IR (ATR, cm-1): νNH = 3383, 3360, νC=O = 1721, νmax = 1526, 1252, 1159, 1125, 1105, 1070, 1047, 
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4-Trifluoromethyl-3-oxo-β-lactams were unexpectedly transformed into 2-[(2,2-
difluorovinyl)amino]-2-oxoacetates as major products, accompanied by minor amounts of 2-oxo-
2-[(2,2,2-trifluoroethyl)amino]acetates, upon treatment with alkyl halides and triethylamine in 
DMSO. This peculiar C3-C4 bond fission reactivity was investigated in-depth, from both an 
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In general, 3-oxo-β-lactams (or azetidine-2,3-diones) can be recognized as versatile precursors 
for the synthesis of a broad variety of β-lactam and non-β-lactam products. For example, 
deployment of 3-oxo-β-lactams has been reported to afford a variety of 3-amino-β-lactams, 3-
hydroxy-β-lactams and amino acid derivatives.81 As can be seen from published reactivity studies 
on trifluoromethylated small-ring heterocycles, the presence of a CF3-group has a pronounced 
effect on their overall behavior in terms of synthetic elaboration. In a previous communications on 
the chemistry of 2-CF3-aziridines and -azetidines revealed an unexpected and even opposite 
reactivity as compared to their 2-alkyl-substituted counterparts.39,82a,82b,28a,82c,28b,82d,23b,82e,19,82f,82g 
Another important feature of trifluoromethylated azaheterocycles comprises their suitability to 
undergo deprotonation in α-position with respect to the strong electron-withdrawing CF3 group, as 
exemplified by the generation of the 2-(trifluoromethyl)aziridin-2-yl anion and its subsequent 
neutralization by means of different types of electrophiles.23 In that respect, the deployment of 4-
trifluoromethyl-3-oxo-β-lactams might offer new opportunities for the installation of an additional 
side chain through abstraction of the acidic C4-proton in α-position with respect to the oxo group 
and the CF3 moiety. Consequently, attempts were made in the present work to address this 
synthetic challenge, and the results of this study are described below. 
 
2. Synthesis of 4-trifluoromethyl-3-oxo-β-lactam building blocks and their 
transformation into amido esters 
 
4-Trifluoromethyl-3-oxo-β-lactams are rather unstable upon prolonged preservation and should 
therefore be freshly prepared and used immediately for further elaboration. To that end, 3-hydroxy-
4-trifluoromethyl-β-lactams 1 were synthesized through hydrogenolysis of the corresponding 3-
benzyloxy-β-lactams, which are easily accessible via [2+2]-cyclocondensation between 
trifluoroaldimines, prepared from the commercially available 1-ethoxy-2,2,2-trifluoroethanol using 
4-methoxyaniline or 4-methoxybenzylamine in toluene under Dean-Stark conditions, and the 
ketene derived from benzyloxyacetyl chloride. A subsequent Albright-Onodera oxidation using 
P2O5 in DMSO afforded the contemplated 3-oxo-4-(trifluoromethyl)azetidin-2-ones 2 in acceptable 
yields (Scheme 1). Having these 3-oxo-β-lactams 2 in hand, their eligibility as substrates for α-
alkylation through the intermediacy of a 3,4-dioxo-2-(trifluoromethyl)azetidin-2-yl anion was 
assessed next. However, treatment of these ketones 2 with a variety of bases (LDA, LiHMDS, n-
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BuLi, NaH, Et3N, NaOH) under different reaction conditions, including variation of the temperature 
(0 °C, -78 °C, -100 °C), solvent (THF, CH2Cl2), and additive (HMPA, TiCl4, Me3SiOTf, ZnBr2), in 
the presence of 1-iodopropane as an electrophile always led to the formation of rather complex 
mixtures. These observations at least confirmed the intrinsic reactivity/instability of 4-
trifluoromethyl-3-oxo-β-lactams. 
Remarkably, in one of these many attempts, the combination of 1.5 equiv of 1-iodopropane and 3 
equiv of Et3N in DMSO at room temperature resulted in a clean and full conversion of the starting 
material 2a. More precisely, this approach provided a mixture of two reaction products in a 87/13 
ratio, from which the major product was identified as propyl 2-[(2,2-difluorovinyl)(4-
methoxybenzyl)amino]-2-oxoacetate 3a and the minor product as propyl 2-oxo-2-[(4-
methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4a upon careful spectroscopic analysis. 
This unexpected and unprecedented reactivity urged us to explore the scope of this new 
transformation in detail. At first, methodology validation was pursued by varying the electrophile 
and, besides 1-iodopropane, also allyl bromide, 1-chloro-3-iodopropane, benzyl bromide and 
iodomethane were thus deployed. In all cases, 4-trifluoromethyl-3-oxo-β-lactams 2 were 
successfully converted into mixtures of N-(2,2-difluorovinyl) amido esters 3 as major products and 
N-(2,2,2-trifluoroethyl) amido esters 4 as minor constituents in a 75-92/8-25 ratio (Table 1), which 
could be easily separated. Instead of DMSO, also DMF was shown to be a suitable solvent to 
induce these reactions, albeit resulting in a lower selectivity (~1/1 mixtures of compounds 3 and 




Scheme 1. Synthesis of 4-trifluoromethyl-3-oxo-β-lactams 2 and their transformation into amido 
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Table 1. Transformation of 4-trifluoromethyl-3-oxo-β-lactams 2 into 2-[(2,2-difluorovinyl)amino]-2-
oxoacetates 3 and 2-oxo-2-[(2,2,2-trifluoroethyl)amino]acetates 4 
Entry R R’ 3 (yielda) 4 (yielda) Ratio 3/4b 
1 PMB Et 3a (56) 4a (12) 87/13 
 2 PMB vinyl 3b (25) 4b (5) 87/13 
3 PMB 1-chloroethyl 3c (42) 4c (10) 80/20 
4 PMB Ph 3d (50) 4d (11) 75/25 
5 PMB H 3e (33) 4e (7) 80/20 
6 PMP Et 3f (30) 4f (9) 79/21 
7 PMP vinyl 3g (35) 4g (-)c 86/14 
 8 PMP 1-chloroethyl 3h (38) 4h (-)c 90/10 
9 PMP  Ph  3i (50) 4i (-)c 92/8 
10 PMP H 3j (42) 4j (5) 88/12 
a isolated yield after HPLC purification 
b determined by means of 1H NMR analysis (CDCl3) of the reaction mixture 
c not isolated 
 
3. Proposal mechanisms of the C3-C4 bond fission in 3-oxo-β-lactams toward amido 
esters 
 
In the next part, efforts were devoted to clarify the peculiar reactivity associated with this 
unexpected transformation.81k To that end, each of the reaction parameters was changed in turn 
in order to see the effect on the outcome. First, the alkyl halide was omitted, affording only a 
complex reaction mixture. Apparently, treatment with Et3N in DMSO does affect the 3-oxo-β-
lactam substrate 2, pointing to a probable deprotonation followed by rapid degradation. Next, the 
base (Et3N) was left out, resulting in mainly recuperation of the starting material. These 
observations underline the importance of combining 1-iodopropane and Et3N to evoke the desired 
reactivity. As the combination of an alkyl halide and Et3N in DMSO is known to be characteristic 
for the Kornblum oxidation,83 the possible intermediacy of an aldehyde in this reaction was 
investigated as well. However, replacement of 1-iodopropane with propanal (the Kornblum 
oxidation product of 1-iodopropane) did not result in conversion of the substrate 2. 
Based on the ester portion present in the obtained products 3/4, it is clear that an oxygen atom 
(probably resulting from water) is introduced during this transformation. In order to verify whether 
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an alcohol could trigger the same reactivity, 3-oxo-β-lactams 2 were treated with propan-1-ol 
(instead of 1-iodopropane) in DMSO in the presence of Et3N. Interestingly, this test reaction indeed 
furnished the same amido esters 3 and 4 in a 98/2 ratio, pointing to a possible formation and 
participation of propanol in the initial 1-iodopropane/Et3N approach to a certain extent. The 
presence of Et3N seemed to be inevitable, as treatment with propanol without this base resulted 
in recuperation of the substrate only. In order to check this rather curious iodopropane-to-propanol 
conversion hypothesis, benzoyl chloride and a fluoride source (TBAF) was added to a solution of 
1-iodopropane and Et3N in DMF, after which formation of a small amount of the corresponding 
propyl benzoate (the reaction product of the in situ formed propanol and benzoyl chloride) at r.t. 
was acknowledged by means of GC-MS. Based on the above-described results, the mechanism 
behind this peculiar transformation might (partly) rely on an initial conversion of the alkyl halide 
into the corresponding alcohol by residual water, which subsequently induced β-lactam ring 
cleavage. Given the fact that Et3N was shown to affect the 3-oxo-β-lactam substrate 2, the 
formation of triethylamine hydrofluoride seems reasonable, and this salt might even act as a 
catalyst to facilitate the alkyl halide-to-alcohol interconversion according to literature information.84 
To acknowledge the potential role of fluoride as a catalyst, Et3N was replaced with TBAF, also 
resulting in the formation of amido esters 3 and 4 in a 97/3 ratio. Possibly, Et3N is necessary to 
provide a catalytic amount of Et3N.HF as a fluoride source in this reaction (through 
dehydrofluorination of substrates 2). It should also be noted that the alkyl halide/TBAF combination 
offers a convenient protocol for the almost exclusive formation of 2-[(2,2-difluorovinyl)amino]-2-
oxoacetates 3 (3/4: 97/3). 
To summarize, careful variation of the reaction parameters allowed us to suggest the following 
unexpected reaction mechanism to partly account for the formation of 2-[(2,2-difluorovinyl)amino]-
2-oxoacetates 3 and 2-oxo-2-[(2,2,2-trifluoroethyl)amino]acetates 4 upon treatment of 4-
trifluoromethyl-3-oxo-β-lactams 2 with an alkyl halide in the presence of Et3N in DMSO or DMF 
(Scheme 2): step 1) (partial) dehydrofluorination of substrates 2 through the action of Et3N, leading 
to the formation of Et3N.HF and 4-(difluoromethylene)azetidine-2,3-dione 5; step 2) (Et3N.HF-
assisted) transformation of the alkyl halide into the corresponding alcohol due to residual water 
present in the solvent and/or reagents; step 3) addition of this alcohol across the ketone carbonyl 
group in 3-oxo-β-lactams followed by subsequent C3-C4 bond fission. Alcohol addition onto 4-
trifluoromethyl-3-oxo-β-lactams 2 provides access to both end products 3 and 4 via the common 
intermediate 7 (route 3.1), whereas reaction with the in situ formed 4-difluoromethylene-β-lactam 
5 only results in production of the main compound 3 (route 3.2). Direct fluoride expulsion from 6B 
to 3 can also be considered. Pathways 3.1 and 3.2 might be competitive, but only route 3.1 can 
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account for the presence of the minor product 4. As an experiment in which a 3-oxo-β-lactam 2 
was treated with propan-1-ol in DMSO showed Et3N to be necessary to provoke reaction, a fast 
proton transfer from 6A to Et3N and subsequent ring opening of anionic intermediate 6B could 
further support the observed reactivity (as the more stable corresponding neutral hemiacetal would 
probably not suffer from ring cleavage).  
 
 
Scheme 2. Possible mechanistic rationalization of the observed reactivity to (partly) explain the 
formation of compounds 3 and 4 
 
The peculiar role of the CF3 group in this story was further acknowledged upon treatment of a 4-
phenyl- and a 4-isopropyl-3-oxo-β-lactam with propanol in DMSO in the presence or absence of 
Et3N, leading to complex mixtures or no conversion of the substrate. Apparently, the strong 
electron-withdrawing properties of the CF3 group are required to induce C3-C4 ring fission. 
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The proposed route, based on an initial alkyl halide-to-alcohol interconversion, should most 
probably be considered as a minor option in the overall mechanism. Nonetheless, as the formation 
of a small amount of propanol (trapped as propyl benzoate) from iodopropane could be 
demonstrated, this unexpected pathway should not be ruled out and probably accounts for part of 
the final product formation. In order to provide additional support for this peculiar mechanistic 
proposal, theoretical calculations were performed to obtain more insight into the preference for 
the various proposed reaction pathways. Particular attention was devoted to the 
dehydrofluorination reaction, necessary to account for the formation of major compounds 3, as 
this step could theoretically occur at different stages throughout the proposed overall mechanism. 
The main objective of this computational study was merely to verify if this proposal is realistic, not 
to claim that this is the only right one. 
The M06-2X/6-31++G(d,p) level of theory was used for geometry optimizations, since this level of 
theory was proven to yield reliable results for reactions involving small N-heterocycles.85,81k 
Furthermore, M06-2X accounts for dispersion effects to some extent.86 However, a benchmarking 
study on dispersion-inclusive DFT methods showed that M06-2X is one of the preferable 
functionals for hydrogen-bonded systems while it is less preferred for dispersion-dominated 
systems.87 Although Hydrogen bonds play an important role in some pathways under study, most 
pathways are dispersion-dominated. Therefore, the electronic energies were determined at the 
B3LYP-D3/6-311++G(d,p) level of theory with inclusion of dispersion corrections using the D3 
dispersion correction scheme.88 These corrections, proposed by Grimme et al., account for 
dispersion effects in complex systems and at long range.89 This methodology has been applied 
successfully to (ring-opening) reactions of 3-oxo-ß-lactams.81k Minima (ground states) and first-
order saddle points (transition states) were characterized by normal mode analysis. The normal 
modes obtained at the M06-2X/6-31++G(d,p) were used as input for the thermal corrections at 1 
atm and 298 K. A continuum model was used to account for the solvent environment.90 Adding 
explicit solvent molecules on top of the reacting molecules, including EtOH, and the base Et3N 
would make the system fairly complex to explore all pathways. All computations were carried out 
with the Gaussian 09 program package.91 
For this theoretical study, R = R’ = Me was chosen. On top of the evidences from the experimental 
study, the calculations clearly showed the necessity of Et3N for the reaction to proceed. Whereas 
activation barriers of over 300 kJ/mol were found for the dehydrofluoration of 4-trifluoromethyl-3-
oxo-β-lactam 2 to 4-(difluoromethylene)azetidine-2,3-dione 5 in preliminary calculations without 
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Et3N, these barriers were lowered tremendously by assistance of Et3N. The Gibbs free energy 
profile for the reaction of 2 to 5 (Scheme 2, step 1) with assistance of Et3N is shown in Figure 1.  
 
Figure 1. Gibbs free energy profile for the dehydrofluoration of 4-trifluoromethyl-3-oxo-β-lactam 2 
to 4-(difluoromethylene)azetidine-2,3-dione 5 with assistance of Et3N (PCM (ε = 46,83) B3LYP-
D3/6-311+G(d,p)//PCM (ε = 46,83) M06-2X/6-31++G(d,p), kJ/mol). Energies relative to the 
separate reactants. Some critical distances are given in Å.  
 
An activation barrier of 79.0 kJ/mol is found for the deprotonation step, whereas an energy barrier 
of 104.5 kJ/mol has to be overcome for defluorination by the protonated base Et3NH+. The latter 
barrier is relatively high and it may be assumed that the defluorination of the deprotonated 3-oxo-
β-lactam 2 will thus not take place. On the other hand, the protonated base Et3NH+, resulting from 
deprotonation of 2, can facilitate the transformation of e.g. ethyl halide to ethanol (Scheme 2, step 
2). 
The Gibbs free energy profile for the addition of ethanol across the ketone carbonyl group in 3-
oxo-β-lactam 2 (Scheme 2, step 3.1, first part) is shown in Figure 2. An activation barrier of 74.7 
kJ/mol is found for the reaction with assistance of Et3N, which substracts the hydroxylic hydrogen 
atom from ethanol during the reaction, whereas a barrier of over 150 kJ/mol was found from 
preliminary calculations without Et3N, showing the necessity of Et3N for the addition of ethanol 
(which is also in agreement with the experimental observations). 
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Figure 2. Gibbs free energy profile for the addition of ethanol to 3-oxo-β-lactam 2 with assistance 
of Et3N (PCM (ε = 46,83) B3LYP-D3/6-311+G(d,p)//PCM (ε = 46,83) M06-2X/6-31++G(d,p), 
kJ/mol). Energies relative to the separate reactants. Some critical distances are given in Å.  
 
Thus, the activation barrier for the addition of ethanol to 2 (Scheme 2, step 3.1, first part) is lower 
than the activation barrier for the conversion of 2 to 5, further suggesting that the dehydrofluoration 
of 3-oxo-β-lactam 2 (step 1) will not take place. Additionally, assistance of ethanol in the 
defluorination of the deprotonated 3-oxo-β-lactam 2 (Scheme 2, step 1) was investigated. 
However, the assistance was found not to lower the activation barrier  
Whereas hemiacetal 6 can easily be deprotonated at the hydroxyl group on the C3 position, 
deprotonation at the C4 carbon atom and dehydrofluoration with formation of 8 are very unlikely. 
On the other hand, ring opening of 6B can lead to intermediate 7, which will be readily protonated 
with formation of the minor product 4, or direct ring opening of 6B with simultaneous defluorination 
can lead to the major product 3 (Scheme 2, step 3.1, last part). Ring opening of 6 with 
simultaneous proton transfer and direct formation of the minor product 4 is less likely since 
protonated Et3N cannot easily approach the carbon atom which has to be protonated. The Gibbs 
free energy profiles for the pathways for the formation of products 3 and 4 from 6B are shown in 
Figure 3.  
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Figure 3. Gibbs free energy profiles for the conversion of intermediate 6B to products 3 and 4 with 
assistance of Et3N (PCM (ε = 46,83) B3LYP-D3/6-311+G(d,p)//PCM (ε = 46,83) M06-2X/6-
31++G(d,p), kJ/mol). Energies relative to reactants 2 with ethanol and Et3N. Some critical 
distances are given in Å. 
 
A clearly lower activation barrier is found for the formation of the major product 3 if ring opening 
of 6B occurs simultaneously with defluorination (ΔG‡ = 59.9 kJ/mol versus 69.1 kJ/mol for the 
formation of the minor product 4), explaining why 3 is the major product. On the other hand, the 
difference between the activation barriers of both pathways is less than 10 kJ/mol, explaining the 
possibility for the formation of 4 as a side product. 
In summary, these calculations showed that deprotonation of 3-oxo-β-lactam 2 by Et3N (Scheme 
2, step 1) could result in formation of the protonated base Et3NH+, which facilitates the 
transformation of ethyl halide to ethanol (Scheme 2, step 2). Subsequently, ethanol can add 
across the ketone carbonyl group in 3-oxo-β-lactam 2 (Scheme 2, step 3.1) with formation of 
intermediate 6, which is transferred to the major product 3 by ring opening with concomitant 
defluorination. Alternatively, ring opening can lead to intermediate 7, which will be readily 
protonated with formation of the minor product 4. In other words, although this mechanistic route 
probably only accounts for a minor fraction of the final products, the calculations show that it 
concerns a realistic pathway. 
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Nonetheless, it is clear that other mechanistic options to explain the observed reactivity cannot be 
ruled out based on the above-described findings. For example, an at first sight more reasonable 
approach is based on the O-alkylation of the enolate anion 10 formed after deprotonation by Et3N, 
producing enol ether 11. Re-protonation at C4 then affords an electrophilic oxonium ion 12, which 
suffers from water addition to afford hemiacetal 13. The latter intermediate finally undergoes a C3-
C4 bond fission (with or without concomitant dehydrofluorination) to result in final structures 3 and 
4 (Scheme 3). Unfortunately, attempts to provide evidence for the intermediacy of enol ethers 11 
by means of NMR or MS were unsuccessful. 
 
 
Scheme 3. Alternative mechanism for the formation of compounds 3 and 4 via an enol ether 
intermediate 11 
 
Although the participation of water seems to be necessary at some point to account for the 
presence of three oxygen atoms in the final products, the role of this adventitious water remains 
curious. In order to demonstrate the intervention of water during the process, a final experiment 
was performed involving treatment of 3-oxo-β-lactam 2b with allyl bromide in dry DMSO in the 
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presence of 10 equiv of 18O-labeled water. The detection of the corresponding molecular m/z ion 
313 in MS for structure 3 (with a M+2 mass as compared to the O16-containing counterpart) 
confirmed the incorporation of H218O during the reaction pathway, and only the expected m/z 311 
ion was observed when no 18O-labeled water was used. Based on NMR analysis before and after 
aqueous work-up, we suppose that water participation during work-up constitutes an important 
pathway in the overall mechanism, and that the role of adventitious water present in the solvent 




Treatment of 4-trifluoromethyl-3-oxo-β-lactams with an alkyl halide and triethylamine in DMSO 
unexpectedly resulted in the formation of 2-[(2,2-difluorovinyl)amino]-2-oxoacetates as major 
products, accompanied by minor amounts of 2-oxo-2-[(2,2,2-trifluoroethyl)amino]acetates, 
through an unprecedented C3-C4 β-lactam bond fission. This peculiar reactivity was investigated 
from both an experimental and a computational point of view in order to shed light on the 
underlying reaction mechanism. Furthermore, the alkyl halide/TBAF combination was shown to 
offer a convenient alternative protocol for the selective formation of 2-[(2,2-difluorovinyl)amino]-2-
oxoacetates 3 from 4-CF3-3-oxo-β-lactams 2. Given the current pharmaceutical interest in 
fluorinated building blocks, these newly obtained fluorinated amido esters might be of importance 






In addition, 4-trifluoromethyl-3-oxo-β-lactams 2 can be suitable substrates to provide novel CF3-
substituted 5-oxa-2-azaspiro[3.4]octan-1-ones 18 (Scheme 4). In that respect, 3-oxo-β-lactams 2 
will be converted into alcohols 14 upon treatment with vinylmagnesium bromide. The resulting 
tertiary alcohol will be transformed into the corresponding allyl ethers 15, which will then be 
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subjected to ring-closing metathesis (RCM) to afford spirodihydrofurans 16. These cyclic enol 
ethers can be used as eligible substrates to access amines 18 through the use of Mitsunobu 
displacement of the secondary alcohol 17, which can be prepared from enol ethers 16 upon 
treatment with (-)-Ipc2BH.92 Spiro-β-lactam compounds are of paramount value to medicinal 
chemistry because of their antiviral and antibacterial properties, as well as for cholesterol 
absorption.93 Thus, spiro-β-lactams 18 bearing a CF3 group might be valuable compounds with 









High Performance Liquid Chromatography (HPLC) was performed on an Agilent 1200 Series with 
UV/DAD detector, the column was of the type Eclipse Plus C18 (4,6 × 50 mm, particle size 3,5 
µm), using solvent system (MeCN/H2O, from 30% to 100% MeCN). Gas chromatography–mass 




RESULTS AND DISCUSSION-PART III 
113 
Synthesis of 4-trifluoromethyl-3-oxoazetidin-2-ones 2 
As a representative example, the synthesis of 1-(4-methoxybenzyl)-4-trifluoromethyl-3-
oxoazetidin-2-one 2a is described. Phosphorus pentoxide (0.52 g, 3.66 mmol, 2 equiv) was added 
slowly to 75 mL of dry DMSO at 0 °C and the resulting mixture was stirred at room temperature 
for 10 min. Then, the starting material cis-3-hydroxy-1-(4-methoxybenzyl)-4-
(trifluoromethyl)azetidin-2-one 1a (0.50 g, 1.82 mmol, 1 equiv), dissolved in 37.5 (mL) of dry 
DMSO, was added dropwise. The resulting mixture was stirred for 18 hours at 150 °C. The reaction 
was quenched with ice-cooled water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The 
combined organic layers were washed five times with brine (5 × 20 mL) to remove the excess of 
DMSO, then dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by 
recrystallization in diethyl ether to give 1-(4-methoxybenzyl)-4-trifluoromethyl-3-oxoazetidin-2-one 
2a in a yield of 46%. 
1-(4-Methoxybenzyl)-4-trifluoromethyl-3-oxoazetidin-2-one 2a 
White crystals. Mp 101 °C. Recrystallization in Et2O. Yield 46%. 1H NMR (400 MHz, 
CDCl3): δ 3.82 (3H, s, OCH3), 4.27 (1H, q, J = 6.0 Hz, CHCF3), 4.30 and 5.21 (2 × 1H, 
2 × d, J = 14.8 Hz, N(HCH)Ar), 6.92 and 7.22 (2 × 2H, 2 × d, J = 8.6 Hz, 
NCH2(CHarom)ortho) and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 46.4 (NCH2Ar), 
55.3 (OCH3), 68.2 (q, J = 34.7 Hz, CHCF3), 114.8 (2 × O(CHarom)ortho), 122.2 (q, J = 
280.1 Hz, CF3), 124.2 (2 × NCH2(CHarom)ortho), 130.3 (2 × OCarom,quat), 160.1 (OCarom,quat), 162.6 
(NC=O), 183.7 (CF3CHC=O). 19F NMR (376.5 MHz, CDCl3): δ -70.37 (3F, d, J = 6.0 Hz, CF3). IR 
(ATR, cm-1): νCHC=O = 1838, νNC=O = 1766, νmax = 1515, 1252, 1181, 1138, 1036, 884, 872, 700, 
650. GC-MS: m/z (%) = 273 (M+, 5), 121 (100), 78 (8). 
1-(4-Methoxyphenyl)-4-trifluoromethyl-3-oxoazetidin-2-one 2b 
Yellow crystals. Mp 72 °C. in Et2O/Hex, 3/1. Yield 54%. 1H NMR (400 MHz, 
CDCl3): δ 3.85 (3H, s, OCH3), 5.02 (1H, q, J = 5.2 Hz, CHCF3), 6.99 and 7.57 (2 
× 2H, 2 × d, J = 9.1 Hz, N(CHarom)ortho) and O(CHarom)ortho). 13C NMR (100.6 MHz, 
CDCl3): δ 55.6 (OCH3), 69.7 (q, J = 35.1 Hz, CHCF3), 114.9 (2 × O(HCarom)ortho), 
119.7 (2 × O(HCarom)meta), 122.2 (q, J = 281.5 Hz, CF3), 129.0 (NCarom,quat), 158.8 (OCarom,quat), 159.2 
(CF3CHC=O), 181.8 (NC=O). 19F NMR (376.5 MHz, CDCl3): δ -68.71 (3F, d, J = 5.2 Hz, CF3). IR 
(ATR, cm-1): νCHC=O = 1820, ν NC=O = 1760, νmax = 1609, 1509, 1248, 1142, 1021, 980, 829. GC-
MS: m/z (%) = 259 (M+, 23), 188 (10), 203 (78), 134 (100), 107 (16), 92 (12), 77 (12). 
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Synthesis of propyl 2-[(2,2-difluorovinyl)(4-methoxybenzyl)amino]-2-oxoacetate 3a and 
propyl 2-[(4-methoxybenzyl)(2,2,2-trifluoroethyl)amino]-2-oxoacetate 4a 
As a representative example, the synthesis of propyl 2-[(2,2-difluorovinyl)(4-
methoxybenzyl)amino]-2-oxoacetate 3a and propyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-
trifluoroethyl)amino]acetate 4a is described. To a solution of 1-(4-methoxybenzyl)-4-
trifluoromethyl-3-oxoazetidin-2-one 2a (0.10 g, 0.37 mmol, 1 equiv) in DMSO (10 mL) was added 
1-iodopropane (0.05 mL, 0.55 mmol, 1.5 equiv) and triethylamine (0.15 mL, 1.11 mmol, 3 equiv) 
at room temperature. The resulting mixture was stirred for two hours at the same temperature. 
The reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (3 x 10 
mL). The combined organic phases were washed with brine (5 x 10 mL). Drying (MgSO4), filtration 
of the drying agent, and removal of the solvent in vacuo afforded a crude product. The 1H NMR of 
the crude product showed it to be a mixture of propyl 2-[(2,2-difluorovinyl)(4-
methoxybenzyl)amino]-2-oxoacetate 3a and propyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-
trifluoroethyl)amino]acetate 4a in a ratio of 87:13, which was separated by means of preparative 
HPLC (Supelco Ascentis C18, H2O-CH3CN, 35:65) giving pure propyl 2-[(2,2-difluorovinyl)(4-
methoxybenzyl)amino]-2-oxoacetate 3a in a yield of 56% and propyl 2-oxo-2-[(4-
methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4a in a yield of 12%.  
Propyl 2-[(2,2-difluorovinyl)(4-methoxybenzyl)amino]-2-oxoacetate 3a  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 35/65, flow rate 6 mL 
min-1, detection at 220 nm, tR= 33.61-33.99 min). Yield 56%. 2 rotamers 81/19 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 0.97 (3H, t, J = 7.0 Hz, OCH2CH2CH3), 1.73 (2H, 
sextet, J = 7.0 Hz, OCH2CH2CH3), 3.80 (3H, s, OCH3), 4.22 (2H, t, J = 7.0 Hz, OCH2CH2CH3), 
4.62 (2H, s, NCH2), 5.31 (1H, d × d, J = 18.0, 3.0 Hz, CHCF2), 6.87 and 7.21 (2 × 2H, 2 × d, J = 
8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 10.1 
(OCH2CH2CH3), 21.7 (OCH2CH2CH3), 49.8 (t, J = 1.6 Hz, NCH2Ar), 55.27 (OCH3), 67.8 
(OCH2CH2CH3), 85.5 (d × d, J = 49.1, 15.1 Hz, CHCF2), 114.16 (2 × O(CHarom)ortho), 126.8 
(NCH2Carom,quat), 130.1 (2 × O(CHarom)meta), 158.5 (d × d, J = 298.1, 292.4 Hz, CF2), 159.5 
(OCarom,quat), 161.8 (t, J = 2.2 Hz, NC=O), 162.2 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -93.21 
(1F, d × d, J = 27.1, 3.0 Hz, FCF), -83.54 (1F, d × d, J = 27.1, 18.0 Hz, FCF).  
Minor rotamer (detectable signals) 
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1H NMR (400 MHz, CDCl3): δ 0.95 (3H, t, J = 7.1 Hz, OCH2CH2CH3), 1.73 (2H, sextet, J = 7.1 Hz, 
OCH2CH2CH3), 3.80 (3H, s, OCH3), 4.25 (2H, t, J = 7.1 Hz, OCH2CH2CH3), 4.57 (2H, s, NCH2), 
5.52 (1H, d, J = 21.5 Hz, CHCF2). 13C NMR (100.6 MHz, CDCl3): δ 10.2 (OCH2CH2CH3), 21.7 
(OCH2CH2CH3), 52.0 (d, J = 3.5 Hz, NCH2), 55.30 (OCH3), 68.1 (OCH2CH2CH3), 84.3 (d × d, J = 
51.6, 12.8 Hz, CHCF2), 114.24 (2 × O(CHarom)ortho), 126.4 (NCH2Carom,quat), 129.0 (2 × 
O(CHarom)meta), 156.9 (d, J = 294.7 Hz, CF2), 159.7 (OCarom,quat), 161.2 (NC=O), 162.3 (OC=O).19F 
NMR (376.5 MHz, CDCl3): δ -97.29 (1F, d, J = 42.1 Hz, FCF), -82.73 (1F, d × d, J = 42.1, 21.5 Hz, 
FCF). 
IR (ATR, cm-1): νOC=O = 1744, νNC=O = 1674, νmax = 1513, 1416, 1243, 1174, 1032, 800. MS (70eV): 
m/z (%): 314 (M+ + 1, 100). HRMS (ESI) calcd for C15H18F2NO4+: 314.1198 [M + H]+. Found: 
314.1204. 
Propyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4a  
Yellowish oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 35/65, flow rate 6 
mL min-1, detection at 220 nm, tR = 40.11-40.25 min). Yield 12%. 2 rotamers 
66/34 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 0.95-1.01 (3H, m, CH2CH3), 1.71-1.81 (2H, m, CH2CH2CH3), 3.82 
(3H, s, OCH3), 3.88 (2H, q, J = 8.9 Hz, CH2CF3), 4.27 (2H, t, J = 6.7 Hz, CH2CH2CH3), 4.53 (2H, 
s, NCH2), 6.91 and 7.22 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR 
(100.6 MHz, CDCl3): δ 10.24 (CH2CH2CH3), 21.8 (CH2CH2CH3), 42.8 (q, J = 34.2 Hz, CHCF3), 
51.3 (NCH2Ar), 55.4 (OCH3), 68.1 (CH2CH2CH3), 114.53 (2 × O(CHarom)ortho), 124.2 (q, J = 281.2 
Hz, CF3), 125.4 (NCH2Carom,quat), 129.6 (2 × O(CHarom)meta), 160.0 (OCarom,quat), 162.4 (NC=O), 
162.6 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -68.44 (3F, t, J = 8.9 Hz, CF3). 
Minor rotanmer  
1H NMR (400 MHz, CDCl3): δ 0.95-1.01 (3H, m, CH2CH3), 1.71-1.81 (2H, m, CH2CH2CH3), 3.81 
(3H, s, OCH3), 3.94 (2H, q, J = 8.9 Hz, CH2CF3), 4.26 (2H, t, J = 6.7 Hz, CH2CH2CH3), 4.71 (2H, 
s, NCH2), 6.90 and 7.20 (2 × 2H, 2 × d, J = 8.3 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR 
(100.6 MHz, CDCl3): δ 10.15 (CH2CH2CH3), 21.7 (CH2CH2CH3), 46.6 (q, J = 28.9 Hz, CHCF3), 
48.2 (NCH2Ar), 55.3 (OCH3), 68.2 (CH2CH2CH3), 114.46 (2 × O(CHarom)ortho), 123.9 (q, J = 282.9 
Hz, CF3), 126.4 (NCH2Carom,quat), 130.0 (NCH2(CHarom)ortho), 159.7 (OCarom,quat), 161.7 (NC=O), 
161.8 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -69.87 (3F, t, J = 8. 9 Hz, CF3). 
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IR (ATR, cm-1): νOC=O = 1737, νNC=O = 1673, νmax = 1514, 1445, 1249, 1154, 1111, 1031, 831. MS 
(70eV): m/z (%): 356 (M+ + 23, 5). HRMS (ESI) calcd for C15H19F3NO4+: 334.1261 [M + H]+. Found: 
334.1268. 
Allyl 2-[(2,2-difluorovinyl)(4-methoxybenzyl)amino]-2-oxoacetate 3b  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 45/55, flow rate 
6 mL min-1, detection at 220 nm, tR= 52.93-53.89 min). Yield 25%. 2 
rotamers 83/17. 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 4.62 (2H, s, NCH2), 4.74 (2H, d × t, J = 6.2, 1.2 
Hz, OCH2CHCH2), 5.30 (1H, d × d, J = 18.2, 3.1 Hz, CHCF2), 5.32 (1H, d × q, J = 10.4, 1.2 Hz, 
OCH2CH(HCH)), 5.40 (1H, d × q, J = 16.9, 1.2 Hz, OCH2CH(HCH)), 5.93 (1H, d × d × t, J = 16.9, 
10.4, 6.2 Hz, OCH2CHCH2), 6.87 and 7.21 (2 × 2H, 2 × d, J = 9.0 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 49.8 (t, J = 2.2 Hz, NCH2), 55.28 (OCH3), 66.6 
(COCH2CHCH2), 85.5 (d × d, J = 49.1, 15.1 Hz, CHCF2), 114.2 (2 × O(CHarom)ortho), 120.3 
(COCH2CHCH2), 126.7 (NCH2Carom,quat), 130.1 (2 × O(CHarom)meta), 130.5 (COCH2CHCH2), 158.4 
(d × d, J = 298.9, 293.0 Hz, CF2), 159.5 (OCarom,quat), 161.5 (t, J = 2.2 Hz, NC=O), 161.7 (OC=O). 
19F NMR (376.5 MHz, CDCl3): δ -93.00 (1F, d × d, J = 26.6, 3.1 Hz, FCF), -83.26 (1F, d × d, J = 
26.6, 18.2 Hz, FCF).  
Minor rotamer (detectable signals) 
1H NMR (400 MHz, CDCl3): δ 3.81 (3H, s, OCH3), 4.56 (2H, s, NCH2), 4.77 (2H, d × t, J = 6.1, 1.2 
Hz, OCH2CHCH2), 5.51 (1H, d × d, J = 21.3, 1.4 Hz, CHCF2), 5.87-5.97 (1H, m, OCH2CHCH2), 
6.88 and 7.20 (2 × 2H, 2 × d, J = 8.8 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 
MHz, CDCl3): δ 52.0 (d, J = 3.9 Hz, NCH2), 55.30 (OCH3), 66.9 (COCH2CHCH2), 84.3 (d × d, J = 
51.5, 12.9 Hz, CHCF2), 114.3 (2 × O(CHarom)ortho), 120.5 (COCH2CHCH2), 126.3 (NCH2Carom,quat), 
129.1 (2 × O(CHarom)meta), 130.4 (COCH2CHCH2), 159.7 (OCarom,quat), 160.8 (NC=O), 161.8 
(OC=O). 19F NMR (376.5 MHz, CDCl3): δ -97.09 (1F, d, J = 41.6 Hz, FCF), -82.55 (1F, d × d, J = 
41.6, 21.3 Hz, FCF).  
IR (ATR, cm-1): νOC=O = 1745, νNC=O = 1674, νmax = 1514, 1414, 1243, 1172, 1032, 937, 800. MS 
(70eV): m/z (%): 312 (M+ +1, 14). HRMS (ESI) calcd for C15H16F2NO4+: 312.1042 [M + H]+. Found: 
312.1044. 
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Allyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4b  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 45/55, flow rate 
6 mL min-1, detection at 220 nm, tR= 63.36-64.73min). Yield 5%. 2 
rotamer 67/33 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.82 (3H, s, OCH3), 3.88 (2H, q, J = 8.9 Hz, CH2CF3), 4.53 (2H, s, 
NCH2), 4.78-4.80 (2H, m, OCH2CHCH2), 5.33 (1H, d × d, J = 10.4, 0.8 Hz, OCH2CH(HCH)), 5.42 
(1H, d × q, J = 17.1, 1.4 Hz, OCH2CH(HCH)), 5.90-6.01 (1H, m, OCH2CHCH2), 6.91 and 7.22 (2 
× 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 42.8 
(q, J = 34.5 Hz, CH2CF3), 51.3 (NCH2Ar), 55.35 (OCH3), 66.9 (OCH2CHCH2), 114.52 (2 × 
O(CHarom)ortho), 120.6 (OCH2CHCH2), 124.2 (q, J = 282.3 Hz, CF3), 125.3 (NCH2Carom,quat), 129.7 
(O(CHarom)meta), 130.4 (OCH2CHCH2), 160.0 (OCarom,quat), 161.9 (NC=O), 162.2 (OC=O). 19F NMR 
(376.5 MHz, CDCl3): δ -68.43 (3F, t, J = 8.9 Hz, CF3). 
Minor rotamer  
1H NMR (400 MHz, CDCl3): δ 3.81 (3H, s, OCH3), 3.93 (2H, q, J = 8.8 Hz, CH2CF3), 4.71 (2H, s, 
NCH2), 4.78-4.80 (2H, m, OCH2CHCH2), 5.34 (1H, d × d, J = 10.2, 1.0 Hz, OCH2CH(HCH)), 5.43 
(1H, d × q, J = 17.4, 1.7 Hz, OCH2CH(HCH)), 5.90-6.01 (1H, m, OCH2CHCH2), 6.89 and 7.19 (2 
× 2H, 2 × d, J = 8.6 Hz, NCH2 (CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 
46.5 (q, J = 34.7 Hz, CH2CF3), 48.2 (NCH2Ar), 55.33 (OCH3), 67.0 (OCH2CHCH2), 114.45 (2 × 
O(CHarom)ortho), 120.4 (OCH2CHCH2), 123.9 (q, J = 281.0 Hz, CF3),126.3 (NCH2Carom,quat), 130.1 
(O(CHarom)meta), 130.4 (OCH2CHCH2), 159.7 (OCarom,quat), 161.2 (NC=O), 161.4 (OC=O). 19F NMR 
(376.5 MHz, CDCl3): δ -69.79 (3F, t, J = 8.8 Hz, CF3). 
IR (ATR, cm-1): νOC=O = 1742, νNC=O = 1675, νmax = 1515, 1446, 1250, 1258, 1117, 1031, 832. GC-
MS: m/z (%) = 331 (M+, 7), 290 (60), 218 (20), 137 (72), 121 (100), 78 (13), 41 (10). 
3-Chloropropyl 2-[(2,2-difluorovinyl)(4-methoxybenzyl)amino]-2-oxoacetate 3c  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 43/57, flow rate 6 
mL min-1, detection at 220 nm, tR = 32.72-33.30 min). Yield 42%. 2 
rotamers 83/17 
Major rotamer 
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1H NMR (400 MHz, CDCl3): δ 2.10-2.20 (2H, m, OCH2CH2CH2Cl), 3.63 (2H, t, J = 6.2 Hz, 
OCH2CH2CH2Cl), 3.81 (3H, s, OCH3), 4.42 (2H, t, J = 6.2 Hz, OCH2CH2CH2Cl), 4.62 (2H, s, NCH2), 
5.32 (1H, d × d, J = 18.1, 2.7 Hz, CHCF2), 6.87 and 7.21 (2 × 2H, 2 × d, J = 8.5 Hz, 
NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 31.1 (OCH2CH2CH2Cl), 40.6 
(OCH2CH2CH2Cl), 49.9 (t, J = 2.2 Hz, NCH2), 55.28 (OCH3), 62.8 (OCH2CH2CH2Cl), 85.5 (d × d, 
J = 48.9, 15.1 Hz, CHCF2), 114.2 (2 × O(CHarom)ortho), 126.6 (NCH2Carom,quat), 130.1 (2 × 
O(CHarom)meta), 158.5 (d × d, J = 298.0, 293.1 Hz, CF3), 159.6 (OCarom,quat), 161.4 (t, J = 2.8 Hz, 
NC=O), 161.89 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -92.77 (1F, d × d, J = 2.7, 26.5 Hz, FCF), 
-83.61 (1F, d × d, J = 26.5, 18.1 Hz, FCF).  
Minor rotamer 
1H NMR (400 MHz, CDCl3): δ 2.10-2.20 (2H, m, OCH2CH2CH2Cl), 3.56 (2H, t, J = 6.2 Hz, 
OCH2CH2CH2Cl), 3.81 (3H, s, OCH3), 4.43 (2H, t, J = 6.2 Hz, OCH2CH2CH2Cl), 4.58 (2H, s, NCH2), 
5.55 (1H, d × d, J = 21.3, 1.1 Hz, CHCF2), 6.89 and 7.18 (2 × 2H, 2 × d, J = 9.0 Hz, O(CHarom)ortho 
and NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 31.0 (OCH2CH2CH2Cl), 40.6 
(OCH2CH2CH2Cl), 52.1 (d, J = 3.6 Hz, NCH2), 55.32 (OCH3), 63.0 (OCH2CH2CH2Cl), 84.5 (d × d, 
J = 51.5, 12.7 Hz, CHCF2), 114.3 (2 × O(CHarom)ortho), 126.4 (NCH2Carom,quat), 128.9 (2 × 
O(CHarom)meta), 155.5 (d × d, J = 295.6, 286.0 Hz, CF3), 159.7 (OCarom,quat), 160.8 (NC=O), 161.94 
(OC=O). 19F NMR (376.5 MHz, CDCl3): δ -97.15 (1F, d, J = 41.7 Hz, FCF), -82.57 (1F, d × d, J = 
41.7, 21.3 Hz, FCF). 
IR (ATR, cm-1): νOC=O = 1745, νNC=O = 1674, νmax = 1513, 1417, 1244, 1173, 1031, 957, 801. MS 
(70eV): m/z (%): 370 (M+ + 23, 20). HRMS (ESI) calcd for C15H17ClF2NO4+: 348.0809 [M + H]+. 
Found: 348.0814. 
3-Chloropropyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4c  
Yellowish oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 43/57, flow rate 
6 mL min-1, detection at 220 nm, tR = 38.47-38.97 min). Yield 10%. 2 
rotamers 65/35 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 2.14-2.23 (2H, m, OCH2CH2CH2Cl), 3.60 (2H, t, J = 6.2 Hz, 
OCH2CH2CH2Cl), 3.82 (3H, s, OCH3), 3.90 (2H, q, J = 8.9 Hz, CH2CF3), 4.467 (2H, t, J = 6.2 Hz, 
OCH2CH2CH2Cl), 4.55 (2H, s, NCH2), 6.91 and 7.21 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 31.0 (OCH2CH2CH2Cl), 40.64 
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(OCH2CH2CH2Cl), 43.1 (q, J = 34.3 Hz, CHCF3), 51.4 (NCH2), 55.4 (OCH3), 63.1 
(OCH2CH2CH2Cl), 114.6 (2 × O(CHarom)ortho), 124.1 (q, J = 281.5 Hz, CF3), 125.4 (NCH2Carom,quat), 
129.5 (2 × O(CHarom)meta), 160.0 (OCarom,quat), 161.4 (NC=O), 162.0 (OC=O). 19F NMR (376.5 MHz, 
CDCl3): δ -68.49 (3F, t, J = 8.9 Hz, CF3).  
Minor rotamer 
1H NMR (400 MHz, CDCl3): δ 2.14-2.23 (2H, m, OCH2CH2CH2Cl), 3.65 (2H, t, J = 6.2 Hz, 
OCH2CH2CH2Cl), 3.81 (3H, s, OCH3), 3.95 (2H, q, J = 8.8 Hz, CH2CF3), 4.463 (2H, t, J = 6.2 Hz, 
OCH2CH2CH2Cl), 4.71 (2H, s, NCH2), 6.90 and 7.19 (2 × 2H, 2 × d, J = 8.5 Hz, NCH2(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 31.1 (OCH2CH2CH2Cl), 40.62 
(OCH2CH2CH2Cl), 46.6 (q, J = 35.0 Hz, CHCF3), 48.4 (NCH2Ar), 55.3 (OCH3), 63.2 
(OCH2CH2CH2Cl), 114.5 (2 × O(CHarom)ortho), 126.2 (NCH2Carom,quat), 126.7 (q, J = 282.4 Hz, CF3), 
130.0 (2 × O(CHarom)meta), 159.7 (OCarom,quat), 161.3 (NC=O), 162.3 (OC=O). 19F NMR (376.5 MHz, 
CDCl3): δ -69.95 (3F, t, J = 8.8 Hz, CF3). 
IR (ATR, cm-1): νOC=O = 1740, νNC=O = 1673, νmax = 1514, 1446, 1249, 1155, 1113, 1025, 831, 656. 
MS (70eV): m/z (%): 368 (M+ + 1, 8). HRMS (ESI) calcd for C15H18ClF3NO4+: 368.0871 [M + H]+. 
Found: 368.0857. 
Benzyl 2-[(2,2-difluorovinyl)(4-methoxybenzyl)amino]-2-oxoacetate 3d  
White solid. Mp 32 °C. HPLC (Supelco Ascentis C18, H2O/CH3CN, 
55/45, flow rate 6 mL min-1, detection at 220 nm, tR = 65.01-66.96 
min). Yield 50%. 2 rotamers 82/18 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.78 (3H, s, OCH3), 4.59 (2H, s, NCH2), 5.19 (1H, d × d, J = 18.1, 
3.5 Hz, CHCF2), 5.27 (2H, s, OCH2), 6.85 and 7.18 (2 × 2H, 2 × d, J = 8.7 Hz, NCH2(CHarom)ortho 
and O(CHarom)ortho), 7.33-7.37 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 49.8 (t, J = 1.7 Hz, 
NCH2), 55.3 (OCH3), 67.8 (OCH2), 85.3 (d × d, J = 49.1, 14.9 Hz, CHCF2), 114.16 (2 × 
O(CHarom,ortho)), 126.7 (NCH2Carom,quat), 128.72, 128.76, 128.86 (5 × OCH2CHarom), 130.1 (2 × 
O(CHarom)ortho), 134.3 (OCH2Carom,quat ), 158.5 (d × d, J = 305.1, 299.5 Hz, CF2), 159.5 (OCarom,quat), 
161.5 (t, J = 2.3 Hz, NC=O), 161.9 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -92.77 (1F, d × d, J 
= 26.1, 3.5 Hz, FCF), -83.17 (1F, d × d, J = 26.1, 18.1 Hz, FCF).  
Minor rotamer 
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1H NMR (400 MHz, CDCl3): δ 3.79 (3H, s, OCH3), 4.48 (2H, s, NCH2), 5.30 (2H, s, OCH2), 5.50 
(1H, d × d, J = 21.3, 1.2 Hz, CHCF2), 6.83 and 7.11 (2 × 2H, 2 × d, J = 8.3 Hz, NCH2(CHarom)ortho 
and O(CHarom)ortho), 7.33-7.37 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 51.9 (d, J = 3.7 
Hz, NCH2), 55.3 (OCH3), 68.1 (OCH2), 84.3 (d × d, J = 51.4, 12.8 Hz, CHCF2), 114.20 (2 × 
O(CHarom)ortho), 126.3 (NCH2Carom,quat), 128.74, 128.94, 128.96 (5 × CHarom), 130.1 (2 × 
O(CHarom)ortho), 134.1 (OCH2CHarom,quat), 154.1 (d, J = 296.2 Hz, CF2), 159.7 (OCarom,quat), 160.8 
(NC=O), 161.9 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -92.16 (1F, d, J = 41.6 Hz, FCF), -82.56 
(1F, d × d, J = 41.6, 21.3 Hz, FCF).  
IR (ATR, cm-1): νOC=O = 1744, νNC=O = 1674, νmax = 1513, 1416, 1243, 1169, 1031, 801, 746, 697. 
MS (70eV): m/z (%): 362 (M+ + 1, 5). HRMS (ESI) calcd for C19H18F2NO4+: m/z calcd: 362.1198 
[M + H]+. Found: 362.1200. 
Benzyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4d 
Yellowish oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 55/45, flow 
rate 6 mL min-1, detection at 220 nm, tR = 77.04-77.39 min). Yield 
11%. 2 rotamers 68/32 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 3.862 (2H, q, J = 8.9 Hz, CH2CF3), 4.45 (2H, s, 
NCH2), 5.321 (2H, s, OCH2), 6.86 and 7.14 (2 × 2H, 2 × d, J = 8.7 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho), 7.32-7.42 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 42.9 (q, J = 34.5 Hz, 
CH2CF3), 51.2 (NCH2Ar), 55.3 (OCH3), 68.1 (OCH2), 114.5 (2 × O(CHarom)ortho), 124.2 (q, J = 280.9 
Hz, CF3), 125.3 (NCH2Carom,quat), 128.72, 128.74, 128.8 (5 × CHarom), 129.6 (2 × O(CHarom)meta), 
134.07 (OCH2Carom,quat), 159.9 (OCHarom,quat), 162.0 (OC=O), 162.3 (NC=O). 19F NMR (376.5 MHz, 
CDCl3): δ -68.43 (3F, t, J = 8.9 Hz, CF3).  
Minor rotamer  
1H NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 3.858 (2H, q, J = 8.8 Hz, CH2CF3), 4.69 (2H, s, 
NCH2), 5.316 (2H, s, OCH2), 6.88 and 7.18 (2 × 2H, 2 × d, J = 8.4 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho), 7.32-7.42 (5H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 46.5 (q, J = 34.4 Hz, 
CH2CF3), 48.2 (NCH2Ar), 55.3 (OCH3), 68.2 (OCH2), 114.5 (2 × O(CHarom)ortho), 123.8 (q, J = 280.8 
Hz, CF3), 126.3 (NCH2Carom,quat), 128.9, 129.0 (5 × CHarom), 130.1 (2 × O(CHarom)meta), 134.10 
(OCH2Carom,quat), 159.7 (OCarom,quat), 161.37 (OC=O), 161.43 (NC=O). 19F NMR (376.5 MHz, 
CDCl3): δ -68.78 (3F, t, J = 8.8 Hz, CF3).  
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IR (ATR, cm-1): νOC=O = 1739, νNC=O = 1672, νmax = 1514, 1445, 1266, 1248, 1153, 1111, 1026, 831, 
736, 696. MS (70eV): m/z (%): 382 (M+ + 1, 10). HRMS (ESI) calcd for C19H22F3N2O4+: m/z calcd: 
399.1526 [M + NH4]+. Found: 399.1523. 
Methyl 2-[(2,2-difluorovinyl)(4-methoxybenzyl)amino]-2-oxoacetate 3e  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 55/45, flow rate 6 
mL min-1, detection at 220 nm, tR = 54.99-66.94 min). Yield 33%. 2 rotamers 
82/18 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 3.86 (3H, s, COOCH3), 4.63 (2H, s, NCH2), 5.32 
(1H, d × d, J = 18.3, 3.0 Hz, CHCF2), 6.87 and 7.20 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 49.9 (t, J = 2.1 Hz, NCH2), 52.8 (COOCH3), 
55.28 (OCH3), 85.5 (d × d, J = 49.2, 15.1 Hz, CHCF2), 114.2 (2 × O(CHarom)ortho), 126.7 
(NCH2Carom,quat), 130.1 (2 × O(CHarom)meta), 158.4 (d × d, J = 299.5, 292.7 Hz, CF2), 159.6 
(OCarom,quat), 161.4 (t, J = 2.1 Hz, NC=O), 162.3 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -93.21 
(1F, d × d, J = 27.4, 3.0 Hz, FCF), -83.64 (1F, d × d, J = 27.4, 18.3 Hz, FCF). 
Minor rotamer 
1H NMR (400 MHz, CDCl3): δ 3.81 (3H, s, OCH3), 3.89 (3H, s, COOCH3), 4.57 (2H, s, NCH2), 5.50 
(1H, d × d, J = 21.3, 1.4 Hz, CHCF2), 6.89 and 7.19 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho 
and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 52.1 (d, J = 3.5 Hz, NCH2), 53.0 (COOCH3), 
55.3 (OCH3), 84.3 (d × d, J = 51.3, 12.8 Hz, CHCF2), 114.3 (2 × O(CHarom)ortho), 126.3 
(NCH2Carom,quat), 129.1 (2 × O(CHarom)meta), 155.6 (d × d, J = 297.2, 286.2 Hz, CF2), 159.7 
(OCarom,quat), 160.8 (NC=O), 162.5 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -97.04 (1F, d, J = 41.2 
Hz, FCF), -82.51 (1F, d × d, J = 41.2, 21.3 Hz, FCF).  
IR (ATR, cm-1): νOC=O = 1745, νNC=O = 1674, νmax = 1513, 1412, 1243, 1200, 1031, 800. MS (70eV): 
m/z (%): 286 (M+ + 1, 5). HRMS (ESI) calcd for C13H14F2NO4+: m/z calcd: 286.0885 [M + H]+. 
Found: 286.0885. 
Methyl 2-oxo-2-[(4-methoxybenzyl)(2,2,2-trifluoroethyl)amino]acetate 4e  
Yellowish oil. HPLC (Supelco Ascentis C18, H2O/CH3CN = 55:45, flow rate 
6 mL min-1, detection at 220 nm, tR = 73.28-86.52 min). Yield 7%. 2 rotamers 
66/34 
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Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.82 (3H, s, OCH3), 3.88 (2H, q, J = 8.9 Hz, CH2CF3), 3.912 (3H, s, 
COOCH3), 4.53 (2H, s, NCH2), 6.91 and 7.22 (2 × 2H, 2 × d, J = 8.9 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 42.8 (q, J = 34.7 Hz, CHCF3), 51.4 (NCH2Ar), 53.0 
(COOCH3), 55.4 (OCH3), 114.6 (2 × O(CHarom)ortho), 124.1 (q, J = 282.9 Hz, CF3), 125.4 
(NCH2Carom,quat), 129.6 (2 × O(CHarom)meta), 160.0 (OCarom,quat), 162.3 (NC=O), 162.6 (OC=O). 19F 
NMR (376.5 MHz, CDCl3): δ -68.44 (3F, t, J = 8.9 Hz, CF3). 
Minor rotamer 
1H NMR (400 MHz, CDCl3): δ 3.81 (3H, s, OCH3), 3.906 (3H, s, COOCH3), 3.96 (2H, q, J = 8.8 
Hz, CH2CF3), 4.71 (2H, s, NCH2), 6.90 and 7.19 (2 × 2H, 2 × d, J = 8.6 Hz, NCH2(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 46.6 (q, J = 34.4 Hz, CHCF3), 48.4 (NCH2Ar), 53.2 
(COOCH3), 55.3 (OCH3), 114.5 (2 × O(CHarom)ortho), 124.0 (q, J = 283.7 Hz, CF3), 126.3 
(NCH2Carom,quat), 130.0 (2 × O(CHarom)meta), 159.7 (OCarom,quat), 161.3 (NC=O), 161.9 (OC=O). 19F 
NMR (376.5 MHz, CDCl3): δ -69.97 (3F, t, J = 8.8 Hz, CF3). 
IR (ATR, cm-1): νOC=O = 1744, νNC=O = 1672, νmax = 1514, 1249, 1153, 1113, 1028, 829. MS (70eV): 
m/z (%): 306 (M+ + 1, 10). HRMS (ESI) calcd for C13H15F3NO4+: m/z calcd: 306.0948 [M + H]+. 
Found: 306.0940. 
Propyl 2-[(2,2-difluorovinyl)(4-methoxyphenyl)amino]-2-oxoacetate 3f 
Yellow oil. Rf = 0.19 (PE/EtOAc, 15/1). Yield 30%. 2 rotamers 86/14 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 0.80 (3H, t, J = 7.1 Hz, OCH2CH2CH3), 1.45 (2H, 
sextet, J = 7.1 Hz, OCH2CH2CH3), 3.82 (3H, s, OCH3), 3.93 (2H, t, J = 7.1 Hz, 
OCH2CH2CH3), 6.08 (1H, d, J = 19.2 Hz, CHCF2), 6.89 and 7.21 (2 × 2H, 2 × d, J = 8.9 Hz, 
N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 10.2 (OCH2CH2CH3), 21.5 
(OCH2CH2CH3), 55.5 (OCH3), 67.6 (OCH2CH2CH3), 87.2 (d × d, J = 51.3, 10.3 Hz, CHCF2), 114.6 
(2 × O(CHarom)ortho), 128.7 (2 × O(CHarom)meta), 130.8 (NCarom,quat), 155.3 (d × d, J = 296.8, 284.2 Hz, 
CF2), 159.9 (OCarom,quat), 161.1 (d, J = 1.8 Hz, NC=O), 161.8 (OC=O). 19F NMR (376.5 MHz, 
CDCl3): δ -98.70 (1F, d, J = 42.2 Hz, FCF), -84.40 (1F, d × d, J = 42.2, 19.2 Hz, FCF). 
Minor rotamer (detectable signals) 
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1H NMR (400 MHz, CDCl3): δ 1.01 (3H, t, J = 7.2 Hz, OCH2CH2CH3), 1.78 (2H, sextet, J = 7.2 Hz, 
OCH2CH2CH3), 3.82 (3H, s, OCH3), 4.28 (2H, t, J = 7.2 Hz, OCH2CH2CH3), 5.73 (1H, d × d, J = 
17.4, 3.4 Hz, CHCF2), 6.93 and 7.25 (2 × 2H, 2 × d, J = 9.0 Hz, N(CHarom)ortho and O(CHarom)ortho). 
13C NMR (100.6 MHz, CDCl3): δ 10.2 (OCH2CH2CH3), 21.8 (OCH2CH2CH3), 55.5 (OCH3), 67.9 
(OCH2CH2CH3), 87.8 (d × d, J = 64.2, 15.7 Hz, CHCF2), 114.6 (2 × O(CHarom)ortho), 126.6 (2 × 
O(CHarom)meta), 131.4 (NCarom,quat), 158.9 (OCarom,quat), 161.4 (d, J = 2.9 Hz, NC=O), 162.4 (OC=O). 
19F NMR (376.5 MHz, CDCl3): δ -93.58 (1F, d × d, J = 26.4, 3.4 Hz, FCF), -84.15 (1F, d × d, J = 
26.4, 17.4 Hz, FCF).  
IR (ATR, cm-1): νOC=O = 1743, νNC=O = 1681, νmax = 1509, 1236, 1030, 922, 839, 795, 672. MS 
(70eV): m/z (%): 300 (M+ + 1, 100). HRMS (ESI) calcd for C14H16 F2 NO4+: 300.1042 [M + H]+. 
Found: 300.1054. 
Propyl 2-oxo-2-[(4-methoxyphenyl)(2,2,2-trifluoroethyl)amino]acetate 4f  
Yellowish oil. Rf = 0.18 (PE/EtOAc, 15/1). Yield 9%.  
1H NMR (400 MHz, CDCl3): δ 0.80 (3H, t, J = 7.1 Hz, OCH2CH2CH3), 1.45 
(2H, sextet, J = 7.1 Hz, OCH2CH2CH3), 3.82 (3H, s, OCH3), 3.91 (2H, t, J = 
7.1 Hz, OCH2CH2CH3), 4.34 (2H, q, J = 8.6 Hz, CH2CF3), 6.90 and 7.21 (2 × 
2H, 2 × d, J = 8.9 Hz, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 10.2 
(OCH2CH2CH3), 21.5 (OCH2CH2CH3), 48.7 (q, J = 34.3 Hz, CHCF3), 55.5 (OCH3), 67.5 
(OCH2CH2CH3), 114.8 (2 × O(CHarom)ortho), 123.7 (q, J = 280.5 Hz, CF3), 129.4 (2 × O(CHarom)meta), 
131.4 (NCarom,quat), 160.1 (OCarom,quat), 161.9 (OC=O), 162.7 (NC=O). 19F NMR (376.5 MHz, CDCl3): 
δ -68.78 (3F, t, J = 8.6 Hz, CF3). 
IR (ATR, cm-1): νOC=O = 1744, νNC=O = 1682, νmax = 1510, 1248, 1217, 1134, 1029, 838, 573. MS 
(70eV): m/z (%): 320 (M+ + 1, 20). HRMS (ESI) calcd for C14H17 F3 NO4+: 320.1104 [M + H]+. Found: 
320.1112. 
Allyl 2-[(2,2-difluorovinyl)(4-methoxyphenyl)amino]-2-oxoacetate 3g  
Yellow oil. Rf = 0.19 (PE/EtOAc, 18/1). Yield 35%. 2 rotamers 85/15 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.82 (3H, s, OCH3), 4.45 (2H, d × t, J = 
6.1, 1.2 Hz, OCH2CHCH2), 5.17 (1H, d × q, J = 10.7, 1.2 Hz, OCH2CH(HCH)), 5.19 (1H, d × q, J 
= 17.0, 1.2 Hz, OCH2CH(HCH)), 5.62 (1H, d × d × t, J = 17.0, 10.7, 6.1 Hz, OCH2CHCH2), 6.07 
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(1H, d, J = 19.1 Hz, CHCF2), 6.88 and 7.20 (2 × 2H, 2 × d, J = 8.9 Hz, N(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.5 (OCH3), 66.4 (OCH2CHCH2), 87.1 (d × d, J 
= 51.3, 10.4 Hz, CHCF2), 114.6 (2 × O(CHarom)ortho), 119.9 (OCH2CHCH2), 128.7 (2 × 
N(CHarom)ortho), 130.4 (OCH2CHCH2), 130.7 (NCarom,quat), 155.3 (d × d, J = 296.8, 284.3 Hz, CF2), 
159.9 (OCarom,quat), 160.8 (NC=O), 161.3 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -98.59 (1F, d, 
J = 42.0 Hz, FCF), -84.27 (1F, d × d, J = 42.0, 19.1 Hz, FCF).  
Minor rotamer (detectable signals) 
1H NMR (400 MHz, CDCl3): δ 3.82 (3H, s, OCH3), 4.80 (2H, d, J = 5.7 Hz, OCH2CHCH2), 5.36 
(1H, d, J = 11.2 Hz, OCH2CH(HCH)), 5.45 (1H, d, J = 16.9 Hz, OCH2CH(HCH)), 5.72 (1H, d × d, 
J = 17.3, 3.1 Hz, CHCF2), 5.98 (1H, d × d × t, J = 16.9, 11.2, 5.7 Hz, OCH2CHCH2), 6.93 and 7.25 
(2 × 2H, 2 × d, J = 8.8 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.5 
(OCH3), 66.7 (OCH2CHCH2), 87.8 (d, J = 33.6 Hz, CHCF2), 114.6 (2 × O(CHarom)ortho), 120.5 
(OCH2CHCH2), 126.6 (2 × N(CHarom)ortho), 130.5 (OCH2CHCH2), 131.3 (NCarom,quat), 158.9 
(OCHarom,quat), 161.9 (OC=O).19F NMR (376.5 MHz, CDCl3): δ -93.36 (1F, d × d, J = 25.9, 3.1 Hz, 
FCF), -83.90 (1F, d × d, J = 25.9, 17.3 Hz, FCF).  
IR (ATR, cm-1): νOC=O = 1745, νNC=O = 1681, νmax = 1510, 1386, 1345, 1236, 1120, 1030, 920, 839, 
794, 674. MS (70eV): m/z (%): 298 (M+ + 1, 100). HRMS (ESI) calcd for C14H14F2NO4+: 298.0885 
[M + 1]+. Found: 298.0892. 
3-Chloropropyl 2-[(2,2-difluorovinyl)(4-methoxyphenyl)amino]-2-oxoacetate 3h  
Yellow oil. Rf = 0.1 (PE/EtOAc, 9/1). Yield 38%. 2 rotamers 88/12 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 1.88 (2H, quintet, J = 6.2 Hz, OCH2CH2CH2Cl), 3.34 (2H, t, J = 6.2 
Hz, OCH2CH2CH2Cl), 3.83 (3H, s, OCH3), 4.13 (2H, t, J = 6.2 Hz, OCH2CH2CH2Cl), 6.06 (1H, d × 
d, J = 19.1, 0.7 Hz, CHCF2), 6.91 and 7.21 (2 × 2H, 2 × d, J = 9.3 Hz, N(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 31.1 (OCH2CH2CH2Cl), 40.5 (OCH2CH2CH2Cl), 
55.5 (OCH3), 62.5 (OCH2CH2CH2Cl), 87.1 (d × d, J = 51.3, 10.4 Hz, CHCF2), 114.8 (2 × 
O(CHarom)ortho), 128.6 (2 × O(CHarom)meta), 130.6 (NCarom,quat), 155.4 (d × d, J = 297.0, 284.7 Hz, 
CF3), 160.0 (OCarom,quat), 160.7 (NC=O), 161.6 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -98.36 
(1F, d, J = 41.2 Hz, FCF), -84.04 (1F, d × d, J = 41.2, 19.1 Hz, FCF).  
Minor rotamer (detectable signals) 
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1H NMR (400 MHz, CDCl3): δ 2.22 (2H, quintet, J = 6.2 Hz, OCH2CH2CH2Cl), 3.67 (2H, t, J = 6.2 
Hz, OCH2CH2CH2Cl), 3.83 (3H, s, OCH3), 4.48 (2H, t, J = 6.2 Hz, OCH2CH2CH2Cl), 5.74 (1H, d × 
d, J = 17.2, 3.3 Hz, CHCF2), 6.94 and 7.25 (2 × 2H, 2 × d, J = 7.9 Hz, N(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 31.1 (OCH2CH2CH2Cl), 40.6 (OCH2CH2CH2Cl), 
52.5 (OCH3), 62.9 (OCH2CH2CH2Cl), 87.8 (d, J = 30.5 Hz, CHCF2), 114.7 (2 × O(CHarom)ortho), 
126.1 (NCarom,quat), 126.6 (2 × O(CHarom)meta), 159.0 (OCarom,quat). 19F NMR (376.5 MHz, CDCl3): δ -
93.13 (1F, d × d, J = 26.6, 3.3 Hz, FCF), -84.28 (1F, d × d, J = 26.6, 17.2 Hz, FCF).  
IR (ATR, cm-1): νOC=O = 1745, νNC=O = 1679, νmax = 1509, 1372, 1237, 1029, 921, 839, 793, 672, 
554. MS (70eV): m/z (%): 334 (M+ + 1, 60). HRMS (ESI) calcd for C14H15 ClF2 NO4+: 334.0652 [M 
+ H]+. Found: 334.0653. 
Benzyl 2-[(2,2-difluorovinyl)(4-methoxyphenyl)amino]-2-oxoacetate 3i  
Yellow oil. Rf = 0.26 (PE/EtOAc, 15/1). Yield 50%. 2 rotamers 87/13  
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.78 (3H, s, OCH3), 5.00 (2H, s, OCH2Ph), 
6.04 (1H, d × d, J = 19.1, 0.6 Hz, CHCF2), 6.72 (2H, d, J = 9.0 Hz, 
O(CHarom)ortho), 7.08-7.11 (4H, m, N(CHarom)ortho and CH2CHarom), 7.25-7.33 (3H, m, CH2CHarom). 13C 
NMR (100.6 MHz, CDCl3): δ 55.4 (OCH3), 67.6 (OCH2Ph), 87.1 (d × d, J = 51.3, 10.4 Hz, CHCF2), 
114.5 (2 × O(CHarom)ortho), 128.48, 128.54, 128.6 (5 × CH2CHarom), 128.87 (2 × N(CHarom)ortho), 130.4 
(NCarom,quat), 134.0 (OCH2Carom,quat), 155.3 (d × d, J = 296.9, 284.4 Hz, CF2), 159.8 (OCarom,quat), 
160.8 (d, J = 2.0 Hz, NC=O), 161.5 (OC=O). 19F NMR (376.5 MHz, CDCl3): δ -95.58 (1F, d, J = 
41.6 Hz, FCF), -84.22 (1F, d × d, J = 41.6, 19.1 Hz, FCF).  
Minor rotamer (detectable signals) 
1H NMR (400 MHz, CDCl3): δ 3.80 (3H, s, OCH3), 5.33 (2H, s, OCH2Ph), 5.60 (1H, d × d, J = 17.1, 
3.4 Hz, CHCF2), 6.91 and 7.22 (2 × 2H, 2 × d, J = 8.4 Hz, N(CHarom)ortho and O(CHarom)ortho), 7.36-
7.43 (5H, m, CH2CHarom). 13C NMR (100.6 MHz, CDCl3): δ 55.5 (OCH3), 68.0 (OCH2Ph), 87.8 (d, 
J = 15.2 Hz, CHCF2), 114.6 (2 × O(CHarom)ortho), 126.6 (2 × N(CHarom)ortho), 128.8, 128.9 (5 × 
CH2CHarom), 131.3 (NCarom,quat), 134.3 (CH2Carom,quat), 158.9 (OCarom,quat), 161.1 (NC=O), 162.1 
(OC=O). 19F NMR (376.5 MHz, CDCl3): δ -93.13 (1F, d × d, J = 25.1, 3.4 Hz, FCF), -83.79 (1F, d 
× d, J = 25.1, 17.1 Hz, FCF). 
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IR (ATR, cm-1): νOC=O = 1743, νNC=O = 1680, νmax = 1509, 1361, 1235, 1030, 919, 838, 735, 696. 
MS (70eV): m/z (%): 348 (M+ + 1, 100). HRMS (ESI) calcd for C18H16F2 NO4+: 348.1042 [M + H]+. 
Found: 348.1034. 
Methyl 2-[(2,2-difluorovinyl)(4-methoxyphenyl)amino]-2-oxoacetate 3j  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 55/45, flow rate 6 mL min-
1, detection at 220 nm, tR = 85.11-90.56 min). Yield 42%. 2 rotamers 83/17 
Major rotamer 
1H NMR (400 MHz, CDCl3): δ 3.58 (3H, s, COOCH3), 3.82 (3H, s, OCH3), 6.06 
(1H, d × d, J = 19.1, 0.5 Hz, CHCF2), 6.89 and 7.20 (2 × 2H, 2 × d, J = 8.9 Hz, N(CHarom)ortho and 
O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 52.5 (COOCH3), 55.5 (OCH3), 87.2 (d × d, J = 
51.3, 10.4 Hz, CHCF2), 114.6 (2 × O(CHarom)ortho), 128.6 (2 × N(CHarom)ortho), 130.7 (NCarom,quat), 
155.4 (d × d, J = 295.9, 283.4 Hz, CF2), 159.9 (OCarom,quat), 160.8 (d, J = 1.7 Hz, NC=O), 162.0 
(OC=O). 19F NMR (376.5 MHz, CDCl3): δ -98.52 (1F, d, J = 41.8 Hz, FCF), -84.20 (1F, d × d, J = 
41.8, 19.1 Hz, FCF).  
Minor rotamer 
1H NMR (400 MHz, CDCl3): δ 3.58 (3H, s, COOCH3), 3.92 (3H, s, OCH3), 5.75 (1H, d × d, J = 
17.3, 3.0 Hz, CHCF2), 6.93 and 7.24 (2 × 2H, 2 × d, J = 9.2 Hz, N(CHarom)ortho and O(CHarom)ortho). 
13C NMR (100.6 MHz, CDCl3): δ 53.0 (COOCH3), 55.5 (OCH3), 87.8 (d × d, J = 48.9, 14.2 Hz, 
CHCF2), 114.6 (2 × O(CHarom)ortho), 126.7 (2 × N(CHarom)ortho), 131.4 (NCarom,quat), 158.8 (d × d, J = 
298.7, 293.3 Hz, CF2), 159.0 (OCarom,quat), 161.0 (NC=O), 162.5 (OC=O). 19F NMR (376.5 MHz, 
CDCl3): δ -93.61 (1F, d × d, J = 26.4, 3.0 Hz, FCF), -84.29 (1F, d × d, J = 26.4, 17.3 Hz, FCF). 
IR (ATR, cm-1): νOC=O = 1746, νNC=O = 1681, νmax = 1509, 1380, 1238, 1122, 1029, 839, 794, 673. 
MS (70eV): m/z (%): 272 (M+ + 1, 100). HRMS (ESI) calcd for C12H12F2 NO4+: 272.0729 [M + H]+. 
Found: 272.0726. 
Methyl 2-oxo-2-[(4-methoxyphenyl)(2,2,2-trifluoroethyl)amino]acetate 4j  
Yellow oil. HPLC (Supelco Ascentis C18, H2O/CH3CN, 55/45, flow rate 6 mL min-
1, detection at 220 nm, tR = 99.55-105.33 min). Yield 5%. 
1H NMR (400 MHz, CDCl3): δ 3.57 (3H, s, COOCH3), 3.83 (3H, s, OCH3), 4.34 
(2H, q, J = 8.7 Hz, CH2CF3), 6.90 and 7.20 (2 × 2H, 2 × d, J = 8.9 Hz, 
N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 48.8 (q, J = 34.3 Hz, CH2CF3), 
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52.4 (COOCH3), 55.5 (OCH3), 114.8 (2 × O(CHarom)ortho), 123.6 (q, J = 280.6 Hz, CHCF3), 129.3 (2 
× N(CHarom)ortho), 131.3 (NCarom,quat), 160.1 (OCarom,quat), 162.1 (NC=O), 162.5 (OC=O). 19F NMR 
(376.5 MHz, CDCl3): δ -68.80 (3F, t, J = 8.7 Hz, CF3). IR (ATR, cm-1): νOC=O = 1748, νNC=O 1682, 
νmax = 1510, 1395, 1249, 1132, 1028, 838, 781, 676. MS (70eV): m/z (%): 292 (M+ + 1, 100). 
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Synthesis and application of 3-methylene-4-(trifluoromethyl)azetidin-2-ones as 




3-Methylene-4-(trifluoromethyl)azetidin-2-ones were efficiently prepared from the corresponding 
3-oxo-4-trifluoromethyl-β-lactams and successfully evaluated as novel building blocks in organic 
synthesis. In particular, Michael additions, electrophilic additions and cycloadditions were applied 
to allow an easy access to a broad variety of stereodefined mono- and spirocyclic 4-CF3-β-lactams 
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Small-ring azaheterocycles are known to entail a certain inherent reactivity associated with their 
high ring-strain energy, rendering the trifluoromethylation of such substrates delicate. The inherent 
reactivity of these synthons allows for the construction of a plethora of valuable heterocycles upon 
careful synthetic manipulation, providing theoretical access to a broad diversity of novel molecular 
scaffolds. In that respect, we embarked on the preparation and exploration of several classes of 
CF3-functionalized small rings as novel substrates in organic synthesis a few years ago.28a,18,51,94 
In particular, β-lactams or azetidin-2-ones represent a versatile class of four-membered 
azaheterocycles,95a,16b,95b,95c,30d as these compounds are celebrated for both their diverse 
biological activities and their synthetic potential as precursors for further synthetic elaboration. In 
the present work, the preparation and exploration of 3-methylene-4-trifluoromethyl-β-lactams as 
novel and versatile building blocks is pursued, en route to the construction of new C3-
functionalized (spirocyclic) β-lactams. The presence of an exocyclic carbon-carbon double bond 
as part of a constrained α,β-unsaturated amide fragment bearing a CF3-group allows for a 
multilateral application of these new synthons in different synthetic directions. More precisely, the 
susceptibility of the alkene moiety with respect to nucleophiles, electrophiles and dipolarophiles 
will be scrutinized with the intention to effect Michael additions, electrophilic additions and 
cycloadditions, respectively. The installation of an electron-withdrawing group at C4 in β-lactams 
has been suggested to be beneficial with respect to the antibacterial properties of these 
compounds,96,13a and thus the replacement of the traditional CH3 substituent (as in the established 
antibiotic Aztreonam) with a CF3 group might provide an interesting new approach in antibacterial 
agent development. 
 
2. Synthesis of 3-methylene-4-(trifluoromethyl)azetidin-2-one building blocks 
 
In spite of their occurrence in several bioactive natural products (exemplified by the β-lactamase 
inhibitor Asparenomycin A1 and the herbical agent Phyllostictine A),97 the chemistry of 3-
alkylidene-β-lactams has received relatively little attention in the literature so far. Synthetic 
approaches to 3-alkylidene-β-lactams rely on different strategies to construct the four-membered 
framework, such as [2+2]-cycloadditions,98 ring-closing or cross-metathesis reactions,99,97d 
palladium-catalyzed oxidative carbonylations,100 and Kinugasa reactions,101 or concern 
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elaborations of preformed β-lactam systems.102 In this study, we pursued the latter strategy to 
provide access to the hitherto unknown 3-methylene-4-trifluoromethyl-β-lactam scaffold. 
A well-established and general entry into olefins relates to the conversion of carbonyl compounds 
upon treatment with phosphorus ylides via intermediate oxaphosphetanes (Wittig reaction).103 
From a retrosynthetic point of view, the premised 3-methylene-β-lactams could thus be accessed 
from the corresponding 3-oxo-β-lactams.102d,104 In a previous communication, cis-3-benzyloxy-4-
(trifluoromethyl)azetidin-2-ones 1 were selected as eligible substrates for the preparation of the 
desired 3-oxo-β-lactams 3 via a debenzylation-oxidation sequence. The first step was 
accomplished upon palladium on carbon-mediated hydrogenolysis (5 bar) in methanol at room 
temperature, providing alcohols 2 in high yields. Subsequent Albright-Onodera oxidation using the 
P2O5/DMSO combination afforded the contemplated new 3-oxo-4-(trifluoromethyl)azetidin-2-ones 
3 in acceptable yields (Scheme 1). The latter ketones 3 proved to be unstable upon prolonged 
preservation and should therefore be used immediately for further elaboration. Once in hand, 3-
oxo-β-lactams 3 were evaluated as substrates for a Wittig olefination upon treatment with 
methylenetriphenylphosphorane, albeit without any success (formation of complex mixtures). In 
order to circumvent this unexpected obstacle, a short detour was proposed based on addition of 
methylmagnesium bromide across the cyclic ketone, followed by alcohol activation and 
elimination. Thus, treatment of azetidine-2,3-diones 3 with methylmagnesium bromide in THF at -
78 °C efficiently provided tertiary alcohols 4. It should be noted that reactions at room temperature 
or 0 °C resulted in decomposition of the substrates 3. Subsequently, alcohols 4 were treated with 
PPh3 in CCl4 to prepare the corresponding intermediate chlorides followed by microwave-assisted 
dehydrochlorination by means of KOtBu in DMSO (Scheme 1). Fortunately, this approach 
furnished the desired 3-methylene-4-(trifluoromethyl)azetidin-2-ones 5 in good yields as a new 
class of β-lactam building blocks for further elaboration. 
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Scheme 1. Synthesis of 3-methylene-4-(trifluoromethyl)azetidin-2-ones 5. 
 
3. Conjugate addition of sulfur and nitrogen nucleophiles across 3-methylene-4-
trifluoromethyl-β-lactams  
 
Because of the cyclic acrylamide motif in 3-methylene-β-lactams 5, in combination with the 
electron-withdrawing CF3-group, the electron-poor C-C double bond might facilitate conjugate 
addition of nucleophiles as a suitable route to 3-functionalized azetidin-2-ones. In that respect, the 
Michael addition of nitrogen and sulfur nucleophiles was assessed next. The addition of 
benzenethiol in THF at room temperature proceed smoothly, but resulted in inseparable mixtures 
of cis- and trans-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-ones 8/9 (ratio 59-74/26-41, 
Scheme 2). On the other hand, conjugate addition of primary and secondary amines provided 
separable mixtures of cis- and trans-3-aminomethyl-4-(trifluoromethyl)azetidin-2-ones 6/7, with 
cis-β-lactams 6 being the major isomers in most cases (Scheme 2, Table 1). The 1,4-addition of 
isobutylamine was realized for 31-39 hours in CH2Cl2 at reflux temperature, whereas pyrrolidine 
and piperidine successfully effected this conjugate addition in THF after 4-18 hours at room 
temperature. The cis-/trans-relationship of the β-lactam substituents in compounds 6 and 7 was 
deduced based on the vicinal H-H coupling constants (CDCl3), in accordance with literature 
information, and full characterization of all isomers 6/7 was made possible after isolation of pure 
material by means of preparative TLC chromatography (SiO2). Finally, 3-isobutylaminomethyl-β-
lactams 6a and 6d were selected for further elaboration, involving reductive β-lactam ring opening 
to intermediate 3-amino-2-(isobutylaminomethyl)butan-1-ols followed by cyclization. Thus, 
consecutive treatment of azetidin-2-ones 6a,d with LiAlH4 in Et2O and triphosgene in THF afforded 
the contemplated new 4-CF3-tetrahydropyrimidin-2-ones 10a,b in good yields (Scheme 2). 
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Pyrimidinones in general are known to have a long track record in medicinal chemistry, for 
example as kinase inhibitors or as anti-HIV agents.105,1a 
 
 
Scheme 2. Conjugate addition of sulfur and nitrogen nucleophiles across 3-methylene-4-CF3-β-
lactams 5. 
 
Table 1. Synthesis of 3-aminomethyl-4-(trifluoromethyl)azetidin-2-ones 6/7. 
Compound R R1, R2 Ratio 6/7 Yield 6 [%][a] Yield 7 [%][a] 
6a,7a PMP H, iBu 67/33 60 29 
6b,7b PMP -(CH2)4- 69/31 39 13 
6c, 7c PMP -(CH2)5- 74/26 44 6 
6d, 7d PMB H, iBu 53/47 38 25 
6e, 7e PMB -(CH2)4- 62/38 18 12 
6f, 7f PMB -(CH2)5- 40/60 15 15 
[a] Yields of isolated products after preparative TLC (SiO2) 
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4. Evaluation of electrophilic additions and cycloadditions of 3-methylene-4-
trifluoromethyl-β-lactams  
 
In the second part, the tendency of 3-methylene-4-trifluoromethyl-β-lactams 5 to undergo classical 
addition reactions across the C-C double bond was investigated. First, hydrogenation on Pd/C 
was evaluated, providing easy and selective access to cis-3-methyl-4-CF3-azetidin-2-ones 11 in 
MeOH at room temperature (Scheme 3). Also electrophilic bromine addition in CH2Cl2 was 
studied, resulting in clean and stereoselective formation of dibrominated 1-(4-methoxyphenyl)-β-
lactam 12a from the corresponding alkene 5a. In the case of 1-(4-methoxybenzyl)-substituted 
substrate 5b, however, a separable mixture of isomers 12b and 13b was formed, in which also 
the N-PMB group experienced bromination. The difference in stereoselectivity between 
bromination of 5a and 5b is remarkable and might be attributable to the interacting steric effects 
exerted by the N-PMB group and the CF3 group in 5b, whereas in 5a the steric influence of the 
more rigid and planar N-PMP substituent is negligible and the bromination is only controlled by 
the CF3 group. In a third approach, Upjohn dihydroxylation of substrates 5 was assessed, involving 
a OsO4-mediated oxidation using N-methylmorpholine-N-oxide (NMO) in a THF/H2O (1/1) solvent 
system. This method smoothly produced vicinal diols 15 in high yields and excellent 
stereoselectivity. The latter diols were subsequently considered to be eligible substrates for the 
preparation of unprecedented β-lactam-based spirocyclic building blocks. In a first example, 
acetalisation was effected upon treatment of diols 15 with pTsOH in 2,2-dimethoxypropane under 
reflux, furnishing 3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-1-ones 16. As a second class of 
target spirocyclic structures, the 5,7-dioxa-2-azaspiro[3.4]octane-1,6-dione scaffold 17 was 
pursued by reaction of diols 15 with triphosgene in CH2Cl2 in the presence of pyridine, affording a 
convenient entry into these new CF3-substituted spirocycles 17 (Scheme 3). 
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Scheme 3. Evaluation of 3-methylene-4-trifluoromethyl-β-lactams 5 for electrophilic additions 
and cycloadditions. 
 
The synthetic exploration of these novel 3-methylene-4-CF3-β-lactam building blocks 5 was 
finalized by evaluating their susceptibility toward cycloaddition reactions. An important strategy in 
that respect comprises the 1,3-dipolar nitrone-olefin cycloaddition to generate 
isoxazolidines,106a,106b,102b,106c,106d,25 which was selected here in order to provide access to novel 
spiro-fused β-lactam isoxazolidine systems. Thus, treatment of 3-methylene-β-lactams 5 with 
either N-phenyl- or N-tert-butyl-α-phenylnitrone in toluene under reflux afforded a convenient entry 
to 7-phenyl-3-trifluoromethyl-5-oxa-2,6-diazaspiro[3.4]octan-1-ones 14, as exemplified by the 
synthesis and characterization of four new derivatives 14a-d (Scheme 3). The major (3S*,4R*,7R*)-
isomers 14 were accompanied by small amount of their 7-epimers, some of which were also 
isolated and characterized spectroscopically.  
An important aspect of these studies concerned the assignment of the correct structures to all 
these new compounds, especially with respect to their relative stereochemistry. In order to secure 
their molecular architecture, a few representative model compounds were selected for single 
crystal X-ray analysis, providing irrefutable evidence for the chemical structure of β-lactams 14, 
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16 and 17 (see Fig. 1 for X-ray structure of compounds 14b and 16a). Furthermore, it was also 
observed that β-lactams with a cis-configured methylene group and a CF3 group are characterized 
by a distinct long-range coupling between one of the two methylene protons at C3 and the fluorine 
atoms from the C4 CF3-group (quartet, J = 1-3 Hz, CDCl3), which is not present in the 
diastereomeric counterparts, allowing for an unequivocal stereochemistry assignment of all 
compounds shown in Scheme 3. 
 
          
             
Fig. 1. Schematic representation and molecular structures of spirocycles 14b and 16a. 
 
As indicated in the Introduction, β-lactams are considered to be the cornerstones of contemporary 
antibacterial therapy, but the rapid emergence of resistant strains necessitates a persistent search 
for new analogues and derivatives. On the other hand, β-lactams also represent flexible 
precursors in organic synthesis, providing access to a broad range of complex target structures. 
In that respect, spirocyclic β-lactams have attracted considerable interest in recent years, both 
from a chemical and a biological point of view.102e,107 Indeed, further synthetic elaboration allows 
the preparation of various highly functionalized (hetero)cycles, in particular focused on the 
synthesis of cyclic amino acid derivatives, and spiroazetidin-2-ones are also associated with 
diverse biological effects, such as antimicrobial, antiviral, and cholesterol absorption inhibition 
activity. Bearing the general importance of CF3-substituted heterocycles within the field of 
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medicinal chemistry in mind, β-lactam-based spirocycles 14, 16 and 17 accommodating a CF3-




3-Methylene-4-(trifluoromethyl)azetidin-2-ones were efficiently prepared via intermediate 3-oxo-4-
trifluoromethyl-β-lactams and successfully deployed as novel substrates for Michael additions, 
electrophilic additions and cycloadditions. In this way, a broad variety of new and stereodefined 
4-CF3-β-lactams were produced, including 3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-ones, 
3-aminomethyl-4-(trifluoromethyl)azetidin-2-ones, 3-methyl-4-(trifluoromethyl)azetidin-2-ones, 3-
bromo-3-bromomethyl-4-(trifluoromethyl)azetidin-2-ones, 3-hydroxy-3-hydroxymethyl-4-
(trifluoromethyl)azetidin-2-ones and 3-trifluoromethyl-5-oxa-2,6-diazaspiro[3.4]octan-1-ones, 
providing many opportunities for further elaboration as shown by the synthesis of 4-
(trifluoromethyl)tetrahydropyrimidin-2-ones, 3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-1-
ones and 3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-diones. In light of the increasing 
demand for new CF3-substituted azaheterocyclic scaffolds from a medicinal chemistry 
perspective, 3-methylene-4-(trifluoromethyl)azetidin-2-ones can indeed be considered as eligible 
building blocks for the construction of a broad variety of mono- and spirocyclic 4-CF3-β-lactams 




Next to the aforementioned reactivities, the presence of an alkene moiety at the C3 position in 3-
methylene-4-(trifluoromethyl)azetidin-2-ones 5 allows for many other chemical transformations to 
access several types of biologically interesting β-lactam derivatives (Scheme 4). For example, 
treatment of 3-methylene-β-lactams 5 with mCPBA in CH2Cl2 could afford 6-trifluoromethyl-1-oxa-
5-azaspiro[2.3]hexan-4-ones 18.108 In analogy with the epoxidation of CF3-nonsubstituted 3-
methylene-β-lactams 5, the direct aziridination of the double bond could lead to the formation of 
new 1-tosyl-6-trifluoromethyl-1,5-diazaspiro[2.3]hexan-4-ones 19 upon the treatment with NBS 
and chloroamine-T.109 In addition, treatment of 3-methylene-β-lactams 5 under either Simmon-
Smith conditions (Et2Zn, CH2I2) or CH2N2 in CH2Cl2 could give rise to novel 6-trifluoromethyl-5-
azaspiro[2.3]hexan-4-ones 20.110,25  





The deployment of 3-methylene-4-CF3-β-lactam 5 as building blocks toward the synthesis of 
novel β-lactam-based spirocycles bearing a trifluoromethyl group might be an appealing field 
from both synthesis and application points of view. 
 
7. Experimental details 
 
Synthesis of 3-hydroxy-3-methyl-4-(trifluoromethyl)azetidin-2-ones 4 
As a representative example, the synthesis of cis-3-hydroxy-1-(4-methoxybenzyl)-3-methyl-4-
(trifluoromethyl)azetidin-2-one 4b is described. A solution of methylmagnesium bromide (0.26 mL, 
2.38 mmol, 3M in Et2O, 1.3 equiv) was added to a solution of 1-(4-methoxybenzyl)-4-
trifluoromethyl-3-oxoazetidin-2-one 3b (0.50 g, 1.83 mmol, 1 equiv) in dry THF (10 mL) at -78 °C 
under a nitrogen atmosphere. The resulting mixture was stirred for 1.5 hours at the same 
temperature. The mixture was quenched by adding a 5% solution of NH4Cl (3 mL) and extracted 
with ethyl acetate (3 x 10 mL). The combined organic phases were washed with brine (2 x 10 mL). 
Drying (MgSO4), filtration of the drying agent, and removal of the solvent in vacuo afforded cis-3-
hydroxy-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one 4b, which was further 
purified by means of column chromatography (PE/EtOAc, 4/1) to furnish pure 4b in a yield of 89%.  
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Cis-3-hydroxy-1-(4-methoxyphenyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one 4a 
Yellowish crystals. Mp 123 °C. Recrystallization in Et2O/Hex, 2/1. Yield 92%. 1H 
NMR (400 MHz, CDCl3): δ 1.73 (3H, s, CH3), 3.44 (1H, s, OH), 3.80 (3H, s, 
OCH3), 4.34 (1H, q, J = 5.9 Hz, CHCF3), 6.90 and 7.40 (2 × 2H, 2 × d, J = 9.0 
Hz, N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 22.2 
(CCH3), 55.5 (OCH3), 63.9 (q, J = 31.7 Hz, CHCF3), 83.0 (CCH3), 114.5 (2 × O(CHarom)ortho), 119.6 
(2 × N(CHarom)ortho), 123.7 (q, J = 280.5 Hz, CF3), 129.4 (N(CHarom)ortho), 157.4 (OCarom,quat), 167.4 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.75 (3F, d, J = 5.9 Hz, CF3). IR (ATR, cm-1): νOH = 3364, 
νC=O = 1745, νmax = 1513, 1289, 1252, 1140, 1091, 1032, 825. MS (70eV): m/z (%): 276 (M+ + 1, 
100). HRMS (ESI) calcd for C12H13F3NO3+: 276.0842 [M + H]+. Found: 276.0838. 
Cis-3-hydroxy-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one 4b 
White crystals. Mp 82 °C. Rf = 0.17 (PE/EtOAc, 4/1). Yield 89%. 1H NMR (400 MHz, 
CDCl3): δ 1.51 (3H, s, CH3), 3.56 (1H, q, J = 6.4 Hz, CHCF3), 3.81 (3H, s, OCH3), 3.90 
(1H, d, J = 14.8 Hz, (HCH)N), 3.92 (1H, s, OH), 4.85 (1H, d, J = 14.8 Hz, (HCH)N), 
6.89 and 7.15 (2 × 2H, 2 × d, J = 8.5 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C 
NMR (100.6 MHz, CDCl3): δ 21.4 (CCH3), 44.6 (ArCH2N), 55.3 (OCH3), 62.4 (q, J = 
31.4 Hz, CHCF3), 83.4 (CCH3), 114.5 (2 × O(HCarom)ortho), 123.9 (q, J = 280.0 Hz, CF3), 125.9 
(NCH2Carom,quat), 129.9 (2 × NCH2(HCarom)ortho), 159.6 (OCarom,quat), 170.4 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -69.86 (3F, d, J = 6.4 Hz, CF3). IR (ATR, cm-1): νOH = 3335, νC=O = 1729, νmax = 
1515, 1282, 1253, 1212, 1162, 1139, 1080, 1033, 810. MS (70eV): m/z (%): 121 (100), 290 (M+ + 
1, 45). HRMS (ESI) calcd for C13H15F3NO3+: 290.0999 [M + H]+. Found: 290.0993.   
Synthesis of 3-methylene-4-(trifluoromethyl)azetidin-2-ones 5 
As a representative example, the synthesis of 1-(4-methoxybenzyl)-3-methylene-4-
(trifluoromethyl)azetidin-2-one 5b is described. A solution of 3-hydroxy-1-(4-methoxybenzyl)-3-
methyl-4-(trifluoromethyl)azetidin-2-one 4b (0.27 g, 0.94 mmol, 1 equiv) and triphenylphosphine 
(0.49 g, 1.87 mmol, 2 equiv ) in carbon tetracholoride (4 mL) was heated under reflux for 43 hours. 
The reaction mixture was then filtered through a small pad of Celite® and concentrated under 
reduced pressure to afford the crude product. The LC-MS and 1H NMR of the crude product 
showed it to be a mixture of 1-(4-methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 
4b and 3-chloro-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one in a ratio of 
65:35, which was separated by flash column chromatography (PE/EtOAc, 9/1) to give pure 1-(4-
methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5b in a yield of 51% as white 
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crystals and 3-chloro-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one in a yield of 
34% as a yellow oil. In the next step, to a solution of 3-chloro-1-(4-methoxybenzyl)-3-methyl-4-
(trifluoromethyl)azetidin-2-one (0.10 g, 0.33 mmol, 1 equiv) in dry dimethyl sulfoxide (10 mL), 
KOtBu (0.07 g, 0.66 mmol, 2 equiv) was slowly added and the mixture was subjected to microwave 
heating for 3.5 hours at 120 °C. Afterward, the reaction mixture was cooled to room temperature 
and was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed five 
times with brine (5 × 10 mL) to remove the excess of DMSO, then, dried over MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by means of column chromatography (PE/EtOAc, 
9/1) to furnish pure 1-(4-methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5b in a 
yield of 21%.  
1-(4-Methoxyphenyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5a 
Yellow crystals. Mp 68 °C. Rf = 0.15 (PE/EtOAc, 9/1). Yield 51%. 1H NMR (400 
MHz, CDCl3): δ 3.81 (3H, s, OCH3), 4.89 (1H, q × t, J = 5.0, 1.3 Hz, CHCF3), 5.56 
and 6.02 (2 × 1H, 2 × s, C(HCH)), 6.91 and 7.42 (2 × 2H, 2 × d, J = 9.1 Hz, 
N(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 55.5 (OCH3), 
59.2 (q, J = 35.6 Hz, CHCF3), 114.1 (CCH2), 114.5 (2 × O(CHarom)ortho), 119.0 (2 × N(CHarom)ortho), 
123.6 (q, J = 281.5 Hz, CF3), 130.0 (NCarom,quat), 140.4 (CCH2), 157.1 (OCarom,quat), 159.5 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -71.87 (3F, d, J = 5.0 Hz, CF3). IR (ATR, cm-1): νC=O = 1742, νmax 
= 1510, 1380, 1279, 1248, 1128, 1024, 866, 826, 715. MS (70eV): m/z (%): 258 (M+ + 1, 100). 
HRMS (ESI) calcd for C12H11F3NO2+: 258.0736 [M + H]+. Found: 258.0731. 
1-(4-Methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5b 
White crystals. Mp < 50 °C. Rf = 0.19 (PE/EtOAc, 9/1). Yield 72%. 1H NMR (400 MHz, 
CDCl3): δ 3.81 (3H, s, OCH3), 4.05 (1H, d, J = 15.0 Hz, (HCH)N), 4.19 (1H, q, J = 5.6 
Hz, CHCF3), 4.90 (1H, d, J = 15.0 Hz, (HCH)N), 5.37 and 5.87 (2 × 1H, 2 × s, C(HCH)), 
6.89 and 7.19 (2 × 2H, 2 × d, J = 8.5 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR 
(100.6 MHz, CDCl3): δ 45.0 (ArCH2N), 55.3 (OCH3), 57.6 (q, J = 35.2 Hz, CHCF3), 
113.0 (CCH2), 114.4 (2 × O(HCarom)ortho), 123.7 (q, J = 279.5 Hz, CF3), 126.3 (NCH2Carom,quat), 129.9 
(2 × NCH2(HCarom)ortho), 141.4 (CCH2), 159.6 (OCarom,quat), 162.4 (C=O). 19F NMR (376.5 MHz, 
CDCl3): δ -73.28 (3F, d, J = 5.6 Hz, CF3). IR (ATR, cm-1): νC=O = 1766, νmax = 1514, 1384, 1278, 
1246, 1126, 1032, 866, 714. MS (70eV): m/z (%): 272 (M+ + 1, 10). HRMS (ESI) calcd for 
C13H13F3NO2+: 272.0893 [M + H]+. Found: 272.0888. 
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Synthesis of 3-aminomethyl-4-(trifluoromethyl)azetidin-2-ones 6-7 
As a representative example, the synthesis of cis-1-(4-methoxybenzyl)-3-(pyrrolidin-1-ylmethyl)-
4-(trifluoromethyl)azetidin-2-one 6e and trans-1-(4-methoxybenzyl)-3-(pyrrolidin-1-ylmethyl)-4-
(trifluoromethyl)azetidin-2-one 7e is described. Pyrolidine (0.02 mL, 0.22 mmol, 1.2 equiv) was 
added to an ice-cooled solution of 1-(4-methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-
one 5b (0.05 g, 0.18 mmol, 1 equiv) in dry THF (5 mL). Then, the reaction mixture was stirred at 
room temperature for four hours. After completion of the reaction, the reaction mixture was 
extracted with EtOAc (3 × 5 mL). The combined organic extracts were washed with brine (3 × 5 
mL). Drying (MgSO4), filtration of the drying agent and evaporation of the solvent in vacuo afforded 
a mixture of cis-1-(4-methoxybenzyl)-3-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 6e 
(18%) and trans-1-(4-methoxybenzyl)-3-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 
7e (12%) in a ratio of 62:38. The two isomers were separated by preparative TLC (PE/EtOAc, 1/1) 
to obtain analytically pure samples. 
Cis-3-[(isobutylamino)methyl]-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 6a 
Yellowish solid. Mp 80 °C. Rf = 0.08 (PE/EtOAc/Et3N, 1/1/0.01). Yield 60%. 1H 
NMR (400 MHz, CDCl3): δ 0.93 and 0.94 (2 × 3H, 2 × d, J = 6.7 Hz, CH(CH3)2), 
1.77 (1H, nonet, J = 6.7 Hz, CH(CH3)2), 2.48 and 2.52 (2H, 2 × (d × d), J = 11.4, 
6.7 Hz, (HCH)CHCH3), 3.03 (1H, d × d, J = 12.3, 6.2 Hz, CHCH(HCH)NH), 3.19 
(1H, d × d × q, J = 12.3, 8.9, 1.7 Hz, CHCH(HCH)NH), 3.80 (3H, s, OCH3), 3.84 
(1H, d × t, J = 8.9, 6.2 Hz, CHCHCF3), 4.59 (1H, quintet, J = 6.2 Hz, CHCF3), 6.89 and 7.35 (2 × 
2H, 2 × d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 20.53, 
20.54 (2 × CH(CH3)2), 28.2 (CH(CH3)2), 44.9 (q, J = 2.4 Hz CHCHCH2NH), 52.0 (CHCHCH2NH), 
54.6 (q, J = 34.1 Hz, CHCF3), 55.5 (OCH3), 58.0 (NHCH2CHCH3), 114.4 (2 × O(HCarom)ortho), 119.7 
(2 × N(HCarom)ortho), 124.3 (q, J = 282.5 Hz, CF3), 129.6 (NCarom,quat), 157.1 (OCarom,quat), 165.7 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ -67.79 (3F, d, J = 6.2 Hz, CF3). IR (ATR, cm-1): νNH = 2961, 
νC=O = 1742, νmax = 1512, 1285, 1240, 1140, 1130, 831, 810, 694, 517. MS (70eV): 331 (M+ + 1, 
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Trans-3-[(isobutylamino)methyl]-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 7a 
Yellow oil. Rf = 0.23 (PE/EtOAc/Et3N, 1/10/01). Yield 29%. 1H NMR (400 MHz, 
CDCl3): δ 0.87 and 0.88 (6H, 2 × d, J = 6.7 Hz, CH(CH3)2), 1.68 (1H, nonet, J = 
6.7 Hz, CH(CH3)2), 2.41 (1H, d × d, J = 11.5, 6.7 Hz, (HCH)CHCH3), 2.48 (1H, d 
× d, J = 11.5, 6.7 Hz, (HCH)CHCH3), 2.95 (1H, d × d, J = 12.9, 5.4 Hz, (HCH)NH), 
3.16 (1H, d × d, J = 12.9, 5.4 Hz, (HCH)NH), 3.53 (1H, t × d, J = 5.4, 2.2 Hz, 
CHCHCF3), 3.80 (3H, s, OCH3), 4.52 (1H, q × d, J = 5.6, 2.2 Hz, CHCF3), 6.89 and 7.35 (2 × 2H, 
2 × d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 20.4 and 20.5 
(2 × CH(CH3)2), 28.3 (CH(CH3)2), 46.1 (CHCH2NH), 52.5 (CHCH2NH), 54.7 (q, J = 34.8 Hz, 
CHCF3), 55.5 (OCH3), 58.0 (NHCH2CHCH3), 114.4 (2 × O(CH arom)ortho), 119.6 (2 × N(CHarom)ortho), 
124.6 (q, J = 278.3 Hz, CF3), 129.8 (NCarom,quat), 157.0 (OCarom,quat), 165.2 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -72.45 (3F, d, J = 5.6 Hz, CF3). IR (ATR, cm-1): νNH = 2957, νC=O = 1759, νmax = 
1512, 1279, 1246, 1159, 1136, 1113, 1032, 829, 694, 519. MS (70eV): 331 (M+ + 1, 100). 
Cis-1-(4-methoxyphenyl)-3-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 6b 
White crystals. Mp 104 °C. Rf = 0.07 (PE/EtOAc, 1/1). Yield 39%. 1H NMR (400 
MHz, CDCl3): δ 1.78-1.85 (4H, m, N(CH2(CH2)2), 2.54-2.60 and 2.67-2.74 (2 × 
2H, 2 × m, N(CH2)2(CH2)2), 2.88 (1H, d × d × q, J = 13.3, 7.8, 1.4 Hz, CH(HCH)N), 
3.10 (1H, d × d × q, J = 13.3, 6.0, 1.3 Hz, CH(HCH)N), 3.80 (3H, s, OCH3), 3.82 
(1H, d × t, J = 7.8, 6.0 Hz, CHCHCF3), 4.61 (1H, quintet, J = 6.0 Hz, CHCF3), 
6.89 and 7.36 (2 × 2H, 2 × d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, 
CDCl3): δ 23.7 (NCH2(CH2)2), 50.1 (q, J = 2.5 Hz, CHCH2N), 52.2 (CHCH2N), 54.5 
(N(CH2)2(CH2)2), 54.7 (q, J = 33.6 Hz, CHCF3), 55.5 (OCH3), 114.4 (2 × O(CHarom)ortho), 119.8 (2 × 
N(CHarom)ortho), 124.4 (q, J = 281.2 Hz, CF3), 129.7 (NCarom,quat), 157.0 (OCarom,quat), 165.4 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -68.04 (3F, d, J = 6.0 Hz, CF3). IR (ATR, cm-1): νC=O = 1749, νmax 
= 1514, 1277, 1248, 1138, 1109, 1030, 839, 808, 694, 521. MS (70eV): 329 (M+ +1, 100). HRMS 
(ESI) for C16H20F3N2O2+: 329.1471 [M + H]+. Found: 329.1477. 
Trans-1-(4-methoxyphenyl)-3-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 7b 
Pale solid. Mp 80 °C. Rf = 0.21 (PE/EtOAc, 1/1). Yield 13%. 1H NMR (400 MHz, 
CDCl3): δ 1.74-1.81 (4H, m, N(CH2(CH2)2), 2.52-2.63 (4H, m, N(CH2)2(CH2)2), 
2.91 (1H, d × d, J = 12.9, 5.6 Hz, CH(HCH)N), 2.96 (1H, d × d, J = 12.9, 7.8 Hz, 
CH(HCH)N), 3.55 (1H, d × d × d, J = 7.8, 5.6, 2.1 Hz, CHCHCF3), 3.80 (3H, s, 
OCH3), 4.52 (1H, q × d, J = 5.5, 2.1 Hz, CHCF3), 6.89 and 7.36 (2 × 2H, 2 × d, J 
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= 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 23.7 (NCH2(CH2)2), 
52.1 (CHCH2N), 53.0 (CHCH2N), 54.5 (N(CH2)2(CH2)2), 55.50 (OCH3), 55.53 (q, J = 34.2 Hz, 
CHCF3), 114.4 (2 × O(CHarom)ortho), 119.4 (2 × N(CHarom)ortho), 124.4 (q, J = 280.5 Hz, CF3), 130.0 
(NCarom,quat), 156.9 (OCarom,quat), 165.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -72.35 (3F, d, J = 
5.5 Hz, CF3). IR (ATR, cm-1): νC=O = 1748, νmax = 1516, 1275, 1254, 1161, 1134, 1028, 837, 808, 
696, 517. MS (70eV): 329 (M+ +1, 100). 
Cis-1-(4-methoxyphenyl)-3-(piperidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 6c 
White crystals. Mp 110 °C. Rf = 0.18 (PE/EtOAc, 1/1). Yield 44%. 1H NMR (400 
MHz, CDCl3): δ 1.41-1.47 (2H, m, N((CH2)2(CH2)2CH2), 1.53-1.67 (4H, m, 
N((CH2)2(CH2)2), 2.37-2.43 and 2.59-2.64 (2 × 2H, 2 × m, N(CH2)2(CH2)2), 2.79 
(1H, d × d × q, J = 13.6, 6.0, 1.4 Hz, CH(HCH)N), 2.88 (1H, d × d × q, J = 13.6, 
6.0, 1.4 Hz, CH(HCH)N), 3.79 (3H, s, OCH3), 3.82 (1H, d × t, J = 6.3, 6.0 Hz, 
CHCHCF3), 4.59 (1H, quintet, J = 6.3 Hz, CHCF3), 6.88 and 7.34 (2 × 2H, 2 × d, J = 9.0 Hz, 
O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 24.1 (NCH2(CH2)2(CH2)2), 26.0 
(N(CH2)2(CH2)2), 51.5 (CHCH2N), 53.0 (q, J = 2.2 Hz, CHCH2N), 54.6 (N(CH2)2(CH2)2), 54.9 (q, J 
= 33.5 Hz, CHCF3), 55.5 (OCH3), 114.4 (2 × O(HCarom)ortho), 119.8 (2 × N(HCarom)ortho), 124.4 (q, J 
= 281.3 Hz, CF3), 129.7 (N(Carom,quat), 157.0 (OCarom,quat), 165.7 (C=O). 19F NMR (376.5 MHz, 
CDCl3): δ -68.15 (3F, d, J = 6.3 Hz, CF3). IR (ATR, cm-1): νC=O = 1746, νmax = 1514, 1285, 1248, 
1136, 1032, 839, 808, 656, 521. MS (70eV): 343 (M+ + 1, 100). HRMS (ESI) for C17H22F3N2O2+: 
343.1628 [M + H]+. Found: 343.1634. 
Trans-1-(4-methoxyphenyl)-3-(piperidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 7c 
Yellow sticky oil. Rf = 0.46 (PE/EtOAc, 1/1). Yield 6%. 1H NMR (400 MHz, 
CDCl3): δ 1.38-1.44 (2H, m, N(CH2)2(CH2)2CH2), 1.52-1.57 (4H, m, 
N(CH2)2(CH2)2), 2.38-2.43 and 2.46-2.51 (2 × 2H, 2 × m, N(CH2)2(CH2)2), 2.77 
(2H, d, J = 6.7 Hz, CH(HCH)N), 3.56 (1H, t × d, J = 6.7, 2.0 Hz, CHCHCF3), 
3.80 (3H, s, OCH3), 4.42 (1H, q × d, J = 5.4, 2.0 Hz, CHCF3), 6.89 and 7.35 (2 
× 2H, 2 × d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 24.1 
(NCH2(CH2)2(CH2)2), 26.0 (N(CH2)2(CH2)2), 50.9 (CHCH2N), 54.9 (N(CH2)2(CH2)2), 55.5 (OCH3), 
55.8 (q, J = 34.4 Hz, CHCF3), 56.0 (CHCH2N), 114.4 (2 × O(CHarom)ortho), 119.5 (2 × N(CHarom )ortho), 
124.6 (q, J = 276.1 Hz, CF3), 130.0 (N(Carom,quat), 156.9 (OCarom,quat), 165.4 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -72.34 (3F, d, J = 5.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1778, νmax = 1499, 1398, 
1283, 1252, 1161, 1132, 1109, 1056, 810, 509, 403. MS (70eV): 343 (M+ + 1, 100). 
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Cis-3-[(isobutylamino)methyl]-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 6d 
White solid. Mp < 46 °C. Rf = 0.11 (PE/EtOAc/Et3N, 2/1/0.01). Yield 38%. 1H NMR 
(400 MHz, CDCl3): δ 0.898 and 0.902 (6H, 2 × d, J = 6.7 Hz, CH(CH3)2), 1.72 (1H, 
nonet, J = 6.7 Hz, CH(CH3)2), 2.41 (1H, d × d, J = 11.3, 6.7 Hz, (HCH)CHCH3), 2.46 
(1H, d × d, J = 11.3, 6.7 Hz, (HCH)CHCH3), 2.91 (1H, d × d, J = 12.4, 6.0 Hz, 
CH3CH(HCH)NH), 3.09 (1H, d × d × q, J = 12.4, 8.8, 1.7 Hz, CHCH(HCH)NH), 3.58 
(1H, d × t, J = 8.8, 6.0 Hz, CHCHCF3), 3.81 (3H, s, OCH3), 3.86 (1H, q × d, J = 7.1, 
6.0 Hz, CHCF3), 3.90 and 4.79 (2 × 1H, 2 × d, J = 15.0, (HCHN)), 6.88 and 7.17 (2 × 2H, 2 × d, J 
= 8.6 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 20.5 (2 × 
CH(CH3)2), 28.2 (CH(CH3)2), 44.8 (NCH2CHCH3, NCH2Carom), 52.5 (CHCHCF3), 53.1 (q, J = 33.7 
Hz, CHCF3), 55.3 (OCH3), 57.9 (CH2CH(CH3)2), 114.3 (2 × O(HCarom)ortho), 124.5 (q, J = 280.3 Hz, 
CF3), 126.6 (NCH2(Carom,quat), 129.8 (2 × NCH2(CHarom)ortho), 159.5 (OCarom,quat), 168.2 (C=O). 19F 
NMR (376.5 MHz, CDCl3): δ -68.81 (3F, d, J = 7.1 Hz, CF3). IR (ATR, cm-1): νNH = 2949, νC=O = 
1749, νmax = 1514, 1246, 1134, 1113, 1032, 839, 806. MS (70eV): 345 (M+ + 1, 100). HRMS (ESI) 
calcd for C17H24F3N2O2+: 345.1784 [M + H]+. Found: 345.1788. 
Trans-3-[(isobutylamino)methyl]-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 7d 
Yellow oil. Rf = 0.40 (PE/EtOAc/Et3N, 2/1/0.01). Yield 25%. 1H NMR (400 MHz, 
CDCl3): δ 0.847 and 0.853 (2 × 3H, 2 × d, J = 6.6 Hz, CH(CH3)2), 1.62 (1H, nonet, J 
= 6.6 Hz, CH(CH3)2), 2.31 (1H, d × d, J = 11.4, 6.6 Hz, (HCH)CHCH3), 2.43 (1H, d × 
d, J = 11.4, 6.6 Hz, (HCH)CHCH3), 2.78 (1H, d × d, J = 12.9, 5.1 Hz, CHCH(HCH)NH), 
3.01 (1H, d × d , J = 12.9, 5.1 Hz, CHCH(HCH)NH), 3.40 (1H, t × d, J = 5.1, 2.5 Hz, 
CHCHCF3), 3.80 (3H, s, OCH3), 3.82 (1H, q × d, J = 5.8, 2.5 Hz, CHCF3), 3.90 and 
4.82 (2 × 1H, 2 × d, J = 15.0, (HCHN)), 6.87 and 7.21 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and 
NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 20.48 and 20.51 (2 × CH(CH3)2), 28.5 
(CH(CH3)2), 44.9 (NCH2Carom), 46.0 (COCHCH2N), 52.6 (CHCHCF3), 53.3 (q, J = 34.2 Hz, CHCF3), 
55.3 (OCH3), 58.0 (CH2CH(CH3)2), 114.2 (2 × O(CHarom)ortho), 124.7 (q, J = 279.2 Hz, CF3), 126.7 
(NCH2(Carom,quat), 129.8 (2 × NCH2(CHarom)ortho), 159.4 (OCarom,quat), 167.7 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -73.65 (3F, d, J = 5.8 Hz, CF3). IR (ATR, cm-1): νNH = 2953, νC=O = 1761, νmax = 
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Cis-1-(4-methoxybenzyl)-3-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 6e 
White crystals. Mp 66 °C. Rf = 0.12 (PE/EtOAc, 1/1). Yield 18%. 1H NMR (400 MHz, 
CDCl3): δ 1.74-1.81 (4H, m, N(CH2(CH2)2), 2.47-2.55 and 2.61-2.68 (2 × 2H, 2 × m, 
N(CH2)2CH2), 2.77 (1H, d × d × q, J = 13.0, 8.3, 1.7 Hz, CH(HCH)N), 2.98 (1H, d × d, 
J = 13.0, 5.4 Hz, CH(HCH)N), 3.57 (1H, d × t, J =8.3, 5.4 Hz, CHCHCF3), 3.81 (3H, s, 
OCH3), 3.86 (1H, q × d, J = 6.9, 5.4 Hz, CHCF3), 3.91 and 4.80 (2 × 1H, 2 × d, J = 14.9 
Hz, (HCH)N), 6.88 and 7.17 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and 
NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 23.6 (NCH2(CH2)2), 44.8 (NCH2Carom), 50.1 (q, 
J = 2.0 Hz, CHCH2N), 52.6 (CHCH2N), 53.2 (q, J = 33.3 Hz, CHCF3), 54.4 (N(CH2)2(CH2)2), 55.3 
(OCH3), 114.3 (2 × O(CHarom)ortho), 124.6 (q, J = 280.5 Hz, CF3), 126.7 (NCH2(Carom,quat), 129.9 (2 
× NCH2(HCarom)ortho), 159.4 (OCarom,quat), 167.9 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.96 (3F, 
d, J = 6.9 Hz, CF3). IR (ATR, cm-1): νC=O = 1751, νmax = 1514, 1288, 1246, 1126, 1111, 1036, 833, 
673, 575, 515. MS (70eV): m/z (%): 343 (M+ + 1, 100). HRMS (ESI) calcd for C17H22F3N2O2+: 
343.1628 [M + H]+. Found: 343.1638. 
Trans-1-(4-methoxybenzyl)-3-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 7e 
Yellowish oil. Rf = 0.43 (PE/EtOAc, 1/1). Yield 12%. 1H NMR (400 MHz, CDCl3): δ 1.69-
1.74 (4H, m, N(CH2(CH2)2), 2.47-2.52 (4H, m, N(CH2)2CH2, 2.75 (1H, d × d, J = 13.3, 
7.5 Hz, CH(HCH)N), 2.80 (1H, d × d, J = 13.3, 5.2 Hz, CH(HCH)N), 3.40 (1H, d × d × 
d, J = 7.5, 5.2, 2.0 Hz, CHCHCF3), 3.77 (1H, q × d, J = 6.1, 2.0 Hz, CHCF3), 3.81 (3H, 
s, OCH3), 3.88 and 4.83 (2 × 1H, 2 × d, J = 15.0 Hz, (HCH)N), 6.88 and 7.19 (2 × 2H, 
2 × d, J = 8.6 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): 
δ 23.6 (NCH2(CH2)2), 44.8 (NCH2), 52.3 (CHCH2N), 52.6 (CHCH2N), 54.2 (q, J = 33.8 Hz, CHCF3), 
54.6 (N(CH2)2(CH2)2), 55.3 (OCH3), 114.2 (2 × O(CHarom)ortho), 124.6 (q, J = 279.5 Hz, CF3), 126.7 
(NCH2(Carom,quat), 129.8 (2 × NCH2(HCarom)ortho), 159.4 (OCarom,quat), 167.7 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -73.48 (3F, d, J = 6.1 Hz, CF3). IR (ATR, cm-1): νC=O = 1767, νmax = 1514, 1277, 
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Cis-1-(4-methoxybenzyl)-3-(piperidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 6f 
White crystals. Mp 76 °C. Rf = 0.13 (PE/EtOAc, 1/1). Yield 15%. 1H NMR (400 MHz, 
CDCl3): δ 1.38-1.44 (2H, m, N(CH2)2(CH2)2CH2), 1.49-1.63 (4H, m, N(CH2)2(CH2)2), 
2.31-2.36 and 2.52-2.59 (2 × 2H, 2 × m, N(CH2)2(CH2)2), 2.69 (1H, d × d × q, J = 13.5, 
7.2, 1.5 Hz, CH(HCH)N), 2.77 (1H, d × d, J = 13.5, 5.5 Hz, CH(HCH)N), 3.58 (1H, d × 
t, J = 7.2, 5.5 Hz, CHCHCF3), 3.81 (3H, s, OCH3), 3.84 (1H, q × d, J = 7.1, 5.5 Hz, 
CHCF3), 3.90 and 4.79 ( 2 × 1H, 2 × d, J = 15.0, (HCH)N), 6.87 and 7.17 (2 × 2H, 2 × 
d, J = 8.6 Hz, NCH2(CHarom)ortho and O(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 
24.1 (N(CH2)2(CH2)2CH2), 26.0 (N(CH2)2(CH2)2), 44.8 (NCH2), 51.5 (CHCH2N), 53.1 (q, J = 2.0 Hz, 
CHCH2N), 53.4 (q, J = 33.1 Hz, CHCF3), 54.5 (N(CH2)2(CH2)2), 55.3 (OCH3), 114.3 (2 × 
O(CHarom)ortho), 124.6 (q, J = 281.7 Hz, CF3), 126.7 (2 × NCH2(Carom,quat), 129.8 (NCH2(CHarom)ortho), 
159.4 (OCarom,quat), 168.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.99 (3F, d, J = 7.1 Hz, CF3). 
IR (ATR, cm-1): νC=O = 1749, νmax = 1514, 1277, 1244, 1150, 1128, 1111, 1038, 972, 943, 831, 806, 
673, 577, 513. MS (70eV): 357 (M+ + 1, 100). HRMS (ESI) calcd for C18H24F3N2O2+: 357.1784 [M 
+ H]+. Found: 357.1779. 
Trans-1-(4-methoxybenzyl)-3-(piperidin-1-ylmethyl)-4-(trifluoromethyl)azetidin-2-one 7f 
Yellow oil. Rf = 0.45 (PE/EtOAc, 1/1). Yield 15%. 1H NMR (400 MHz, CDCl3): δ 1.35-
1.40 (2H, m, N(CH2)2(CH2)2CH2), 1.45-1.52 (4H, m, N(CH2)2(CH2)2), 2.36-2.39 (4H, m, 
N(CH2)2(CH2)2), 2.61 (2H, d, J = 6.0 Hz, CH(HCH)N), 3.41 (1H, t × d, J = 6.0, 2.0 Hz, 
CHCHCF3), 3.72 (1H, q × d, J = 6.1, 2.0 Hz, CHCF3), 3.81 (3H, s, OCH3), 3.88 and 
4.83 (2 × 1H, 2 × d, J = 15.0, (HCH)N), 6.89 and 7.21 (2 × 2H, 2 × d, J = 8.6 Hz, 
O(CHarom)ortho and NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 24.0 
(N(CH2)2(CH2)2CH2), 25.9 (N(CH2)2(CH2)2), 44.8 (NCH2), 51.3 (CHCH2N), 54.2 (q, J = 33.8 Hz, 
CHCF3), 55.1 (N(CH2)2(CH2)2), 55.3 (CHCH2N), 55.4 (OCH3), 114.3 (2 × O(CHarom)ortho), 124.6 (q, 
J = 281.9 Hz, CF3), 126.8 (NCH2(Carom,quat), 129.8 (2 × NCH2(HCarom)ortho), 159.4 (OCarom,quat), 167.9 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ -74.42 (3F, d, J = 6.1 Hz, CF3). IR (ATR, cm-1): νC=O = 
1767, νmax = 1514, 1277, 1244, 1155, 1130, 1107, 1034, 955, 841, 820, 565, 511. MS (70eV): 357 
(M+ + 1, 100). 
Synthesis of 3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-ones 8-9 
As a representative example, the synthesis of cis-1-(4-methoxybenzyl)-3-phenylthiomethyl-4-
(trifluoromethyl)azetidin-2-one 8b and trans-1-(4-methoxybenzyl)-3-phenylthiomethyl-4-
(trifluoromethyl)azetidin-2-one 9b is described. Triethylamine (0.04 mL, 0.28 mmol, 1.5 equiv) was 
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added dropwise to a stirred solution of 1-(4-methoxybenzyl)-3-methylene-4-
(trifluoromethyl)azetidin-2-one 5b (0.05 g, 0.18 mmol, 1 equiv) and benzenethiol (0.03 mL, 0.26 
mmol, 1.4 equiv) in dry THF (5 mL) at 0 °C, and the reaction mixture was allowed to continue for 
two hours at room temperature. After completion of the reaction as monitored by LC-MS, the 
reaction mixture was extracted with EtOAc (3 × 5 mL), then the organic layers were dried over 
MgSO4. The solvent was evaporated, which resulted in a mixture of cis-1-(4-methoxybenzyl)-3-
phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 8b and trans-1-(4-methoxybenzyl)-3-
phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 9b in a ratio of 59:41. The mixture was purified 
by preparative TLC (PE/EtOAc, 12/1) to provide the desired sulfides 8b and 9b as white crystals 
in a yield of 79%. 
Cis-1-(4-methoxyphenyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 8a and 
trans-1-(4-methoxyphenyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 9a: White 
crystals. Mp 87 °C. Rf = 0.27 (PE/EtOAc, 9/1). Yield 81%. Cis:trans, 74:26. IR (ATR, cm-1): νC=O = 
1749, νmax = 1512, 1287, 1250, 1142, 1125, 1086, 1030, 950, 831, 806, 737, 689, 521, 475. MS 
(70eV): 368 [M+ + 1].  
Cis-1-(4-methoxyphenyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 8a 
1H NMR (400 MHz, CDCl3): δ 3.30 (1H, d × d, J = 14.4, 7.5 Hz, CH(HCH)S), 
3.46 (1H, d × d, J = 14.4, 7.5 Hz, CH(HCH)S), 3.78 (1H, t × d, J = 7.5, 6.1 Hz, 
CHCHCF3), 3.79 (3H, s, OCH3), 4.60 (1H, quintet, J = 6.1 Hz, CHCF3), 6.877 
(2H, d, J = 9.1 Hz, O(CHarom)ortho), 7.24-7.46 (7H, m, N(CHarom)ortho and 
SCHarom). 13C NMR (100.6 MHz, CDCl3): δ 28.8 (q, J = 2.3 Hz, CHCH2S), 51.3 
(CHCH2S), 55.3 (q, J = 33.6 Hz, CHCF3), 55.5 (OCH3), 114.4 (2 × O(HCarom)ortho), 119.8 (2 × 
N(HCarom)ortho), 124.2 (q, J = 281.5 Hz, CF3), 127.2 (SCarom), 129.3 (NCarom,quat), 129.4, 130.8 and 
134.4 (SCarom), 157.2 (OCarom,quat), 164.4 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -67.57 (3F, d, J 
= 6.1 Hz, CF3). 
Trans-1-(4-methoxyphenyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 9a 
1H NMR (400 MHz, CDCl3): δ 3.20 (1H, d × d, J = 13.9, 9.3 Hz, CH(HCH)S), 
3.49 (1H, d × d, J = 13.9, 4.2 Hz, CH(HCH)S), 3.59 (1H, d × d × d, J = 9.3, 
4.2, 2.1 Hz, CHCHCF3), 3.80 (3H, s, OCH3), 4.39 (1H, q × d, J = 5.4, 2.1 Hz, 
CHCF3), 6.883 (2H, d, J = 9.2 Hz, O(CHarom,ortho)), 7.24-7.46 (7H, m, 
N(CHarom)ortho and SCHarom). 13C NMR (100.6 MHz, CDCl3): δ 32.3 (CHCH2S), 
51.5 (CHCH2S), 55.5 (OCH3), 56.5 (q, J = 34.7 Hz, CHCF3), 114.4 (2 × 
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O(CHarom)ortho), 119.6 (2 × N(CHarom)ortho), 124.1 (q, J = 289.7 Hz, CF3), 127.5 (SCarom), 129.3 
(NCarom,quat), 129.6, 130.9 and 133.8 (SCarom), 157.2 (OCarom,quat), 163.8 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -72.16 (3F, d, J = 5.4 Hz, CF3). 
Cis-1-(4-methoxybenzyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 8b and 
trans-1-(4-methoxybenzyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 9b: White 
crystals. Mp 60 °C. Rf = 0.09 (PE/EtOAc, 12/1). Yield 79%. Cis:trans, 59:41. IR (ATR, cm-1 ): νC=O 
= 1751, νmax = 1514, 1288, 1246, 1177, 1159, 1150, 1132, 1123, 1090, 1035, 829, 816, 739, 691, 
669, 515, 474. MS (70eV): 382 [M+ +1, 100].   
Cis-1-(4-methoxybenzyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 8b 
1H NMR (400 MHz, CDCl3): δ 3.20 (1H, d × d, J = 14.1, 7.7 Hz, CH(HCH)S), 3.38 
(1H, d × d, J = 14.1, 7.7 Hz, CH(HCH)S), 3.53 (1H, t × d, J = 7.7, 6.3 Hz, 
CHCHCF3), 3.79 (3H, s, OCH3), 3.86 (1H, quintet, J = 6.3 Hz, CHCF3), 3.89 and 
4.81 (2 × 1H, J = 14.8 Hz, (HCH)N), 6.86 and 7.15 (2 × 2H, 2 × d, J = 8.6 Hz, 
O(CHarom)ortho and NCH2(CHarom)ortho), 7.21-7.32 and 7.36-7.39 (5H, 2 × m, 
SCHarom). 13C NMR (100.6 MHz, CDCl3): δ 28.7 (q, J = 2.2 Hz, CHCH2S), 44.9 
(NCH2), 51.7 (CHCH2S), 53.8 (q, J = 33.3 Hz, CHCF3), 55.3 (OCH3), 114.36 (2 × 
O(CHarom)ortho), 124.4 (q, J = 280.7 Hz, CF3), 126.4 (NCH2Carom,quat), 127.0 (SCarom), 129.2 (SCarom), 
129.89 (NCH2(HCarom)ortho), 130.52 (SCarom), 134.5 (SCarom,quat), 159.51 (OCarom,quat), 166.8 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -68.40 (3F, d, J = 6.3 Hz, CF3).  
Trans-1-(4-methoxybenzyl)-3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-one 9b 
1H NMR (400 MHz, CDCl3): δ 2.97 (1H, d × d, J = 13.9, 9.5 Hz, CH(HCH)S), 3.37 
(1H, d × d, J = 13.9, 3.9 Hz, CH(HCH)S), 3.45 (1H, d × d × d, J = 9.5, 3.9, 2.0 Hz, 
CHCHCF3), 3.64 (1H, q × d, J =5.8, 2.0 Hz, CHCF3), 3.82 (3H, s, OCH3), 3.88 and 
4.81 (2 × 1H, J = 15.0 Hz, (HCH)N), 6.89 and 7.19 (2 × 2H, d, J = 8.6 Hz, 
NCH2(CHarom)ortho and O(CHarom)ortho), 7.21-7.32 and 7.36-7.39 (5H, 2 × m, 
SCHarom). 13C NMR (100.6 MHz, CDCl3): δ 31.8 (CHCH2S), 45.0 (NCH2), 51.5 
(CHCH2S), 55.1 (q, J = 34.3 Hz, CHCF3), 55.3 (OCH3), 114.37 (2 × O(CHarom)ortho), 
124.2 (q, J = 279.7 Hz, CF3), 126.5 (NCH2Carom,quat), 127.2 (SCarom), 129.2 (SCarom), 129.95 (2 × 
NCH2(HCarom)ortho), 130.48 (SCarom), 134.1 (SCarom,quat), 159.53 (OCarom,quat), 166.4 (C=O). 19F NMR 
(376.5 MHz, CDCl3): δ -73.34 (3F, d, J = 5.8 Hz, CF3).  
 




As a representative example, the synthesis of trans-5-hydroxymethyl-1-isobutyl-3-(4-
methoxybenzyl)-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-one 10b is described. LiAlH4 (0.30 
mL, 0.30 mmol, 1M in Et2O, 2 equiv) was added in small portions to a solution of cis-3-
[(isobutylamino)methyl]-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 6d (0.05 g, 0.15 
mmol, 1 equiv) in dry Et2O (5 mL) at 0 °C. After heating for 30 minutes at reflux temperature under 
a nitrogen atmosphere, the reaction mixture was cooled to 0 °C, quenched with water (5 mL) and 
extracted with Et2O (3 × 5 mL). Drying (MgSO4), filtration of the drying agent, and evaporation of 
the solvent in vacuo produced the crude product, then, dry THF (5 mL) and triphosgene (0.02 mL, 
1 equiv) were added to the crude product. The resulting mixture was stirred for two hours at room 
temperature, after which the reaction mixture was extracted with EtOAc (3 × 5 mL). Drying 
(MgSO4), filtration of the drying agent and evaporation of the solvent in vacuo afforded trans-5-
hydroxymethyl-1-isobutyl-3-(4-methoxybenzyl)-4-(trifluoromethyl)tetrahydropyrimidin-2(1H)-one 
10b (69%), which was purified by preparative TLC (PE/EtOAc, 1/1) to obtain an analytically pure 
sample.    
Trans-5-hydroxymethyl-1-isobutyl-3-(4-methoxyphenyl)-4-
(trifluoromethyl)tetrahydropyrimidin-2(1H)-one 10a 
White crystals. Mp 142 °C. Rf = 0.17 (PE/EtOAc, 1/1). Yield 41%. 1H NMR 
(400 MHz, CDCl3): δ 0.89 and 0.90 (2 × 3H, 2 × d, J = 6.8 Hz, CH(CH3)2), 
1.97 (1H, nonet, J = 7.0 Hz, CH(CH3)2), 2.31 (1H, t, J = 4.7 Hz, OH), 2.42-
2.47 (1H, m, CH2CHCHCF3), 3.00 (1H, d × d, J = 13.6, 7.0 Hz, 
N(HCH)CHCH3), 3.08 (1H, d, J = 12.7 Hz, N(HCH)CHCH2OH), 3.36 (1H, d × d, J = 13.6, 7.5 Hz, 
N(HCH)CHCH3), 3.69 (1H, d × d, J = 12.7, 4.7 Hz, N(HCH)CHCH2OH), 3.74-3.85 (5H, m, 
CHCH2OH and OCH3), 4.43 (1H, q, J = 7.6 Hz, CHCF3), 6.86 and 7.16 (2 × 2H, 2 × d, J = 8.9 Hz, 
O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 19.7 and 20.2 (2 × CH(CH3)2), 
26.8 (CH(CH3)2), 32.3 (CH2CHCHCF3), 44.9 (q, J = 1.5 Hz, NCH2CHCH2OH), 55.4 (OCH3), 56.1 
(CH2CH(CH3)2), 60.1 (q, J = 29.2 Hz, CHCF3), 61.5 (CH2OH), 114.1 (2 × O(HCarom)ortho), 125.4 (q, 
J = 285.3 Hz, CF3), 129.3 (2 × N(CHarom)ortho), 136.1 (NCarom,quat), 154.0 (C=O), 158.1 (OCarom,quat). 
19F NMR (376.5 MHz, CDCl3): δ -72.03 (3F, d, J = 7.6 Hz, CF3). IR (ATR, cm-1): νOH = 3368, νC=O 
= 1628, νmax = 1514, 1501, 1466, 1225, 1161, 1134, 1084, 1067, 824, 746, 700, 669, 571. MS 
(70eV): 361 (M+ + 1, 100). HRMS (ESI) calcd for C17H24F3N2O3+: 361.1734 [M + H]+. Found: 
361.1736. 




Brownish sticky oil. Rf = 0.28 (PE/EtOAc, 1/1). Yield 69%. 1H NMR (400 
MHz, CDCl3): δ 0.82 (1H, t, J = 5.4 Hz, OH), 0.89 and 0.91 (2 × 3H, 2 × 
d , J = 6.4 Hz, CH(CH3)2), 1.94 (1H, nonet, J = 7.2 Hz, CH(CH3)2), 2.21-
2.26 (1H, m, CH2CHCHCF3), 2.92 (1H, d, J = 12.6 Hz, 
N(HCH)CHCH2OH), 2.95 (1H, d × d, J = 13.6, 7.2 Hz, N(HCH)CHCH3), 3.10-3.17 (1H, m, 
CH(HCH)OH), 3.35 (1H, d × t, J = 10.4, 5.4 Hz, CH(HCH)OH), 3.42 (1H, d × d, J = 13.6, 7.2 Hz, 
N(HCH)CHCH3), 3.57 (1H, d × d, J = 12.6, 5.2 Hz, N(HCH)CHCH2OH), 3.72 (1H, d, J = 14.7 Hz, 
N(HCH), 3.77-3.83 (4H, m, CHCF3 and OCH3), 5.63 (1H, d, J = 14.7 Hz, N(HCH), 6.88 and 7.28 
(2 × 2H, 2 × d, J = 8.4 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 
19.7 and 20.2 (2 × CH(CH3)2), 26.7 (CH(CH3)2), 31.8 (CH2CHCHCF3), 44.4 (NCH2CHCH2OH), 
49.3 (NCH2), 53.8 (q, J = 29.6 Hz, CHCF3), 55.3 (OCH3), 56.1 (CH2CH(CH3)2), 61.4 (CHCH2OH), 
114.1 (2 × O(HCarom)ortho), 126.0 (q, J = 285.4 Hz, CF3), 129.9 (NCH2Carom,quat), 130.5 (2 × 
NCH2(CHarom)ortho), 154.4 (C=O), 159.3 (OCarom,quat). 19F NMR (376.5 MHz, CDCl3): δ -71.70 (3F, 
d, J = 7.6 Hz, CF3). IR (ATR, cm-1): νOH = 3387, νC=O = 1620, νmax = 1506, 1466, 1265, 1234, 1157, 
1136, 1123, 1055, 1038, 812, 756, 743, 700, 581. MS (70eV): 375 (M+ + 1, 100). HRMS (ESI) 
calcd for C18H26F3N2O3+: 375.1890 [M + H]+. Found: 375.1888. 
Synthesis of cis-3-methyl-4-(trifluoromethyl)azetidin-2-ones 11 
As a representative example, the synthesis of cis-1-(4-methoxybenzyl)-3-methyl-4-
(trifluoromethyl)azetidin-2-one 11b is described. palladium on activated carbon (20% w/w) was 
added to a solution of 1-(4-methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5b 
(0.04 g, 0.15 mmol, 1 equiv) in MeOH (2 mL). The resulting mixture was placed in a Parr 
apparatus. The inside of the Parr apparatus was then degassed and filled with hydrogen gas, after 
which the mixture was stirred for three hours at room temperature while applying 5 bar of hydrogen 
gas. Filtration of the heterogenous mixture through Celite® and evaporation of the solvent in vacuo 
afforded cis-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one 11b (87%) as an 
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Cis-1-(4-methoxyphenyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one 11a 
White crystals. Mp 86 °C. Rf = 0.36 (PE/EtOAc, 41). Yield 79%. 1H NMR (400 
MHz, CDCl3): δ 1.45 (3H, d × q, J = 7.7, 1.7 Hz, CHCH3), 3.68 (1H, q × d, J = 
7.7, 5.9 Hz, CHCH3), 3.79 (3H, s, OCH3), 4.52 (1H, quintet, J = 5.9 Hz, CHCF3), 
6.89 and 7.36 (2 × 2H, 2 × d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C 
NMR (100.6 MHz, CDCl3): δ 9.1 (q, J = 2.4 Hz, CHCH3), 46.9 (CHCH3), 55.1 (q, J = 33.2 Hz, 
CHCF3), 55.5 (OCH3), 114.4 (2 × O(CHarom)ortho), 119.6 (2 × N (CHarom)ortho), 124.4 (q, J = 281.0 
Hz, CF3), 129.8 (NCarom,quat), 157.0 (OCarom,quat), 166.8 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -
67.67 (3F, d, J = 5.9 Hz, CF3). IR (ATR, cm-1): νC=O = 1743, νmax = 1513, 1394, 1281, 1246, 1137, 
1025, 830. MS (70eV): m/z (%): 260 (M+ + 1, 100). HRMS (ESI) calcd for C12H13F3NO2+: 260.0893 
[M + H]+. Found: 260.0886. 
Cis-1-(4-methoxybenzyl)-3-methyl-4-(trifluoromethyl)azetidin-2-one 11b 
White solid. Mp 46 °C. Yield 87%. 1H NMR (400 MHz, CDCl3): δ 1.34 (3H, d × q, J = 
7.6, 1.6 Hz, CHCH3), 3.43 (1H, q × d, J = 7.6, 5.4 Hz, CHCH3), 3.80 (1H, q × d, J = 7.0, 
5.4 Hz, CHCF3), 3.81 (3H, s, OCH3), 3.90 and 4.79 (2 × 1H, 2 × d, J = 15.0 Hz, 
(HCH)N), 6.88 and 7.18 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 
13C NMR (100.6 MHz, CDCl3): δ 8.9 (q, J = 1.6 Hz, CHCH3), 44.7 (ArCH2N), 47.2 
(CHCH3), 53.6 (q, J = 32.7 Hz, CHCF3), 55.3 (OCH3), 114.3 (2 × O(HCarom)ortho), 124.6 (q, J = 280.3 
Hz, CF3), 126.8 (NCH2Carom,quat), 129.8 (2 × NCH2(CHarom)ortho), 159.4 (OCarom,quat), 169.2 (C=O). 
19F NMR (376.5 MHz, CDCl3): δ -68.74 (3F, d, J = 7.0 Hz, CF3). IR (ATR, cm-1): νC=O = 1750, νmax 
= 1514, 1248, 1131, 1034, 964, 828, 752, 659. MS (70eV): m/z (%): 121 (100), 274 (M+ + 1, 10). 
HRMS (ESI) calcd for C13H15F3NO2+: 274.1049 [M + H]+. Found: 274.1055. 
Synthesis of 3-bromo-3-bromomethyl-4-(trifluoromethyl)azetidin-2-ones 12-13 
As a representative example, the synthesis of cis-3-bromo-3-bromomethyl-1-(4-methoxyphenyl)-
4-(trifluoromethyl)azetidin-2-one 12a is described. Pyridine (0.02 mL, 1 equiv) was added to a 
solution of 1-(4-methoxyphenyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5a (0.05 g, 0.19 
mmol, 1 equiv) in dry CH2Cl2 (7 mL) under a nitrogen atmosphere, then an excess of bromine was 
slowly added. The reaction was stirred for four hours at room temperature. The mixture was 
quenched with water (10 mL) and extracted with dichloromethane (3 x 7 mL), the combined 
organic phases were washed with brine (2 x 10 mL). Drying (MgSO4), filtration of the drying agent, 
and removal of the solvent in vacuo afforded cis-3-bromo-3-bromomethyl-1-(4-methoxyphenyl)-4-
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(trifluoromethyl)azetidin-2-one 12a (74%), which was further purified by means of column 
chromatography (PE/EtOAc, 15/1) in order to obtain an analytically pure compound.  
Cis-3-bromo-3-bromomethyl-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 12a 
Brown oil. Rf = 0.10 (PE/EtOAc, 15/1). Yield 74%. 1H NMR (400 MHz, CDCl3): δ 
3.81 (3H, s, OCH3), 3.93 and 4.09 (2 × 1H, 2 × d, J = 11.3 Hz, BrC(HCH)Br), 
4.87 (1H, q, J = 5.7 Hz, CHCF3), 6.92 and 7.38 (2H, 2 × d, J = 9.0 Hz, 
O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 32.6 
(BrCCH2Br), 55.5 (OCH3), 57.9 (BrCCH2Br), 60.7 (q, J = 34.1 Hz, CHCF3), 114.6 (2 × 
O(CHarom)ortho), 121.0 (2 × N(CHarom)ortho), 122.8 (q, J = 281.0 Hz, CF3), 127.8 (NCarom,quat),158.2 
(OCarom,quat), 160.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -67.48 (3F, d, J = 5.7 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1776, νmax = 1510, 1389, 1248, 1169, 1142, 1028, 831, 557, 523. GC-MS: m/z 
(%) = 257 (84), 203 (31), 188 (16), 149 (100), 134 (65). 
Cis-3-bromo-1-(3-bromo-4-methoxybenzyl)-3-bromomethyl-4-(trifluoromethyl)azetidin-2-
one 12b 
Yellowish crystals. Mp 96 °C. Rf = 0.25 (PE/EtOAc, 15/1). Yield 23%. 1H NMR (400 
MHz, CDCl3): δ 3.78 (1H, d, J = 11.4 Hz, BrC(HCH)Br), 3.91 (3H, s, OCH3), 3.94 (1H, 
d, J = 15.0 Hz, (HCH)N), 3.97 (1H, d, J = 11.4 Hz, BrC(HCH)Br), 4.23 (1H, q, J = 6.1 
Hz, CHCF3), 4.85 (1H, d, J = 15.0 Hz, (HCH)N), 6.87 (1H, d, J = 8.5 Hz, O(CHarom)ortho), 
7.25 (1H, d × d, J = 8.5, 2.2 Hz, O(CHarom)meta) and 7.55 (1H, d, J = 2.2 Hz, 
NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 32.0 (BrCCH2Br), 45.2 (ArCH2N), 56.3 (OCH3), 
58.0 (BrCCH2Br), 59.0 (q, J = 34.2 Hz, CHCF3), 111.8, 111.9 (2 × O(CHarom)ortho), 122.8 (q, J = 
279.0 Hz, CF3), 126.4 (NCH2Carom,quat), 129.6 (OCHarom,meta), 134.2 (NCH2(CHarom)ortho), 156.1 
(OCarom,quat), 162.2 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.29 (3F, d, J = 6.1 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1786, νmax = 1497, 1391, 1285, 1252, 1163, 1109, 1053, 1018, 970, 941, 814, 
754, 691, 627, 596, 554, 486, 436, 409. GC-MS: m/z (%) = 509 (M+, 6), 351 (12), 270 (16), 201 









White crystals. Mp 110 °C. Rf = 0.27 (PE/EtOAc, 15/1). Yield 36%. 1H NMR (400 MHz, 
CDCl3): δ 3.88 (1H, d, J = 12.1 Hz, BrC(HCH)Br), 3.92 (3H, s, OCH3), 3.929 (1H, d, J 
= 12.1 Hz, BrC(HCH)Br), 3.933 (1H, d, J = 15.1 Hz, (HCH)N), 4.14 (1H, q, J = 6.4 Hz, 
CHCF3), 4.88 (1H, d, J = 15.1 Hz, (HCH)N), 6.91 (1H, d, J = 8.4 Hz, O(CHarom)ortho), 
7.19 (1H, d × d, J = 8.4, 2.1 Hz, O(CHarom)meta) and 7.45 (1H, d, J = 2.1 Hz, 
NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 30.2 (q, J = 2.5 Hz, BrCCH2Br), 44.8 (ArCH2N), 
56.3 (OCH3), 63.3 (BrCCH2Br), 64.8 (q, J = 34.3 Hz, CHCF3), 112.2, 112.3 (2 × O(HCarom)ortho), 
124.3 (q, J = 281.3 Hz, CF3), 126.1 (NCH2Carom,quat), 128.8 (O(CHarom)meta), 133.4 
(NCH2(CHarom)ortho), 156.2 (OCarom,quat), 162.6 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.37 (3F, 
d, J = 6.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1778, νmax = 1497, 1396, 1285, 1250, 1184, 1171, 1128, 
1109, 1053, 968, 939, 883, 814, 706, 683, 619, 596, 554, 507, 434, 403. GC-MS: m/z (%) = 511 
(M+, 3), 349 (11), 270 (15), 199 (100), 105 (11), 77 (22). 
Synthesis of 3-trifluoromethyl-5-oxa-2,6-diazaspiro[3.4]octan-1-ones 14 
As a representative example, the synthesis of (3S*,4R*,7R*)-6-tert-butyl-2-(4-methoxybenzyl)-7-
phenyl-3-trifluoromethyl-5-oxa-2,6-diazaspiro[3.4]octan-1-one 14d is described. N-tert-butyl-α-
phenylnitrone (0.07 g, 0.42 mmol, 1.4 equiv) was added to a solution of 1-(4-methoxybenzyl)-3-
methylene-4-(trifluoromethyl)azetidin-2-one 5b (0.08 g, 0.30 mmol, 1 equiv) in dry toluene (7 mL). 
The mixture was stirred for 47 hours at reflux temperature. After completion of the reaction, the 
reaction mixture was extracted with EtOAc (3 × 10 mL). Drying (MgSO4), filtration of the drying 
agent and evaporation of the solvent in vacuo afforded 6-tert-butyl-2-(4-methoxybenzyl)-7-phenyl-
3-trifluoromethyl-5-oxa-2,6-diazaspiro[3.4]octan-1-one 14d (43%), which was purified by means 
of flash chromatography on silica gel (PE/EtOAc, 20/1) to obtain an analytically pure sample. 
(3S*,4R*,7R*)-2-(4-Methoxyphenyl)-6,7-diphenyl-3-trifluoromethyl-5-oxa-2,6-
diazaspiro[3.4]octan-1-one 14a 
White crystals. Mp 135 °C. Recrystallization in Et2O. Yield 57%. 1H NMR 
(400 MHz, CDCl3): δ 2.96 (1H, d × d, J = 13.4, 9.0 Hz, PhCH(HCH)), 3.19 
(1H, d × d, J = 13.4, 6.7 Hz, PhCH(HCH)), 3.81 (3H, s, OCH3), 4.73 (1H, d 
× d, J = 9.0, 6.7 Hz, PhCHCH2), 4.79 (1H, q, J = 6.0 Hz, CHCF3), 6.92 (2H, 
d, J = 9.0 Hz, N(CHarom)ortho), 7.03-7.07 (3H, m, CHarom), 7.18-7.22 (2H, m, 
CHarom), 7.31-7.38 (3H, m, CHarom), 7.39 (2H, d, J = 9.0 Hz, O(CHarom)ortho), 7.45-7.47 (2H, m, 
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CHarom). 13C NMR (100.6 MHz, CDCl3): δ 41.4 (q, J = 1.5 Hz, PhCHCH2), 55.5 (OCH3), 63.9 (q, J 
= 33.1 Hz, CHCF3), 71.2 (PhCHCH2), 91.3 (CCHCF3), 114.5 (2 × O(CHarom)ortho), 118.7, 120.6 (2 
× CHarom), 123.4 (q, J = 281.2 Hz, CF3), 124.7, 127.2 (2 × CHarom), 128.3, 128.67 (2 × CHarom), 
128.74 (NCarom,quat), 129.0 (2 × N(CHarom)ortho), 138.0 (CHCarom,quat), 149.3 (ONCarom,quat), 157.6 
(OCarom,quat), 164.4 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.00 (3F, d, J = 6.0 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1760, νmax = 1515, 1396, 1256, 1140, 1079, 1027, 688. MS (70eV): m/z (%): 




Yellow sticky oil. Yield 13% (HPLC). 1H NMR (400 MHz, CDCl3): δ 3.00 (1H, 
d × d, J =13.6, 8.0 Hz, PhCH(HCH)), 3.24 (1H, d × d, J = 13.6, 7.7 Hz, 
PhCH(HCH)), 3.81 (3H, s, OCH3), 4.70 (1H, t, J = 7.8 Hz, PhCHCH2), 4.71 
(1H, q, J = 5.8 Hz, CHCF3), 6.91 (2H, d, J = 9.0 Hz, O(CHarom)ortho), 6.98-
7.02 (3H, m, CHarom), 7.20-7.24 (2H, m, CHarom), 7.30-7.34 (1H, m, CHarom), 
7.39 (1H, d, J = 9.0 Hz, N(CHarom)ortho), 7.37-7.41 (2H, m, CHarom), 7.54-7.56 (2H, m, CHarom). 13C 
NMR (100.6 MHz, CDCl3): δ 41.2 (q, J = 1.0 Hz, PhCHCH2), 55.5 (OCH3), 64.2 (q, J = 32.9 Hz, 
CHCF3), 69.0 (PhCHCH2), 91.6 (CCHCF3), 114.5 (2 × O(CHarom)ortho), 116.6, 120.5 (2 × CHarom), 
123.4, 123.6 (q, J = 281.5 Hz, CF3), 127.2 (2 × CHarom), 128.2, 128.77 (2 × CHarom), 128.82 
(NCarom,quat), 129.0 (2 × N(CHarom)ortho), 139.1 (CHCarom,quat), 149.4 (ONCarom,quat), 157.6 (OCarom,quat), 
163.6 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.78 (3F, d, J = 5.8 Hz, CF3). IR (ATR, cm-1): νC=O 
= 1773, νmax = 1510, 1389, 1248, 1136, 1028, 835, 756, 692, 525. MS (70eV): m/z (%): 182 




White crystals. Mp 175 °C. Recrystallization from Et2O. Yield 49%. 1H 
NMR (400 MHz, CDCl3): δ 1.04 (9H, s, C(CH3)3), 2.78 (1H, d × d, J = 13.3, 
10.4 Hz, PhCH(HCH)), 3.00 (1H, d × d, J = 13.3, 6.8 Hz, PhCH(HCH)), 
3.80 (3H, s, OCH3), 4.47 (1H, d × d, J = 10.4, 6.8 Hz, PhCHCH2), 4.66 (1H, 
q, J = 6.0 Hz, CHCF3), 6.91 (2H, d, J = 9.0 Hz, O(CHarom)ortho), 7.24-7.28 
and 7.31-7.34 (3H, 2 × m, CHarom), 7.39 (2H, d, J = 9.0 Hz, N(CHarom)ortho), 7.45-7.47 (2H, 2 × m, 
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CHarom). 13C NMR (100.6 MHz, CDCl3): δ 26.4 C(CH3)3), 43.8 (q, J = 2.4 Hz, PhCHCH2), 55.5 
(OCH3), 59.9 (C(CH3)3), 63.9 (PhCHCH2), 64.1 (q, J = 32.7 Hz, CHCF3), 90.5 (CCHCF3), 114.4 (2 
× O(CHarom)ortho), 120.5 (NCarom,quat), 123.5 (q, J = 281.3 Hz, CF3), 127.2, 127.7, 128.7 (5 × CHarom), 
129.0 (2 × N(CHarom)ortho), 140.9 (CHCarom,quat), 157.4 (OCarom,quat), 165.3 (C=O). 19F NMR (376.5 
MHz, CDCl3): δ -68.87 (3F, d, J = 6.0 Hz, CF3). IR (ATR, cm-1): νC=O = 1751, νmax = 1514, 1392, 
1250, 1163, 1136, 1134, 829, 766, 731, 702, 521. MS (70eV): m/z (%): 435 (M+ + 1, 100). HRMS 
(ESI) calcd for C23H26F3N2O3+: 435.1890 [M + H]+. Found:435.1902.  
(3S*,4R*,7R*)-2-(4-Methoxybenzyl)-6,7-diphenyl-3-trifluoromethyl-5-oxa-2,6-
diazaspiro[3.4]octan-1-one 14c 
White crystals. Mp 104 °C. Recrystallization from Et2O. Yield 50%. 1H 
NMR (400 MHz, CDCl3): δ 2.83 (1H, d × d, J = 13.5, 8.9 Hz,  
PhCH(HCH)), 3.10 1H, d × d, J = 13.5, 6.9 Hz, PhCH(HCH)), 3.82 (3H, 
s, OCH3), 3.97 (1H, d, J = 15.0 Hz,(HCH)N), 4.09 (1H, q, J = 6.5 Hz , 
CHCF3), 4.66 (1H, d × d, J = 8.9, 6.9 Hz, PhCHCH2), 4.90 (1H, d, J = 15.0 Hz,(HCH)N), 6.91 (2H, 
d, J = 8.7 Hz, O(CHarom)ortho), 7.03-7.06 (3H, m, CHarom), 7.18-7.23 (2H, m, CHarom), 7.22 (2H, d, J 
= 8.7 Hz, NCH2(CHarom)ortho), 7.28-7.36 (3H, m, CHarom), 7.39-7.42 (2H, m, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 41.2 (PhCHCH2), 44.9 (NCH2Ar), 55.3 (OCH3), 62.4 (q, J = 32.9 Hz, CHCF3), 71.1 
(PhCHCH2), 91.6 (CCHCF3), 114.5 (2 × O(CHarom)ortho), 118.7 (CHarom), 123.5 (q, J = 283.9 Hz, 
CF3), 124.7 (CHarom), 125.8 (NCarom,quat), 127.2, 128.2, 128.6, 128.9 (CHarom), 129.8 (2 × 
N(CHarom)ortho), 138.1 (CHCarom,quat), 149.4 (ONCarom,quat), 159.6 (OCarom,quat), 167.0 (C=O). 19F NMR 
(376.5 MHz, CDCl3): δ -70.13 (3F, d, J = 6.5 Hz, CF3). IR (ATR, cm-1): νC=O = 1773, νmax = 1512, 
1398, 1246, 1145, 1084, 1030, 754, 693. MS (70eV): m/z (%): 469 (M+ + 1, 20). HRMS (ESI) calcd 
for C26H24F3N2O3+: 469.1734 [M + H]+. Found: 469.1755. 
(3S*,4R*,7S*)-2-(4-Methoxybenzyl)-6,7-diphenyl-3-trifluoromethyl-5-oxa-2,6-
diazaspiro[3.4]octan-1-one 
Colorless oil. Yield 10% (HPLC). 1H NMR (400 MHz, CDCl3): δ 2.89 
(1H, d × d, J = 13.4, 7.9 Hz, PhCH(HCH)), 3.12 1H, d × d, J = 13.4, 7.9 
Hz, PhCH(HCH)), 3.83 (3H, s, OCH3), 3.96 (1H, d, J = 15.2 
Hz,(HCH)N), 4.02 (1H, q, J = 6.4 Hz , CHCF3), 4.62 (1H, t, J = 7.9 Hz, 
PhCHCH2), 4.90 (1H, d, J = 15.2 Hz,(HCH)N), 6.92 (2H, d, J = 8.7 Hz, O(CHarom)ortho, 6.89-7.00 
(3H, m, CHarom), 7.15-7.19 (2H, m, CHarom), 7.23 (2H, d, J = 8.7 Hz, NCH2(CHarom)ortho), 7.29-7.33 
and 7.35-7.39 (3H, 2 × m, CHarom), 7.51-7.53 (2H, m, CHarom) . 13C NMR (100.6 MHz, CDCl3): δ 
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40.7 (q, J = 1.7 Hz, PhCHCH2), 45.0 (NCH2Ar), 55.3 (OCH3), 62.3 (q, J = 33.0 Hz, CHCF3), 69.1 
(PhCHCH2), 92.0 (CCHCF3), 114.4 (2 × O(CHarom)ortho), 116.5 (CHarom), 123.3 (CHarom), 125.8 
(NCarom,quat), 125.9 (q, J = 284.6 Hz, CF3), 127.1, 128.1, 128.7, 128.9 (CHarom), 129.9 
(O(CHarom)ortho), 139.2 (CHCarom,quat), 149.5 (ONCarom,quat), 159.6 (OCarom,quat), 166.3 (C=O). 19F 
NMR (376.5 MHz, CDCl3): δ -70.08 (3F, d, J = 6.4 Hz, CF3). IR (ATR, cm-1): νC=O = 1783, νmax = 
1513, 1249, 1175, 758, 695. MS (70eV): m/z (%): 121 (100%), 182 (60%), 469 (M+ + 1, 20). HRMS 
(ESI) calcd for C26H24F3N2O3+: 469.1734 [M + H]+. Found: 469.1737. 
(3S*,4R*,7R*)-6-Tert-butyl-2-(4-methoxybenzyl)-7-phenyl-3-trifluoromethyl-5-oxa-2,6-
diazaspiro[3.4]octan-1-one 14d 
Yellowish crystals. Mp 89 °C. Rf = 0.25 (PE/EtOAc, 20/1). Yield 43%. 
1H NMR (400 MHz, CDCl3): δ 1.02 (9H, s, C(CH3)3), 2.65 (1H, d × d, J 
= 12.8, 9.9 Hz, PhCH(HCH)), 2.92 (1H, d × d, J = 12.8, 6.7 Hz, 
PhCH(HCH)), 3.82 (3H, s, OCH3), 3.96 (1H, d, J = 15.1 Hz, (HCH)N), 
3.97 (1H, q, J = 6.4 Hz, CHCF3), 4.39 (1H, d × d, J = 9.9, 6.7 Hz, PhCHCH2), 4.84 (1H, d, J = 15.1 
Hz, (HCH)N), 6.90 and 7.20 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and NCH2(CHarom)ortho), 7.23-
7.32 (3H, m, CHarom), 7.40-7.42 (2H, m, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 26.3 C(CH3)3), 
43.6 (PhCHCH2), 44.7 (NCH2Ar), 55.3 (OCH3), 59.8 (C(CH3)3), 62.9 (q, J = 32.5 Hz, CHCF3), 63.7 
(PhCHCH2), 90.8 (CCHCF3), 114.3 (2 × O(CHarom)ortho), 123.6 (q, J = 280.3 Hz, CF3), 126.1 
(NCH2Carom,quat), 127.2, 127.6, 128.6 (5 × CHarom), 129.7 (NCH2(CHarom)ortho), 141.0 (CHCarom,quat), 
159.5 (OCarom,quat), 168.0 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -70.03 (3F, d, J = 6.4 Hz, CF3). 
MS (70eV): m/z (%): 449 (M+ + 1, 100). HRMS (ESI) calcd for C24H28F3N2O3+: 449.2047 [M + H]+. 
Found: 449.2056. 
Synthesis of 3-hydroxy-3-hydroxymethyl-4-(trifluoromethyl)azetidin-2-ones 15 
As a representative example, the synthesis of trans-3-hydroxy-3-hydroxymethyl-1-(4-
methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 15b is described. N-methylmorpholine-N-oxide 
(0.11 g, 0.93 mmol, 2.5 equiv) and OsO4 (10% mol, 0.22 mL, 4% in water) were added to a solution 
of 1-(4-methoxybenzyl)-3-methylene-4-(trifluoromethyl)azetidin-2-one 5b (0.10 g, 0.37 mmol, 1 
equiv) in THF-H2O (1:1, 10 mL), and the mixture was stirred for 26 hours at room temperature. 
Subsequently, an aqueous saturated solution of Na2S2O3 (1 mL) was added and the mixture was 
stirred for 10 min. The reaction mixture was filtered and the filtrate was extracted with ethyl acetate 
(3 x 15 mL). The combined extracts were washed with brine (2 x 10 mL). Drying MgSO4, filtration 
of the drying agent and evaporation of the solvent in vacuo afforded trans-3-hydroxy-3-
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hydroxymethyl-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 15b (92%), which was 
purified by recrystallization in Et2O. 
Trans-3-hydroxy-3-hydroxymethyl-1-(4-methoxyphenyl)-4-(trifluoromethyl)azetidin-2-one 
15a 
White solid. Mp 151 °C. Recrystallization from Et2O. Yield 87%. 1H NMR (400 
MHz, CD3OD): δ 3.79 (3H, s, OCH3), 3.93 and 3.98 (2 × 1H, 2 × d, J = 12.1 Hz, 
CH2OH), 4.66 (1H, q, J = 6.9 Hz, CHCF3), 6.95 and 7.35 (2 × 2H, 2 × d, J = 9.0 
Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CD3OD): δ 54.5 
(OCH3), 60.3 (q, J = 2.5 Hz, CH2OH), 64.6 (q, J = 33.7 Hz, CHCF3), 86.7 (COH), 114.0 (2 × 
O(CHarom)ortho), 121.0 (2 × N(CHarom)ortho), 123.9 (q, J = 280.3 Hz, CF3), 128.6 (NCarom,quat), 157.8 
(OCarom,quat), 167.0 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -68.16 (3F, d, J = 6.9 Hz, CF3). IR 
(ATR, cm-1): νOH = 3462, νC=O = 1735, νmax = 1516, 1256, 1173, 1130, 1096, 1082, 1028, 997, 835, 
808, 698. MS (70eV): m/z (%): 292 (M+ + 1, 100). HRMS (ESI) for calcd for C12H13F3NO4+: 
292.0791. Found: 292.0801 [M + H]+. 
Trans-3-hydroxy-3-hydroxymethyl-1-(4-methoxybenzyl)-4-(trifluoromethyl)azetidin-2-one 
15b 
Colorless solid. Mp 93 °C. Recrystallization from Hex/Et2O, 1/2. Yield 92%. 1H NMR 
(400 MHz, CD3OD): δ 3.81 (3H, s, OCH3), 3.86 (1H, q, J = 7.4 Hz, CHCF3), 3.87 and 
3.90 (2 × 1H, 2 × d, J = 12.1 Hz, HCHOH), 4.09 and 4.74 (2 × 1H, 2 × d, J = 15.2 Hz, 
HCHN), 6.94 and 7.24 (2 × 2H, 2 × d, J = 8.7 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 
13C NMR (100.6 MHz, CD3OD): δ 44.2 (NCH2), 54.3 (OCH3), 60.3 (q, J = 2.1 Hz, 
CH2OH), 63.2 (q, J = 33.8 Hz, CHCF3), 87.0 (CH2COH), 113.8 (2 × O(CHarom)ortho), 123.8 (q, J = 
279.4 Hz, CF3), 126.5 (2 × NCH2(CHarom)ortho), 129.5 (NCH2Carom,quat), 159.7 (OCarom,quat), 169.6 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.72 (3F, d, J = 7.4 Hz, CF3). IR (ATR, cm-1): νOH = 3433, 
νC=O = 1732, νmax =1516, 1290, 1254, 1130, 1099, 1053, 1030, 885, 821, 698, 522, 438. MS (70eV): 
m/z (%): 306 (M+ + 1, 100). HRMS (ESI) calcd for C13H15F3NO4+: 306.0948. Found: 306.0944 [M 
+ H]+. 
Synthesis of 6,6-dimethyl-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-1-ones 16 
As a representative example, the synthesis of trans-2-(4-methoxyphenyl)-6,6-dimethyl-3-
trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-1-one 16a is described. A solution of diol 15a (0.05 
g, 0.17 mmol, 1 equiv) and p-toluenesulfonic acid (0.03 g, 0.19 mmol, 1.1 equiv) in 
dimethoxypropane (3 mL) was heated for two hours at reflux temperature. The reaction mixture 
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was cooled to room temperature and extracted with ethyl acetate (3 x 7 mL). Drying (MgSO4), 
filtration of the drying agent and evaporation of the solvent in vacuo afforded trans-2-(4-
methoxyphenyl)-6,6-dimethyl-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-1-one 16a (95%), 
which was purified by recrystallization (Hex/Et2O, 2/1) to obtain an analytically pure sample. 
Trans-2-(4-methoxyphenyl)-6,6-dimethyl-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-
1-one 16a 
Brownish crystals. Mp 89 °C. Recrystallization in Hex/Et2O, 2/1. Yield 95%. 1H 
NMR (400 MHz, CDCl3): δ 1.50 and 1.53 (2 × 3H, 2 × s, C(CH3)2), 3.80 (3H, s, 
OCH3), 4.37 (1H, d × q, J = 10.2, 0.6 Hz, C(HCH)O), 4.43 (1H, d × q, J = 10.2, 
1.3 Hz, C(HCH)O), 4.61 (1H, q, J = 6.1 Hz, CHCF3), 6.90 and 7.35 (2 × 2H, 2 
× d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 25.4 and 25.7 
(C(CH3)2), 55.5 (OCH3), 64.1 (q, J = 33.2 Hz, CHCF3), 65.2 (q, J = 3.2 Hz, CH2OC), 89.8 (CCHCF3), 
112.4 (OCO), 114.5 (2 × O(CHarom)ortho), 120.5 (2 × N(CHarom)ortho), 123.5 (q, J = 280.7 Hz, CF3), 
128.7 (NCarom,quat), 157.6 (OCarom,quat), 164.9 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -69.25 (3F, d, 
J = 6.1 Hz, CF3). IR (ATR, cm-1): νC=O = 1778, νmax = 1499, 1398, 1285, 1252, 1171, 1128, 1110, 
1055, 970, 814, 621, 596, 407. MS (70eV): m/z (%): 332 (M+ + 1, 100). HRMS (ESI) calcd for 
C15H17F3NO4+: 332.1104 [M + H]+. Found: 332.1103.  
Trans-2-(4-methoxybenzyl)-6,6-dimethyl-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-
1-one 16b 
Yellow oil. Rf = 0.31 (Hex/Et2O, 5/1). Yield 47%. 1H NMR (400 MHz, 
CDCl3): δ 1.40 and 1.50 (2 × 3H, 2 × s, C(CH3)2), 3.81 (3H, s, OCH3), 3.91 
(1H, q, J = 6.6 Hz, CHCF3), 3.92 (1H, d, J = 14.9 Hz, (HCH)N), 4.28 (1H, 
d, J = 10.1 Hz, C(HCH)O), 4.32 (1H, d × q, J = 10.1, 1.3 Hz, C(HCH)O), 4.87 (1H, d, J = 14.9 Hz, 
(HCH)N), 6.90 and 7.19 (2 × 2H, 2 × d, J = 8.7 Hz, O(CHarom)ortho and NCH2(CHarom)ortho). 13C NMR 
(100.6 MHz, CDCl3): δ 25.49 and 25.51 (C(CH3)2), 44.8 (NCH2), 55.3 (OCH3), 62.2 (q, J = 32.9 
Hz, CHCF3), 65.0 (q, J = 2.8 Hz, OCH2C), 90.0 (CCHCF3), 112.2 (OCO), 114.4 (2 × O(CHarom)ortho), 
123.6 (q, J = 280.0 Hz, CF3), 125.8 (NCH2(Carom,quat), 129.9 (2 × NCH2(HCarom)ortho), 159.6 
(OCarom,quat), 167.4 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -70.35 (3F, d, J = 6.6 Hz, CF3). IR 
(ATR, cm-1): νC=O = 1778, νmax = 1514, 1285, 1246, 1167, 1150, 1069, 1032, 843, 691, 586, 511. 
MS (70eV): m/z (%): 346 (M+ + 1, 100). HRMS (ESI) calcd for C16H19F3NO4+: 346.1261 [M + H]+. 
Found: 346.1268. 
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Synthesis of 3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-diones 17 
As a representative example, the synthesis of trans-2-(4-methoxybenzyl)-3-trifluoromethyl-5,7-
dioxa-2-azaspiro[3.4]octane-1,6-dione 17b is described. To a solution of diol 15b (0.05 g, 0.16 
mmol, 1 equiv) in dry dichloromethane (3 mL) at 0 °C was treated with pyridine (0.06 mL, 0.80 
mmol, 5 equiv) and triphosgene (0.02 mL, 0.13 mmol, 0.80 equiv). The mixture was stirred for one 
hour at 0 °C, quenched with a saturated solution of NH4Cl (1 mL) and extracted with CH2Cl2 (3 × 
5 mL). The combined organic extracts were washed with an aqueous solution of HCl (2 mL, 1 M) 
and brine (3 × 5 mL), dried over MgSO4, filtered and evaporated under reduced pressure to 
obtained pure trans-2-(4-methoxybenzyl)-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-
dione 17b in a yield of 97%. 
Trans-2-(4-methoxyphenyl)-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-dione 
17a 
Light-brown solid. Mp 116 °C. Yield 97%. 1H NMR (400 MHz, CDCl3): δ 3.82 
(3H, s, OCH3), 4.81 (1H, d × q, J = 10.7, 1.3 Hz, C(HCH)O), 4.86 (1H, d, J = 
10.7 Hz, C(HCH)O), 4.88 (1H, q, J = 5.7 Hz, CHCF3), 6.94 and 7.36 (2 × 2H, 2 
× d, J = 9.0 Hz, O(CHarom)ortho and N(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): 
δ 55.6 (OCH3), 63.2 (q, J = 34.0 Hz, CHCF3), 64.3 (q, J = 3.3 Hz, CH2OC), 87.7 
(CCHCF3), 114.8 (2 × O(CHarom)ortho), 120.8 (2 × N(CHarom)ortho), 122.6 (q, J = 281.5 Hz, CF3), 127.5 
(NCarom,quat), 151.4 (OC=O), 158.4 (OCarom,quat), 159.1 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -
69.00 (3F, d, J = 5.7 Hz, CF3). IR (ATR, cm-1): νC=O = 1825, νC=O = 1763, νmax = 1514, 1290, 1252, 
1140, 1032, 839, 820, 760, 729, 700, 640, 523. MS (70eV): 335 [M+ + 18]. HRMS (ESI) calcd for 
C13H11F3NO5+: 318.0584. Found: 318.0575 [M + H]+. 
Trans-2-(4-methoxybenzyl)-3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-dione 
17b 
Yellowish solid. Mp 93 °C. Yield 97%. 1H NMR (400 MHz, CDCl3): δ 3.82 (3H, s, 
OCH3), 3.97 (1H, d, J = 15.0 Hz, N(HCH), 4.15 (1H, q, J = 6.1 Hz, CHCF3), 4.69 (1H, 
d × q, J = 10.5, 1.2 Hz, C(HCH)O), 4.76 (1H, d, J = 10.5, C(HCH)O), 4.92 (1H, d, J 
= 15.0 Hz, N(HCH)), 6.92 and 7.19 (2 × 2H, 2 × d, J = 8.6 Hz, O(CHarom)ortho and 
NCH2(CHarom)ortho). 13C NMR (100.6 MHz, CDCl3): δ 45.5 (NCH2), 55.4 (OCH3), 61.0 
(q, J = 33.9 Hz, CHCF3), 64.2 (q, J = 2.9 Hz, CCH2O), 88.0 (CCHCF3), 114.7 (2 × 
O(CHarom)ortho), 122.7 (q, J = 280.5 Hz, CF3), 124.4 (NCH2Carom,quat), 129.9 (2 × NCH2(CHarom)ortho), 
151.5 (O(C=O)O), 160.0 (OCarom,quat), 161.9 (C=O). 19F NMR (376.5 MHz, CDCl3): δ -70.22 (3F, d, 
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J = 6.1 Hz, CF3). IR (ATR, cm-1): νC=O = 1840, νC=O = 1773, νmax = 1514, 1281, 1256, 1177, 1146, 
1078, 1063, 1034, 947, 820, 752, 692, 586, 525. MS (70eV): 349 [M+ + 18]. HRMS (ESI) calcd for 
C14H13F3NO5+: 332.0740. Found: 332.0740 [M + H]+. 
Single crystal X-ray diffraction 
X-ray analysis was performed by Prof. Kristof Van Hecke (XStruct, Department of Inorganic and 
Physical Chemistry, Faculty of Sciences, Ghent University). 
For the structures of compounds 14b and 16a, X-ray intensity data were collected at 293 K and 
100 K, respectively, on a Supernova Dual Source (Cu at zero) diffractometer equipped with an 
Atlas CCD detector using  scans and CuK ( = 1.54184 Å) radiation. The images were 
interpreted and integrated with the program CrysAlisPro. Using Olex2, the structures were solved 
by direct methods using the ShelXS structure solution program and refined by full-matrix least-
squares on F2 using the ShelXL program package. Non-hydrogen atoms were anisotropically 
refined and the hydrogen atoms in the riding mode and isotropic temperature factors fixed at 1.2 
times U(eq) of the parent atoms (1.5 times for methyl group). 
CCDC 1529989-1529991 contains the supplementary crystallographic data for these molecules 
and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the 
Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44- 
1223-336033; or deposit@ccdc.cam.ac.uk). 
Crystal data for compound 14b:  
C23H25F3N2O3, M = 434.45, monoclinic, space group P21/c (No. 14), a = 19.5141(5) Å, b = 
6.07188(13) Å, c = 18.6214(4) Å, β = 105.212(3)°, V = 2129.09(9) Å3 , Z = 4, T = 293 K, Dcalc = 
1.355 g cm-3 , μ(Cu-Kα) = 0.909 mm-1, F(000) = 912, 31426 reflections measured, 4365 unique 
(Rint = 0.0798) which were used in all calculations. The final R1 was 0.0552 (I >2 (I)) and wR2 
was 0.1735 (all data). The asymmetric unit has chirality at C1(S), C3(S) and C14(R). Obviously, 
because of the centro-symmetric space group P21/c, also the inverse configuration is present in 
the crystal structure. 
Crystal data for compound 16a:  
C15H16F3NO4, M = 331.29, monoclinic, space group P21/c (No. 14), a = 16.0443(13) Å, b = 6.2322 
(3) Å, c = 16.7935(11) Å, β = 115.517(10)°, V = 1515.4(2) Å3 , Z = 4, T = 100 K, Dcalc = 1.452 g 
cm-3 , μ(Cu-Kα) = 1.120 mm-1, F(000) = 688, 14467 reflections measured, 2957 unique (Rint = 
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0.1022) which were used in all calculations. The final R1 was 0.0584 (I >2 (I)) and wR2 was 
0.1763 (all data). The asymmetric unit has chirality at C1(S) and C6(S). Obviously, because of the 

















In recent years, organofluorine compounds have been increasingly used in organic and medicinal 
chemistry. Indeed, the inclusion of fluorine into organic molecules is known to alter chemical and 
biological properties such as pKa, lipophilicity, metabolic stability and bioavailability. The 
increasing interest in fluorinated compounds has stimulated the development of novel methods to 
incorporate one or more fluorine atoms, for example a trifluoromethyl group, into organic 
molecules. The preparation of CF3-substituted molecules can be accomplished by either the 
deployment of CF3-containing building blocks or by using trifluoromethylating agents. However, 
the incorporation of a trifluoromethyl group into small molecules such as β-lactams or azetidine-
2-ones has been accompanied with a considerable challenge to handle trifluoromethylating agents 
during the synthesis (harsh conditions, hazardous reactions…). Therefore, the building block 
approach has been deployed here as an efficient alternative. 
In addition to their well-known pharmacological properties, β-lactams represent potential 
intermediates for organic synthesis due to the inherent strain of the four-membered ring, which 
allows for further elaboration toward a variety of nitrogen-containing acyclic and heterocyclic target 
compounds. In light of the pronounced effect of fluorine introduction, β-lactams containing a 
trifluoromethyl group can be considered as interesting entities for the construction of novel targets 
with promising applications. Nevertheless, the chemistry of CF3-substituted β-lactams has not 
been explored as intensively as that of their lower homologs, CF3-aziridines, which have already 
demonstrated their broad applicability as versatile building blocks through ring-opening and ring-
transformation reactions. The synthesis and deployment of 4-trifluoromethyl-β-lactams i, ii, iii, iv 
as novel building blocks (fluorinated synthon approach) was accomplished in this PhD thesis, 
resulting in a broad spectrum of functionalized CF3-amines and CF3-azaheterocycles upon further 






In the first part, 3-alkoxy/aryloxy-4-CF3-azetidin-2-one i building blocks were efficiently prepared 
starting from commercially available 1-ethoxy-2,2,2-trifluoroethanol v via imination and 
subsequent Staudinger synthesis with alkyl/aryloxyacetyl chlorides. The synthetic potential of the 
resulting 4-CF3-β-lactams i toward C2-N ring-opening reactions was evaluated based on an 
indirect or a direct approach. In the indirect approach, 4-CF3-β-lactams i were subjected to initial 
carbonyl removal upon treatment with AlH2Cl, providing azetidine intermediates vi. Activation of 
the latter azetidines vi by trimethyloxonium tetrafluoroborate and subsequent ring opening using 
different oxygen and nitrogen nucleophiles gave rise to a variety of functionalized α-
(trifluoromethyl)amines vii. On the other hand, the direct reductive ring opening of 4-CF3-β-
lactams i was accomplished upon treatment with LiAlH4, furnishing 3-aminopropan-1-ols viii. 
Cyclization of the latter γ-amino alcohols viii employing formaldehyde or ethyl chloroformate was 
evaluated leading to new 1,3-oxazinanes ix and 1,3-oxazinan-2-ones x, respectively. Besides 
that, attempts were made to synthesize 1,4-oxazepane analogs through cyclization of the 






In the second part, a set of new 3-hydroxy-4-CF3-β-lactams ii as a second type of building blocks 
was successfully synthesized from the corresponding 3-benzyloxy-4-CF3-β-lactams i (R2 = Bn) in 
high yields through hydrogenolysis. 2-Hydroxy-4-CF3-β-lactams ii were shown to be suitable 
substrates for ring contraction toward the synthesis of 2-substituted 3-(trifluoromethyl)aziridines 
via 3-chloro-4-CF3-β-lactam intermediates. In that respect, treatment of alcohols ii with Ph3P in 
CCl4 afforded trans-3-chloro-4-CF3-β-lactams xii. The LiAlH4-mediated reductive ring opening of 
chlorides xii provided γ-amino alcohols xiii in high yields (90-96%). The latter alcohols xiii were 
subjected to tBuOK-induced ring closure, furnishing 3-trifluoromethylated 2-(hydroxymethyl) 
aziridines xiv in 27-61% yield. On the other hand, direct treatment of chlorides xii with KOH in 
methanol resulted in the corresponding aziridine-2-carboxylates xv in 25-73% yield.  
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Furthermore, alcohols ii proved to be suitable substrates for the synthesis of novel 3-[2,2,2-
trifluoro-1-(arylamino)ethyl]-1,4-dioxan-2-ones xviii in high yields via intramolecular cyclization of 
3-(2-hydroxyethoxy)-β-lactam intermediates xvii upon treatment with an excess of K2CO3. The 3-
(2-hydroxyethoxy)-β-lactams xvii were prepared from allyloxy products xvi through an ozonolysis 




In analogy with 4-CF3-azetidin-2-ones i, 3-chloro-4-CF3-β-lactams xii were shown to be eligible 
substrates for the preparation of new α-CF3-substituted aminopropane derivatives xx. Ring 
opening of azetidine intermediates xix, derived from chlorides xii, was performed by treatment 
with sodium acetate or tert-butylamine. In addition, the cyclization of amino alcohols xiii with 
formaldehyde and ethyl chloroformate also furnished the corresponding new functionalized 1,3-





In the next part, the oxidation of alcohols ii using P2O5/DMSO gave rise to 3-oxo-4-
(trifluoromethyl)azetidin-2-ones iii as a third class of new building blocks. Ring opening of 3-oxo-
β-lactams iii through C3-C4 bond fission was unexpectedly observed in attempts to form and trap 
the corresponding 2,3-dioxoazetidin-4-yl anions, resulting in 2-[(2,2-difluorovinyl)amino]-2-
oxoacetates xxiii as major products (25-56%) accompanied by minor amounts of 2-oxo-2-[(2,2,2-
trifluoroethyl)amino]acetates xxiv (5-12%) upon treatment with alkyl halides and triethylamine in 
DMSO. This extraordinary reactivity was investigated in-depth from both an experimental and a 






In the final part of this PhD thesis, treatment of azetidine-2,3-diones iii with methylmagnesium 
bromide provided tertiary alcohols xxv in excellent yields. Subsequently, these alcohols xxv were 
treated with PPh3 in CCl4 to prepare the corresponding intermediate chlorides, followed by 
microwave-assisted dehydrochlorination by means of KOtBu in DMSO, to furnish 3-methylene-4-
(trifluoromethyl)azetidin-2-ones iv in good yields as a fourth new class of β-lactam building blocks 




The presence of an exocyclic carbon-carbon double bond in 3-methylene-4-
(trifluoromethyl)azetidin-2-ones iv allowed for the deployment of different synthetic strategies. In 
particular, the Michael addition of sulfur and nitrogen nucleophiles onto 4-CF3-β-lactams iv 
furnished the corresponding 3-phenylthiomethyl-4-(trifluoromethyl)azetidin-2-ones xxvi and 3-
aminomethyl-4-(trifluoromethyl)azetidin-2-ones xxvii. 3-Isobutylaminomethyl-β-lactams xxvi 
were then selected for further elaboration, involving reductive β-lactam ring opening using LiAlH4, 
followed by cyclization with triphosgene, leading to new 4-CF3-tetrahydropyrimidin-2-ones xxviii 
in good yields. The aptitude of 3-methylene-4-trifluoromethyl-β-lactams iv to undergo classical 
addition reactions across the C-C double bond was also investigated. First, hydrogenation of 3-
methylene-4-(trifluoromethyl)azetidin-2-ones iv on Pd/C provided a selective access to 3-methyl-
4-(trifluoromethyl)azetidin-2-ones xxix in good yields. Furthermore, electrophilic bromine addition 
to 4-CF3-β-lactams iv in the presence of pyridine resulted in 3-bromo-3-bromomethyl-4-
(trifluoromethyl)azetidin-2-ones xxx. In addition, 3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octan-
1-ones xxxii and 3-trifluoromethyl-5,7-dioxa-2-azaspiro[3.4]octane-1,6-diones xxxiii were 
prepared upon treatment of the corresponding diols xxxi, derived from the OsO4-mediated 
oxidation of 3-methylene-β-lactams iv, with pTsOH in 2,2-dimethoxypropane and with 
triphosgene, respectively. 
Furthermore, 4-CF3-β-lactams iv were shown to be susceptible to 1,3-dipolar nitrone-olefin 
cycloaddition reactions to generate isoxazolidine systems. Treatment of 3-methylene-β-lactams 
iv with either N-phenyl- or N-tert-butyl-α-phenylnitrone afforded a convenient entry to 7-phenyl-3-
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trifluoromethyl-5-oxa-2,6-diazaspiro[3.4]octan-1-ones xxxiv, which were assigned as 
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In conclusion, a set of four new 4-trifluoromethyl-β-lactam building blocks was successfully 
synthesized in this PhD thesis. These compounds have been shown to be powerful substrates for 
ring-opening reactions, ring-rearrangement reactions, Michael additions, electrophilic additions 
and cycloadditions en route to a broad variety of functionalized CF3-amines and CF3-
azaheterocycles. In light of the fascinating properties of the CF3 group introduction, 4-CF3-β-
lactams can indeed be considered as very promising structures for further development in the field 
















Organofluorverbindingen worden steeds meer gebruikt in de organische en medicinale chemie. 
Het incorporeren van fluor in organische moleculen beïnvloedt chemische en biologische 
eigenschappen zoals pKa, lipofiliciteit, metabolische stabiliteit en biologische beschikbaarheid. De 
toenemende interesse in gefluoreerde verbindingen heeft de ontwikkeling van nieuwe methoden 
om één of meerdere fluoratomen, bijvoorbeeld een trifluormethylgroep, in organische moleculen 
te introduceren, gestimuleerd. De bereiding van CF3-gesubstitueerde moleculen kan verwezenlijkt 
worden door ofwel bouwstenen die een CF3-groep bevatten te gebruiken, ofwel door 
trifluormethyleringsreagentia te benutten. Echter, het incorporeren van een trifluormethylgroep in 
een kleine molecule (zoals een β-lactam of een azetidin-2-on) gaat gepaard met een aanzienlijk 
risico tijdens de synthese door de condities en de gevaren verbonden aan het gebruik van 
trifluormethyleringsreagentia. Daarom wordt het gebruik van gefluoreerde bouwstenen hier 
aangewend als een efficiënt alternatief. 
β-lactamen vertonen, naast hun welgekende farmacologische eigenschappen, potentieel om als 
intermediairen gebruikt te worden in de organische synthese. Dit omwille van de inherente 
spanning in de vierring, die verdere omzetting naar acyclische en heterocyclische 
stikstofverbindingen toelaat. β-lactamen met een trifluormethylgroep kunnen, omwille van het 
uitgesproken effect van fluor op de eigenschappen, als interessante bouwstenen voor de 
ontwikkeling van nieuwe doelstructuren met veelbelovende toepassingen beschouwd worden. 
Echter, de chemie van CF3-gesubstitueerde β-lactamen werd nog niet zo uitvoerig onderzocht als 
die van CF3-aziridinen, hun driering-homologen. Voor deze laatste werd reeds een brede 
toepasbaarheid als veelzijdige bouwstenen voor ring-openingsreacties en ring-
transformatiereacties aangetoond. De synthese en het gebruik van 4-trifluormethyl-β-lactamen i, 
ii, iii, iv als nieuwe bouwstenen (“gefluoreerde synthon strategie”) werd in deze doctoraatsthesis 
verwezenlijkt, hetgeen resulteerde in een breed spectrum van gefunctionaliseerde CF3-aminen en 




In het eerste deel werden 3-alkoxy/aryloxy-4-CF3-azetidin-2-on-bouwstenen i op een efficiënte 
wijze bereid startende van het commercieel beschikbare 1-ethoxy-2,2,2-trifluorethanol v via 
iminering en daaropvolgende Staudingersynthese met alkyl/aryloxyacetylchlorides. Het 
synthetisch potentieel van de resulterende 4-CF3-β-lactamen i m.b.t C2-N ringopeningsreacties 
werd geëvalueerd op een indirecte of een directe wijze. Op de indirecte wijze werden 4-CF3-β-
lactamen i onderworpen aan een initieel verwijderen van de carbonylgroep door behandeling met 
AlH2Cl, hetgeen resulteerde in de azetidine-intermediairen vi. Activatie van deze azetidinen vi met 
trimethyloxoniumtetrafluorboraat en daaropvolgende ringopeningsreactie door verschillende 
zuurstof- en stikstofbevattende nucleofielen resulteerde in een waaier aan gefunctionaliseerde α-
(trifluormethyl)aminen vii. De directe reductieve ring-openingsreactie van 4-CF3-β-lactamen i 
werd gerealiseerd door behandeling met LiAlH4, resulterend in 3-aminopropaan-1-olen viii. 
Cyclisatie van deze 3-aminopropaan-1-olen viii met formaldehyde of ethylchloorformiaat werd 
geëvalueerd, hetgeen leidde tot nieuwe 1,3-oxazinanen ix en 1,3-oxazinan-2-onen x, 
respectievelijk. Daarnaast werd gepoogd om 1,4-oxazepaananalogen te synthetiseren door 
cyclisatie van de overeenkomstige amiden xi, afgeleid van de 3-aminopropaan-1-olen viii door N-





In het tweede deel werd met succes een reeks nieuwe 3-hydroxy-4-CF3-β-lactamen ii 
gesynthetiseerd met hoge opbrengsten door de hydrogenolyse van de overeenkomstige 3-
benzyloxy-4-CF3-β-lactamen i (R2 = Bn). Er werd aangetoond dat 2-hydroxy-4-CF3-β-lactamen ii 
geschikte substraten zijn voor ringcontractie, leidend tot de synthese van 2-gesubstitueerde 3-
(trifluormethyl)aziridinen via 3-chloor-4-CF3-β-lactamintermediairen. Hier resulteerde behandeling 
van de alcoholen ii met Ph3P in CCl4 in trans-3-chloor-4-CF3-β-lactamen xii. De 
ringopeningsreactie met behulp van de chloriden xii leverde hoge opbrengsten (90-96%) aan γ-
amino-alcoholen xiii. Deze alcoholen werden onderworpen aan tBuOK-geïnduceerde ringsluiting, 
hetgeen aanleiding gaf tot 3-trifluorgemethyleerde 2-(hydroxymethyl)aziridinen xiv in 27-61% 
rendement. Anderzijds resulteerde de directe behandeling van de chloriden xii met KOH in 
methanol in de overeenkomstige aziridine-2-carboxylaten xv in 25-73% rendement.  
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Verder werd aangetoond dat de alcoholen ii geschikte substraten zijn voor de synthese van 
nieuwe 3-[2,2,2-trifluor-1-(arylamino)ethyl]-1,4-dioxan-2-onen xviii in hoge opbrengsten via 
intermoleculaire cyclisatie van de 3-(2-hydroxyethoxy)-β-lactamintermediairen xvii na 
behandeling met een overmaat K2CO3. De 3-(2-hydroxyethoxy)-β-lactamen xvii werden bereid 





In analogie met de 4-CF3-azetidin-2-onen i werd er voor de 3-chloor-4-CF3-β-lactamen xii 
aangetoond dat het geschikte substraten zijn voor de bereiding van nieuwe α-CF3-gesubstitueerde 
aminopropaanderivaten xx. Een ringopeningsreactie van de azetidine-intermediairen xix, afgeleid 
van de chloriden xii, werd uitgevoerd door behandeling met natriumacetaat of tert-butylamine. 
Hiernaast leverde de cyclisatie van de amino-alcoholen xiii met formaldehyde en 






In het volgende deel werden de alcoholen ii geoxideerd met behulp van P2O5/DMSO, resulterend 
in 3-oxo-4-(trifluormethyl)azetidin-2-onen iii als een derde klasse van nieuwe bouwstenen. De 
ringopeningsreactie van 3-oxo-β-lactamen iii door splitsing van de C3-C4-binding werd 
onverwachts waargenomen toen gepoogd werd om de overeenkomstige 2,3-dioxoazetidine-4-yl- 
anionen te vormen. Dit resulteerde in 2-[(2,2-difluorvinyl)amino]-2-oxoacetaten xxiii als 
belangerijkste producten (25-56%), met kleine hoeveelheden 2-oxo-2-[(2,2,2-
trifluorethyl)amino]acetaten xxiv (5-12%) na behandeling met alkylhaliden en triethylamine in 
DMSO. Deze uitzonderlijke reactiviteit werd dieper onderzocht, zowel experimenteel als 
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xxiii (75-92/8-25) xxiv 
R1 = PMP, PMB 
R3 = Et, vinyl, 
1-chloroethyl, Ph, H 
(25-56%) 
R1 = PMP, PMB 
R3 = Et, vinyl, 




In het laatste deel van deze doctoraatsthesis werden uitstekende opbrengsten aan tertiaire 
alcoholen xxv bekomen door behandeling van de azetidin-2,3-dionen iii met methylmagnesium-
bromide. Daaropvolgend werden deze alcoholen xxv behandeld met PPh3 in CCl4 om de 
overeenkomstige intermediaire chloriden te bekomen. Dit werd gevolgd door een microgolf-
geassisteerde dehydrochlorering met KOtBu in DMSO, hetgeen leidde tot 3-methyleen-4-





De aanwezigheid van een exocyclische koolstof-koolstof dubbele binding in 3-methyleen-4-
(trifluormethyl)azetidin-2-onen iv maakte het mogelijk om verschillende synthetische strategieën 
toe te passen. Michaeladditie van zwavel- en stikstofbevattende nucleofielen op 4-CF3-β-lactamen 
iv leverde de overeenkomstige 3-fenylthiomethyl-4-(trifluormethyl)azetidin-2-onen xxvi en 3-
aminomethyl-4-(trifluormethyl)azetidin-2-onen xxvii. De 3-isobutylaminomethyl-β-lactamen xxvi 
werden dan geselecteerd voor een reductieve β-lactam ringopeningsreactie met LiAlH4, gevolgd 
door cyclisatie met trifosgeen, hetgeen resulteerde in nieuwe 4-CF3-tetrahydropyrimidin-2-onen 
xxviii in goede opbrengsten. Verder resulteerde de elektrofiele additie van broom aan 4-CF3-β-
lactamen iv (in aanwezigheid van pyridine) in 3-broom-3-broommethyl-4-(trifluormethyl)azetidin-
2-onen xxx. Daarnaast werden de 3-trifluormethyl-5,7-dioxa-2-azaspiro[3.4]octaan-1-onen xxxii 
en 3-trifluormethyl-5,7-dioxa-2-azaspiro[3.4]octaan-1,6-dionen xxxiii bereid door behandeling 
van de overeenkomstige diolen xxxi, afgeleid van de OsO4-gemedieerde oxidatie van de 3-
methyleen-β-lactamen iv, met pTsOH in 2,2-dimethoxypropaan en met trifosgeen, respectievelijk.  
Verder werd aangetoond dat 1,3-dipolaire nitron-olefien-cycloadditiereacties op 4-CF3-β-lactamen 
iv mogelijk waren die leiden tot isoxazolidinesystemen. Behandeling van de 3-methyleen-β-
lactamen iv met ofwel N-fenyl- ofwel N-tert-butyl-α-phenylnitron resulteerde in een handige route 
tot 7-fenyl-3-trifluormethyl-5-oxa-2,6-diazaspiro[3.4]octaan-1-onen xxxiv, dewelke als 





In deze doctoraatsthesis werden met succes vier nieuwe 4-trifluormethyl-β-lactambouwstenen 
gesynthetiseerd. Er werd aangetoond dat deze verbindingen krachtige substraten vormen voor 
reacties waarbij de ring geopend of herschikt wordt, alsook Michaeladdities, elektrofiele addities 
en cycloaddities. Deze leidden allen tot een brede waaier aan gefunctionaliseerde CF3-aminen en 
CF3-azaheterocyclische verbindingen. In het licht van de uitzonderlijke eigenschappen die de CF3-
groep aan een molecule geeft, kunnen we hier inderdaad besluiten dat de 4-CF3-β-lactamen als 
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veelbelovende structuren voor verdere ontwikkelingen in de medicinale chemie en chemische 
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